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EFFECTS OF ANTHOCYANINS AND THEIR METABOLITES ON 
THE FUNCTION OF HUMAN ENDOTHELIAL CELLS AND 
PLATELETS in vitro 
 
ABSTRACT 
Increasing number of scientific evidence suggests the beneficial role of dietary 
anthocyanins, phytochemicals mainly present in berries and derived products, in 
cardiovascular health. These anthocyanin health benefits may be attributed to their effect 
on endothelial cells or platelets that represent the key players in the development of 
cardiovascular diseases (CVD). However, the exact molecular mechanisms underlying 
anthocyanin cardioprotective effects are not fully understood. The aim of this thesis was 
to investigate the effect of anthocyanins and their metabolites in vitro on endothelial and 
platelet function and identify the underlying mechanisms of their action using 
physiologically relevant conditions. 
Results from this thesis showed that the pretreatment of endothelial cells with 
physiologically relevant concentrations of circulating anthocyanins and their metabolites 
attenuated monocyte adhesion to activated endothelial cells as well as their 
transendothelial migration, which are the initial steps in the development of 
atherosclerosis that precede CVD. In agreement with these results, gene expression 
analysis revealed that the treatment of endothelial cells with these compounds modulated 
the expression of genes involved in regulation of cell-cell adhesion, actin cytoskeleton 
reorganisation, focal adhesion and leukocyte transmigration. Bioinformatics analyses of 
gene expression data allowed the identification of potential transcription factors involved 
in the observed nutrigenomic effects and cell signalling proteins regulating their activity. 
Molecular docking analyses further revealed cell signalling proteins to which these 
bioactives may bind to and potentially affect their activity and the activation of 
downstream signalling proteins and transcription factors, effects that were in agreement 
with the results of Western blot analyses. Anthocyanins and their metabolites also 
modulated the expression of microRNAs, especially those involved in regulation of 
endothelial cell permeability, contributing to the observed changes in endothelial cell 
function. 
In addition to their effects on endothelial cells, anthocyanins and their metabolites 
displayed the capacity to modulate platelet function by decreasing platelet activation and 
their aggregation with leukocytes, the processes that are important contributors to CVD 
development. 
In conclusion, results from this thesis revealed the positive effects of anthocyanins 
and their metabolites, at physiologically relevant concentrations, on endothelial and 
platelet function and provided new insights into the mechanisms underlying their 
cardioprotective effects. 
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cell adhesion, monocyte transendothelial migration, platelet activation, platelet-leukocyte 
aggregation 
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RÔLE DES ANTHOCYANES ET CES METABOLITES SUR LA 
FONCTION DES CELLULES ENDOTHELIALES ET 
PLAQUETTES HUMAINE in vitro 
RESUME 
Les maladies cardiovasculaires sont un ensemble de troubles affectant le cœur et les 
vaisseaux sanguins, qui représentent la première cause de morbidité et de mortalité dans 
le monde. Ils comprennent les maladies coronariennes, les maladies cérébrovasculaires 
et les maladies artérielles périphériques, avec l’athérosclérose étant le principal processus 
pathologique sous-jacent de leur développement. L’athérosclérose, une maladie 
inflammatoire chronique des artères de gros et moyen calibre, est caractérisée par des 
lésions athéromateuses qui sont formées par l’accumulation de lipides, des éléments 
cellulaires et fibreux dans la paroi artérielle. Ces lésions perturbent le flux sanguin et dans 
les cas les plus graves tels que la rupture de la plaque et la thrombose peuvent entraîner 
un infarctus du myocarde ou accident vasculaire cérébral. L’athérosclérose est initiée par 
des altérations de la fonction endothéliale qui favorisent le recrutement et l’adhérence des 
leucocytes circulants et leur migration transendothéliale dans la paroi du vaisseau 
sanguin. Dans l’espace sous-endothélial, les leucocytes se différencient en macrophages 
activés, prennent les lipoprotéines oxydées et forme les cellules spumeuses, ce qui 
conduit à la formation des lésions athéromateuses. Les plaquettes contribuent également 
au développement d’athérosclérose par leurs interactions avec les leucocytes et les 
cellules endothéliales qui se produisent lors de l’activation plaquettaire. Ces interactions 
favorisent l’adhésion leucocytaire et la migration transendothéliale, augmentant ainsi les 
réponses inflammatoires et la progression de l’athérosclérose. Par conséquent, 
l’interaction entre les cellules endothéliales, les plaquettes et les leucocytes représentent 
une cible intéressante pour la prévention des maladies cardiovasculaires. 
L’alimentation joue un rôle important dans la promotion et le maintien de la santé. 
Elle contribue à développement et la progression des maladies cardiovasculaires, mais 
peut également présenter une modification de style de vie très importante pour la 
prévention et la gestion des maladies cardiovasculaires. De nombreuses études 
épidémiologiques et cliniques ont suggéré des effets bénéfiques des régimes riches en 
fruits et légumes sur la santé cardiovasculaire. Ces propriétés, favorisant les effets 
bénéfiques des fruits et légumes, ont été attribuées non seulement à leur faible valeur en 
calories, les niveaux élevés de fibres et oligo-éléments essentiels, mais aussi à leur 
composition en micronutriements, comme les polyphénols. Les polyphénols constituent 
le groupe des composés photochimiques le plus nombreux et largement distribué dans le 
royaume des végétaux. Ces composés, structurellement très diversifiés, sont largement 
présents dans les aliments végétaux tels que les fruits, les légumes et les céréales, 
présentant le groupe le plus important de composants alimentaires non-nutritifs. 
Les anthocyanes représentent un sous-groupe de polyphénols, abondant dans 
l’alimentation humaine en raison de leur forte présence dans les baies et les produits 
dérivés de baies. L’intérêt en anthocyanes a considérablement augmenté au cours des 
deux dernières décennies, en raison de divers effets bénéfiques pour la santé associée à la 
consommation d’aliments d’origine végétale riches en anthocyanes. Un nombre croissant 
de preuves suggère le rôle important des anthocyanes alimentaires dans la prévention et 
le traitement des maladies cardiovasculaires. Les études épidémiologiques ont montré 
une relation inverse entre la consommation d’anthocyanes et le risque d’hypertension 
artérielle, d’infarctus du myocarde et de mortalité cardiovasculaires. Plusieurs études 
cliniques avec des anthocyanes ou des aliments riches en anthocyanes ont montré des 
changements favorables sur la fonction endothéliale ou plaquettaire, la pression artérielle 
et le taux de cholestérol. Plusieurs interventions nutritionnelles réalisées avec des souris 
déficientes en apolipoprotéine E, qui développent spontanément l’athérosclérose, ont 
rapportées que des extraits riches en anthocyanes ou des composés purs, administrés à 
des doses nutritionnelles, réduit la formation de lésions athéromateuses dans l’aorte de 
ces souris. De plus, la supplémentation en anthocyanes augmente la survie après un 
infarctus du myocarde induit, diminue le développement de thrombus et améliore la 
tension artérielle, les profils lipidiques et vasodilatation endothélium-dépendante dans 
plusieurs études utilisant différents modèles animaux de maladies cardiovasculaires. Un 
certain nombre d’études in vitro ont été réalisées pour identifier les mécanismes par 
lesquels les anthocyanes exercent leurs effets cardioprotecteurs. Ces avantages pour la 
santé ont été précédemment associés à leurs propriétés antioxydantes directes, tandis que 
des études plus récentes ont suggéré l’implication de mécanismes d’action plus 
complexes comme la modulation de l’expression génique, de la signalisation cellulaire et 
de l’expression de microARN. Cependant, la majorité des études in vitro disponibles 
présentent plusieurs limitations. L’une des limites dans la recherche sur les effets 
biologiques des anthocyanes c’est que ces études ne prennent généralement pas en 
compte l’absorption, la distribution, le métabolisme et l’élimination de ces composés dans 
le corps humain. Dans les aliments, ces composés sont principalement présents sous 
forme de glycosides. Une fois ingérées, les anthocyanes sont absorbées par l’estomac et 
sont présentes rapidement dans la circulation sanguine sous forme inchangée. Leur 
absorption se poursuit dans l’intestin grêle, suivie de leur conjugaison dans le foie et la 
production de dérivés méthylés, glucuronidés et sulfatés. Les anthocyanes inchangées et 
ces métabolites atteignent une concentration plasmatique maximale d’environ 0.1 µM 
vers 2 heures, après un apport alimentaire de 2400 mg d’anthocyanes. Ces composés sont 
éliminés de la circulation dans les 6 heures, principalement par excrétion rénale. Les 
anthocyanes qui passent la partie supérieure du tractus gastro-intestinal sont dégradées 
par le microbiote colique, ce qui donne lieu à des acides phénoliques, tels que 
protocatéchique, vanillique ou l’acide férulique. Ces composés atteignent la 
concentration plasmatique maximale (0.2 µM-2 µM) dans les 15 heures après ingestion 
et sont présents dans la circulation jusqu’à 48 heures. Les acides phénoliques peuvent 
également se trouver dans la circulation sous la forme de sulfate, de glucuronide ou de 
produits de méthylation. De plus, il a été suggéré que la dégradation des anthocyanes ne 
nécessite pas nécessairement l’action du microbiote colique et qu’une certaine 
dégradation chimique est susceptible de se produire dans la partie supérieure du tractus 
gastro-intestinal et de la circulation. Pris ensemble, les métabolites d’anthocyanes 
apparaissent rapidement dans le sérum, présentent des profils biphasiques, avec le pic 
initial dans les 2 heures âpres l’ingestion, suivi d’un autre pic entre 6 et 48 heures. Malgré 
les preuves d’un métabolisme important des anthocyanes dans le corps humain, les études 
in vitro disponibles utilisent principalement des composés parents ou des extraits plutôt 
que des métabolites circulants, à des concentrations élevées et supra-physiologiques 
(jusqu’à 200 µM) et de longues périodes d'exposition des cellules (jusqu’à 24 heures), 
produisant ainsi des résultats sans pertinence physiologique. 
Une autre limitation des études mécanistes in vitro est qu’ils utilisent, le plus souvent, 
des approches ciblées pour étudier l’effet sur l’expression des gènes, mettant l’accent sur 
l’impact sur quelques cibles spécifiques, qui ne convient pas pour les évaluations du mode 
d’action multicible et complexe qui était attribué aux polyphénols. En outre, 
contrairement au nombre relativement important d’études portant sur l’effet des 
anthocyanes sur la fonction des cellules endothéliales, le nombre d’études examinant 
leurs effets sur la fonction plaquettaire est limité. Ces études in vitro se concentrent 
principalement à étudier l’effet des extraits riches en anthocyanes ou composés purs sur 
activation des plaquettes et l’agrégation des plaquettes avec des cellules endothéliales ou 
entre elles, généralement dans les conditions non-physiologiques. En outre, l’effet des 
anthocyanes et de leurs métabolites sur l’agrégation plaquettaire avec des leucocytes doit 
encore être mis en place. Ainsi, en dépit du nombre croissant de données 
épidémiologiques, cliniques et préclinique des effets cardioprotectrices anthocyanes, 
leurs mécanismes exacts d’actions ne sont pas encore pleinement compris. 
L’objectif principal de cette thèse était d’étudier l’impact des anthocyanes et de leurs 
métabolites sur la fonction endothéliale et des plaquettes et d’identifier les mécanismes 
moléculaires sous-jacents de l’action, en utilisant des conditions physiologiques (les 
formes et les doses de composés et dure d’exposition des cellules). 
Les composés examinés sont les anthocyanes : cyanidine-3-glucoside, cyanidine-3-
arabinoside, la cyanidine-3-galactoside, delphinidine-3-glucoside et péonidine-3-
glucoside et leurs métabolites : 4-hydroxybenzaldéhydes, les acides protocatéchiques, 
vanilliques, féruliques et hippuriques. Les anthocyanes testées sont présentes en grande 
quantité dans divers fruits, notamment dans les baies, dans divers produits dérivés des 
fruits (par exemple les jus et les vins) et dans certains légumes et céréales. En outre, ils 
peuvent être trouvés dans les bleuets qui sont les sources d’anthocyanes les plus 
couramment consommés. Les métabolites d’anthocyanes qui ont été examinés auparavant 
dans la circulation sanguine après la consommation de divers aliments riches en 
anthocyanes. De plus, ces métabolites ont été confirmés comme des produits de 
dégradation d’anthocyane issue de petit intestin et du côlon dans une étude de 
biodisponibilité des anthocyanes avec cyanidine-3-glucoside isotopiquement marqué. 
L’impact des composés testés sur la fonction des cellules endothéliales a été évalué 
par la mesure de l’adhérence des monocytes aux cellules endothéliales activées et la 
migration transendothéliale de monocytes qui représentent les étapes initiales du 
développement de l’athérosclérose. Ces investigations ont été réalisées en utilisant des 
cellules endothéliales primaires, des cellules endothéliales de veine ombilicale humaine 
(HUVECs), un système de modèle in vitro couramment utilisé pour explorer 
l’inflammation vasculaire dans l’athérosclérose. Ces cellules ont été traitées avec des 
anthocyanes et leur métabolites dans la gamme de concentration allant de 0.1 µM à 2 µM, 
ce qui correspondait à leurs taux plasmatiques circulant après la prise d’aliments riches 
en anthocyanes. Les résultats des études de biodisponibilité des anthocyanes montrent 
que ces composés sont présents dans le sang pendant une courte période de temps, 
contrairement à leurs métabolites de l’intestin qui sont détectables jusqu’à 48 heures après 
la consommation. En outre, dans deux études récentes qui ont utilisé les baies de sureau 
ou cyanidine-3-glucoside marqué isotopiquement, une quantité importante de 4-
hydroxybenzaldéhyde a été observé dans plasma quelques heures après l’ingestion. Ces 
résultats suggèrent que le 4-hydroxybenzaldéhyde est probablement un produit de 
dégradation d’anthocyanes, produite dans la partie supérieure de tractus gastro-intestinal. 
Par conséquent, les cellules endothéliales sont traitées avec des anthocyanes et 4-
hydroxybenzaldéhyde pendant 3 heures et avec les métabolites coliques pendant 18 
heures. Pour créer un environnement proathérogène, les cellules ont été stimulées avec 
une cytokine, facteur de nécrose tumorale alpha (TNFα), qui est le majeur régulateur de 
l’inflammation et provoque un dysfonctionnement endothélial. Par la suite, les cellules 
endothéliales ont été co-incubées avec les monocytes et l’adhésion des monocytes a été 
mesurée par cytométrie en flux. L’activation des cellules endothéliales avec TNFα a 
induit l’adhérence des monocytes sur la monocouche de cellules endothéliales. Les 
résultats des essais d’adhésion de monocytes ont montré que, à l’exception de 4-
hydroxybenzaldéhyde, le prétraitement de cellules HUVEC avec des anthocyanes et de 
leurs métabolites a entraîné une réduction significative de l’adhérence des monocytes aux 
cellules endothéliales activées par TNFα. Cet effet a été observé en particulier à des 
concentrations des composés qui sont les plus proches de leurs niveaux plasmatiques 
circulants précédemment rapportés. L’effet dose-réponse de composés testés sur les 
interactions cellulaires de monocytes endothéliaux est essentiellement non linéaire, qui 
est en ligne avec l’absence d’un effet dose-réponse rapportée pour d’autres polyphénols 
dans les cellules endothéliales ou d’autres types de cellules. Parmi les anthocyanes 
examinées, le delphinidine-3-glucoside présentait la plus grande capacité à atténuer 
l’adhésion des monocytes. Les résultats des essais d’adhérence ont également révélé 
l’activité de métabolites de l’intestin à réduire l’adhérence des monocytes aux cellules 
endothéliales activées, avec l’effet le plus fort observé pour l’acide protocatéchique. 
L’impact de ces composés est similaire à celle des anthocyanes, ce qui suggère que la 
transformation microbienne intestinale produit des métabolites qui peuvent avoir des 
effets bénéfiques sur la fonction endothéliale que leurs composés parents. Ces résultats 
impliquent que non seulement les anthocyanes, mais aussi leurs métabolites, détectables 
dans la circulation la plus longue, peuvent exercer une activité biologique dans les cellules 
endothéliales et probablement contribuent aux effets cardioprotecteurs associés à la 
consommation habituelle d’aliments riches en anthocyanes. L’influence des anthocyanes 
sur l’adhésion des monocytes aux cellules endothéliales activées a été précédemment 
rapportée. Cependant, ces effets ont été observés en utilisant des extraits à base 
d’anthocyanes et des aglycones ainsi que des concentrations supra-physiologiques de 
glycosides, avec de longues périodes d’exposition des cellules. Ainsi, les résultats de cette 
thèse présentent les premières preuves physiologiquement pertinentes de l’impact des 
anthocyanes testées sur l’adhésion des cellules endothéliales des monocytes. Les effets 
précédemment évalués d’acides protocatéchique et férulique sont conformes aux résultats 
de cette thèse, tandis que les effets des acides hippuriques et vanilliques sur l’adhérence 
des monocytes aux cellules endothéliales sont rapportés pour la première fois. 
Pour étudier l’effet synergique potentiel de composés qui sont présents dans la 
circulation dans le même temps après l’ingestion d’aliments riches en anthocyanes, deux 
mélanges de composés qui sont présents dans la circulation pendant un court (mélange 
A) ou une longue période de temps (mélange B) ont été créés. Le mélange A contenait 
du cyanidine-3-glucoside, du cyanidine-3-arabinoside, du cyanidine-3-galactoside, du 
delphinidine-3-glucoside, du péonidine-3-glucoside et du 4-hydroxybenzaldéhyde. La 
concentration finale des composés dans ce mélange, qui a été ajouté aux cellules 
endothéliales, était 0.1 µM pour les anthocyanes et 0.5 µM pour le 4-
hydroxybenzaldéhyde. Le mélange B était composé de l’acide protocatéchique, l’acide 
vanillique, l’acide férulique et l’acide hippurique, administré aux cellules endothéliales à 
la concentration finale de 0.2 µM, 2 µM, 1 µM et 2 µM, respectivement. Les 
concentrations de composés dans ces mélanges étaient les plus proches de celles 
précédemment identifiées dans le plasma humain dans les études de biodisponibilité des 
anthocyanes. En outre, la condition appelée le mélange A+B a été créé pour imiter, le 
plus fidèlement possible, la pharmacocinétique anthocyanes suite à l’ingestion de sources 
riches en anthocyanes en traitant les cellules endothéliales avec le mélange de composés 
qui apparaissent rapidement dans la circulation sanguine et puis avec le mélange de 
métabolites de l’intestin qui apparaissent plus tard et restent dans la circulation le plus 
longtemps. Les résultats de ces tests d’adhésion ont révélé la capacité des mélanges à 
réduire significativement l’adhérence des monocytes aux HUVEC activés par TNFα. 
Cependant, aucun effet additif des composés individuels des mélanges n’a pas été 
observé. L’absence d’effet additif a déjà été observée avec différents mélanges de 
polyphénols et peut être expliquée par la compétition entre les composés du mélange pour 
la même cible d’action. 
Les mélanges d’anthocyanes et de leurs métabolites ont ensuite été utilisés pour 
étudier l’effet de ces composés sur la migration transendothéliale des monocytes, étape 
qui suit l’adhésion. Les résultats de ces expériences ont montré une réduction significative 
de la migration des monocytes induite par la protéine chimiotactique monocytaire 1 
(MCP-1) à travers des cellules endothéliales prétraitées avec les mélanges. Ces résultats 
représentent le premier rapport sur la capacité des anthocyanes et de leurs métabolites 
intestinaux à réduire la migration transendothéliale des monocytes à des conditions 
physiologiquement pertinentes. Ces résultats suggèrent que les anthocyanes et leurs 
métabolites peuvent affecter les premières étapes du développement de l’athérosclérose 
en diminuant la perméabilité des cellules endothéliales aux leucocytes. Cette hypothèse 
peut être étayée par les résultats d’études animales qui a rapporté la réduction de lésions 
athéromateuses chez les souris déficientes en apolipoprotéine E qui ont consommé un 
régime supplémenté avec des extraits riches en anthocyanes ou des composés purs. 
Pour identifier les mécanismes moléculaires sous-jacents aux effets observés sur 
l’adhésion des monocytes et la migration transendothéliale, l’impact de ces composés sur 
l’expression des gènes dans les cellules endothéliales a ensuite été évaluée. Ces 
expériences ont été réalisées à l’aide macroarray (cartes TaqMan Low Density Array) qui 
ont permis d’évaluer simultanément les niveaux d’expression de 93 gènes impliqués dans 
la régulation de la fonction endothéliale. L’analyse de l’expression génique a révélé que 
le traitement des cellules endothéliales avec les mélanges d’anthocyanes et de leurs 
métabolites module l’expression des gènes impliqués dans la régulation de l’adhésion 
cellule-cellule, l’adhésion focale, les jonctions serrées, la transmigration leucocytaire et 
la réorganisation de cytosquelette d’actine. Ainsi, ces modulations de l’expression des 
gènes dans les cellules endothéliales par des mélanges peuvent être associées à une 
diminution de l’adhérence des monocytes et la migration transendothéliale, présentant 
des cibles moléculaires sous-jacents l’effet observé sur les cellules endothéliales. 
L’expression génique est contrôlée au niveau transcriptionnel par des facteurs de 
transcription dont l’activité est régulée par des voies de signalisation. Les résultats 
d’expression génique ont été analysés avec différents outils bioinformatiques pour 
identifier les facteurs de transcription et des protéines de signalisation qui pourraient être 
impliquées dans l’effet nutrigénomique des composés testés. L’amarrage moléculaire (en 
anglais, molecular docking) a été utilisé pour prédire si anthocyanes et leurs métabolites 
peuvent se lier à ces protéines de signalisation cellulaire et les facteurs de transcription et 
exercer leur activité biologique. Cette technique de calcul est de plus en plus utilisée 
comme instrument d’identification de cibles moléculaires de composés bioactifs naturels. 
Dans cette thèse, l’amarrage moléculaire a été réalisée avec 62 protéines de signalisation 
et facteurs de transcription identifiées, qui sont impliqués dans la régulation de différents 
processus cellulaires tels que l’inflammation, la prolifération cellulaire, la migration et la 
survie. Les résultats de ces analyses suggèrent que les anthocyanes et leurs métabolites 
présentent la capacité de se lier aux certaines protéines de signalisation cellulaire. Les 
anthocyanes étaient des ligands plus forts que leurs métabolites. De plus, les affinités de 
liaison similaires pour les mêmes cibles ont été cibles ont été observées lorsque l’on 
compare les composées au sein des groupes anthocyanes et des métabolites, ce qui 
contribue à l’hypothèse que l’absence d’effet cumulatif des composés dans les mélanges 
est le résultat de leur compétition pour la même cible d’action. Des données 
bibliographiques suggèrent que les anthocyanes et leurs métabolites peuvent se lier à des 
domaines de la protéine kinase de plusieurs protéines de signalisation cellulaire (par 
exemple FAK1, MEK2, IKKα, JAK3, p38β) et éventuellement affecter leur activité et la 
phosphorylation des protéines de signalisation en aval. Les résultats de la littérature 
disponible ont montré que la liaison de différents inhibiteurs aux domaines de kinase de 
ces protéines de signalisation cellulaire conduit à réduction de leur activité, ce qui a été 
associé à la réduction de perméabilité endothéliale, c’est-à-dire l’adhérence et la 
migration transendothéliale des leucocytes. 
Pour associer des résultats obtenus par amarrage moléculaire avec l’effet in vitro sur 
des voies de signalisation cellulaire, l’impact des anthocyanes et de leurs métabolites sur 
l’activation des protéines de signalisation cellulaire et des facteurs de transcription ont 
été étudiées. Les résultats des analyses Western blot ont montré que le traitement des 
cellules endothéliales avec le mélange A réduit la phosphorylation d’ERK1/2 et de NF-
κB-p65, alors que mélange B a diminué la phosphorylation de NF-κB-p65. Ces résultats 
suggèrent que les anthocyanes et leurs métabolites en se liant à différentes protéines de 
signalisation cellulaire peuvent affecter leur activité et par conséquent celle des facteurs 
de transcription, ce qui affecte la perméabilité endothéliale, présentant les mécanismes 
possibles d’action sous-jacents leurs propriétés cardioprotecteurs. 
En plus de la régulation par des protéines de signalisation cellulaire et les facteurs de 
transcription, l’expression des gènes peut également être réglée au niveau post-
transcriptionnel par les microARNs. Ces ARN non-codants contrôlent divers processus 
cellulaires et des changements dans leurs profils d’expression ont été décrits dans diverses 
maladies, telles que les maladies cardiovasculaires. La capacité des anthocyanes ou leurs 
métabolites à moduler l’expression de microARN a été décrite cependant, les études sont 
encore limitées. Dans cette thèse, l’effet des anthocyanes et de leurs métabolites sur 
l’expression du microARN a été examiné en utilisant les puces à microARN. Les résultats 
de l’analyse d’expression de microARN ont montré pour la première fois la capacité des 
anthocyanes et de leurs métabolites, aux conditions physiologiquement pertinentes, à 
moduler l’expression de microARN et des cellules endothéliales stimulées par le TNFα. 
Les composés testés particulièrement touchaient l’expression des microARNs impliqués 
dans la régulation de la perméabilité des cellules endothéliales (par exemple let-7f, miR-
181b, miR-125a et miR-26a), ce qui contribue aux changements observés dans la fonction 
des cellules endothéliales. Ainsi, ces résultats ont montré que la modulation de 
l’expression du microRNA présente également un mécanisme par lequel ces composés 
peuvent exercer leurs effets bénéfiques. 
En plus des investigations de l’effet d’anthocyanes et de leurs métabolites sur la 
fonction des cellules endothéliales comme l’une des cibles importantes dans la prévention 
des maladies cardiovasculaires, cette thèse a également évalué l’impact de ces composés 
sur la fonction plaquettaire. Ces études comprenaient les évaluations de l’effet des 
anthocyanes et de leurs métabolites sur l’activation des plaquettes et l’agrégation 
plaquettaire leucocytaire en réponse à adénosine diphosphate exogène. L’adénosine 
diphosphate est un agoniste plaquettaire qui est stocké dans leurs granules denses et libéré 
après leur activation. La réponse plaquettaire aux faibles niveaux de cette molécule a été 
rapportée comme un paramètre avec une valeur prédictive des événements 
cardiovasculaires et présente donc une cible rationnelle pour l’évaluation des effets 
bénéfiques de ces composés sur la santé cardiovasculaire. Pour ces études, le sang prélevé 
chez les sept donneurs masculins en bonne santé a été incubé avec 0.1 µM d’anthocyanes, 
0.5 µM de 4-hydroxybenzaldéhyde, 0.2 µM d’acide protocatéchique, 2 µM d’acide 
vanillique, 1 µM d’acide férulique ou 2 µM d’acide hippurique. Par la suite, les 
échantillons de sang ont été stimulés avec de l’adénosine diphosphate, marqués et 
analysés par cytométrie de flux. L’impact des composés testés sur la fonction plaquettaire 
a été évalué en mesurant l’expression des marqueurs d’activation, le P-sélectine et le 
GPIIb/IIIa, ainsi que la formation d’agrégats plaquettes-monocytes et plaquettes-
neutrophiles. Le P-sélectine présente une molécule d’adhésion cellulaire qui est stocké 
dans les granules alpha des plaquettes et qui est transporté à la surface des plaquettes 
seulement après l’activation plaquettaire. Cette molécule assure l’adhésion avec les 
neutrophiles et les monocytes par liaison à son ligand PSGL-1 exprimé sur la surface des 
leucocytes. L’activation des plaquettes est également associée à une activation 
conformationnelle du GPIIb/IIIa, un récepteur de fibrinogène responsable d’agrégation 
plaquettaire avec autres plaquettes, qui aussi contribue à l’agrégation des plaquettes avec 
des leucocytes. L’utilisation de cytométrie de flux avec les échantillons de sang total a 
permis non seulement de mesurer avec sensibilité ces marqueurs qui sont très pertinents 
pour la prévention des maladies cardiovasculaires, mais aussi de diminuer l’activation 
extracorporelle plaquettaire et de produire des résultats fiables qui peuvent être attribués 
exclusivement à un effet direct des composés testés sur la fonction plaquettaire. Les 
résultats de ces expériences ont montré que, sauf l’acide vanillique, les anthocyanes et 
leurs métabolites affectés de manière significative au moins l’un des paramètres étudiés, 
activation plaquettaire ou agrégation plaquettaire avec des leucocytes. Ces résultats 
impliquent que les effets antiplaquettaires bénéfiques associés à la consommation 
d’aliments riches en anthocyanes pourraient aussi être une conséquence de l’action 
combinée des anthocyanes et de leurs métabolites sur la fonction plaquettaire. Les 
composés testés ont un effet variable sur la fonction plaquettaire. Parmi les anthocyanes 
testées, le cyandin-3-arabinoside affiche la plus grande capacité à moduler la fonction des 
plaquettes, car il réduit le pourcentage de plaquettes P-sélectine positives la densité de ce 
récepteur aussi que le pourcentage d’agrégats plaquettes-neutrophiles. En revanche, 
péonidine-3-glucoside, delphinidine-3-glucoside ou cyanidine-3-glucoside affectés 
l’activation des plaquettes en atténuant l’expression surface de P-sélectine ou de 
GPIIb/IIIa, tandis que la cyanidine-3-galactoside réduit l’agrégation plaquettaire avec des 
neutrophiles. Le 4-hydroxybenzaldéhyde a été le plus efficace entre les métabolites, car 
il induit une réduction significative de l’activation plaquettaire, ainsi que l’agrégation des 
plaquettes avec les neutrophiles et les monocytes. Il est intéressant de noter que le 4-
hydroxybenzaldéhyde était le seul composé testé qui ne montre pas l’effet significatif sur 
l’adhésion des monocytes aux cellules endothéliales dans les expériences d’adhésion 
cellulaire. Ces résultats suggèrent qu’en agissant sur les plaquettes et pas sur les cellules 
endothéliales, ce métabolite pourrait potentiellement réduire les interactions entre les 
leucocytes et les cellules endothéliales et exercer un effet protecteur contre le 
développement de l’athérosclérose. Un nombre limité de données publiées sur les effets 
d’anthocyanes et leurs métabolites sur l’activation plaquettaire et l’agrégation avec 
leucocytes en conditions in vitro, soulignent l’importance des résultats obtenus dans cette 
thèse. L’impact des anthocyanes, peonidine-3-glucoside, cyanidine-3-galactoside et 
cyanidine-3-arabinoside, ainsi que des métabolites 4-hydroxybenzaldéhyde et acide 
vanillique sur l’activation des plaquettes, n’a pas été évalué avant. En outre, cette thèse 
rapporte pour la première fois la capacité des anthocyanes et de leurs métabolites à 
affecter l’agrégation plaquettaire avec les leucocytes, un marqueur qui est un indicateur 
encore plus sensible du risque de maladie cardiovasculaire que l’activation plaquettaire. 
Sur la base de tous les résultats de cette thèse, plusieurs conclusions peuvent être 
tirées. Les anthocyanes et leurs métabolites, dans des conditions physiologiquement 
pertinentes, peuvent réduire l’adhésion des monocytes et la migration transendothéliale, 
étapes initiales du développement de l’athérosclérose, en maintenant l’intégrité et la 
fonction des cellules endothéliales. Ces effets semblent être exercés par des mécanismes 
d’action complexe. Ces mécanismes incluent la capacité des anthocyanes et de leurs 
métabolites à interagir avec les protéines de signalisation cellulaire et à moduler leur 
activité et par conséquent l’activité des facteurs de transcription, conduisant à des 
changements dans l’expression des gènes ainsi que leur capacité à moduler l’expression 
des microARNs. En outre, les résultats de cette thèse ont également montré la capacité 
d’anthocyanes circulantes et de leurs métabolites d’atténuer l’activation plaquettaire et 
leur agrégation avec les leucocytes, les processus qui contribuent au développement des 
maladies cardiovasculaires. Ainsi, cette thèse a révélé les effets positifs des anthocyanes 
et de leurs métabolites sur la fonction endothéliale et plaquettaire et a fourni de nouvelles 
informations sur les mécanismes sous-jacents de leurs effets cardioprotecteurs. 
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UTICAJ ANTOCIJANA I NJIHOVIH METABOLITA NA 
FUNKCIJU ENDOTELNIH ĆELIJA I TROMBOCITA ČOVEKA in 
vitro 
 
SAŽETAK 
Kardiovaskularne bolesti predstavljaju oboljenja koja zahvataju srce i krvne sudove i 
najčešći su uzrok obolevanja i umiranja u svetu. Prema mestu javljanja mogu se podeliti 
na bolesti srca, cerebrovaskularne bolesti i bolesti perifernih krvnih sudova. Osnovni 
uzročnik kardiovaskularnih bolesti je ateroskleroza, hronično zapaljensko oboljenje 
velikih i srednje velikih arterijskih krvnih sudova koje se karakteriše aterosklerotičnim 
lezijama koje nastaju nakupljanjem lipida, ćelija i proteina vezivnog tkiva unutar zida 
krvnog suda. Ove patološke promene krvnih sudova ometaju normalan protok krvi, a u 
kasnijim stadijumima bolesti mogu dovesti i do pucanja plaka i aterotromboze, što za 
posledicu može imati infarkt miokarda ili šlog. Sam nastanak ateroskleroze povezan je sa 
poremećenom funkcijom endotela krvnog suda koja podstiče adheziju leukocita za 
aktivirane endotelne ćelije i njihovu transendotelnu migraciju. Unutar zida krvnog suda 
monociti se diferenciraju u makrofage, vrše ingestiju oksidovanog LDL holesterola i 
formiraju penušave ćelije čije nakupljanje vremenom dovodi do formiranja 
aterosklerotičnih lezija. Važnu ulogu u nastanku ateroskleroze imaju i trombociti. 
Interakcija aktiviranih trombocita sa leukocitima i endotelnim ćelijama podstiče adheziju 
leukocita i njihovu transendotelnu migraciju i time dodatno podstiče zapaljenski proces i 
razvoj ateroskleroze. Stoga, ispitivanje uzajamnog delovanja endotelnih ćelija, leukocita 
i trombocita predstavlja značajno područje istraživanja u cilju prevencije i kontrole 
kardiovaskularnih bolesti. 
Ishrana ima važnu ulogu, kako u nastanku i razvoju kardiovaskularnih bolest, tako i 
u njihovoj prevenciji i lečenju. Rezultati brojnih epidemioloških i kliničkih studija 
pokazuju povoljno delovanje ishrane bogate voćem i povrćem na kardiovaskularno 
zdravlje. Ovo pozitivno delovanje namirnica biljnog porekla pripisuje se delom njihovom 
niskom energetskom vrednošću, visokom sadržaju vlakana i esencijalnih 
mikronutrijenata, ali pre svega nenutritivnim, biološki aktivnim sastojcima, poput 
polifenola. Polifenoli predstavljaju najbrojniju i najzastupljeniju grupu sekundarnih 
metabolita biljaka. Ova strukturno veoma raznolika grupa jedinjenja je široko zastupljena 
u namirnicama biljnog porekla, poput voća, povrća i žitarica, čineći najznačajniju grupu 
nenutritivnih sastojaka namirnica. Antocijani predstavljaju podgrupu polifenolnih 
jedinjenja koja je u ljudskoj ishrani prevashodno zastupljena preko unosa bobičastog voća 
i proizvoda dobijenih njegovom preradom. Tokom protekle dve decenije ova jedinjenja 
su se našla u žiži interesovanja i naučne zajednice i javnosti, zbog pokazane veze između 
ishrane bogate namirnicama sa visokim sadržajem antocijana i raznovrsnih pozitivnih 
efekata na zdravlje. Sve veći broj naučnih dokaza ukazuje na važnu ulogu antocijana u 
prevenciji i lečenju kardiovaskularnih bolesti. Rezultati epidemioloških studija pokazali 
su inverznu korelaciju između dijetarnog unosa antocijana i rizika od hipertenzije, 
infarkta miokarda ili stope smrtnosti od kardiovaskularnih bolesti. Takođe, povoljne 
promene u funkciji endotela i trombocita, kao i poboljšanje krvnog pritiska i lipidnog 
statusa, uočeni su u brojnim kliničkim studijama nakon konzumacije antocijana ili 
namirnica bogatih ovim jedinjenjima. Studije na miševima sa nedostatkom 
apolipoproteina E, koji predstavljaju životinjski model za proučavanje ateroskleroze, 
pokazale su da suplementacija ekstraktima bogatim antocijanima dovodi do značajnog 
smanjenja nastanka arteriosklerotičnih lezija. Takođe, poboljšano preživljavanje nakon 
infarkta miokarda, sprečavanje nastanka tromba kao i poboljšanje krvnog pritiska, 
lipidnog statusa i endotel-zavisne vazorelaksacije, zabeleženi su u različitim životinjskim 
modelima za proučavanje kardiovaskularnih bolesti, nakon suplementacije namirnicama 
bogatim antocijanima. Veliki broj in vitro studija sproveden je u cilju identifikacije 
mehanizama kardioprotektivnog delovanja antocijana. Opisano pozitivno delovanje ovih 
jedinjenja ranije se pripisivalo njihovim antioksidativnim svojstvima, dok novije studije 
ukazuju na složene molekularne mehanizme delovanja poput modulacije ekspresije gena, 
aktivacije signalnih puteva i ekspresije mikro-RNK. Međutim, dostupne in vitro studije 
uglavnom poseduju nekoliko ograničenja. Jedan od nedostataka jeste da većina studija 
prilikom ispitivanja biološkog dejstva antocijana ne uzima u obzir njihovu apsorpciju, 
distribuciju, metabolizam i ekskreciju iz ljudskog organizma. U namirnicama biljnog 
porekla ova jedinjenja su uglavnom prisutna u obliku glikozida. Nakon ingestije, 
antocijani mogu biti apsorbovani u želucu (uz pomoć nosača) i u neizmenjenom obliku 
dospeti u krvotok. Njihova apsorpcija se nastavlja u tankom crevu, nakon čega portalnom 
venom dospevaju u jetru gde se metabolišu do metilovanih proizvoda, i konjugata sa 
glukuronskom i sumpornom kiselinom. Zajedno sa neizmenjenim antocijanima, ovi 
metaboliti dostižu maksimalnu koncentraciju u plazmi od oko 0.1 µM u roku od 2 sata, 
pri dijetarnom unosu ≤2400 mg antocijana. Iz cirkulacije se eliminišu, prevashodno 
renalnom ekskrecijom, u roku od 6 sati. Deo antocijana, koji se ne apsorbuje u tankom 
crevu, dospeva u debelo crevo gde podleže delovanju mikroflore debelog creva, usled 
čega dolazi do stvaranja fenolnih kiselina poput protokatehuinske, vanilinske ili 
ferulinske. Ova jedinjenja dostižu maksimalnu koncentraciju u plazmi (0.2 -2 µM) u roku 
od 15 sati nakon ingestije, a prisutna su u cirkulaciji i do 48 sati. Fenolne kiseline se u 
cirkulaciji takođe mogu javiti u obliku sulfata, glukuronida ili proizvoda metilovanja. Na 
osnovu svega navedenog može se zaključiti da se antocijani intenzivno metabolišu u 
ljudskom organizmu. Međutim, u većini in vitro studija korišćeni su ekstrakti ili 
jedinjenja koja nisu zastupljena u cirkulaciji, u koncentracijama daleko većim od 
fizioloških (i do 200 µM) i sa dugim vremenom ekspozicije ćelija, dajući rezultate koji 
nisu fiziološki relevantni. Pored ovoga, još jedan nedostatak in vitro studija jeste 
ispitivanje delovanja antocijana na pojedine, ciljane gene ili proteine, što ne predstavlja 
pogodan pristup za procenu njihovog plejotropnog delovanja koje je pokazano in vivo. 
Takođe, za razliku od relativno velikog broja studija koje prikazuju dejstvo antocijana na 
funkciju endotelnih ćelija, broj studija koje ispituju njihovo delovanje na funkciju 
trombocita je ograničen. Ove in vitro studije se uglavnom zasnivaju na ispitivanju dejstva 
antocijana i ekstrakata bogatih antocijanima na aktivaciju trombocita i njihovu agregaciju 
sa endotelnim ćelijama i drugim trombocitima. Sa druge strane, dejstvo antocijanina i 
njihovih metabolita na agregaciju trombocita sa leukocitima nije ispitivano u in vitro 
uslovima. Stoga, uprkos sve većem broju epidemioloških, kliničkih i pretkliničkih dokaza 
o kardioprotektivnom dejstvu antocijana, tačni mehanizmi njihovog delovanja i dalje nisu 
u potpunosti razjašnjeni. Shodno navedenom, cilj ove doktorske disertacije bio je da se 
ispita uticaj antocijana i njihovih metabolita na funkciju endotelnih ćelija i trombocita, 
kao i da se identifikuju mehanizmi njihovog delovanja u fiziološki relevantnim uslovima 
in vitro. 
Jedinjenja, čiji je efekat ispitivan u ovoj tezi, uključivala su antocijane: cijanidin-3-
glukozid, cijanidin-3-arabinozid, cijanidin-3-galaktozid, delfinidin-3-glukozid i 
peonidin-3-glukozid, kao i metabolite antocijana: 4-hidroksibenzaldehid, 
protokatehuinsku, vanilinsku, ferulinsku i hipurnu kiselinu. Pomenuti antocijani prisutni 
su u značajnim koncentracijama u različitom voću (posebno bobičastom) i proizvodima 
dobijenim njegovom preradom (poput vina i sokova), dok se svih pet antocijana mogu 
naći u borovnicama, koje predstavljaju najčešće konzumiran izvor antocijana. Metaboliti 
ispitivani u ovoj doktorskoj disertaciji, prisutni su u cirkulaciji nakon konzumiranja 
različitih namirnica bogatih antocijanima. Takođe, ovi metaboliti su nedavno 
identifikovani kao proizvodi razgradnje antocijana u tankom i debelom crevu, u studiji 
koja je ispitivala biološku raspoloživost radioizotopski obeleženog cijanidin-3-glukozida 
u ljudskom organizmu. 
Uticaj ispitivanih jedinjenja na funkciju endotelnih ćelija određivan je merenjem 
adhezije monocita za aktivirane endotelne ćelije, kao i njihove transendotelijalne 
migracije, procesa koji predstavljaju početne korake u nastanku ateroskleroze i prethode 
razvoju kardiovaskularnih bolesti. U ovim istraživanjima korišćene su primarne kulture 
humanih endotelnih ćelija pupčane vene (HUVEC), koje predstavljaju pogodan in vitro 
ćelijski model za proučavanje vaskularne inflamacije u aterosklerozi. Ove ćelije tretirane 
su ispitivanim jedinjenjima u rasponu koncentracija od 0.1 µM do 2 µM, odnosno u 
koncentracijama koje se u krvi mogu postići dijetarnim unosom antocijana. Podaci iz 
studija biološke raspoloživosti antocijana pokazuju da su ova jedinjenja kratko prisutna 
u cirkulaciji za razliku od njihovih metabolita (fenolnih kiselina i njihovih derivata) koji 
se u cirkulaciji mogu zadržati i do 48 sati nakon ingestije. Takođe, značajna koncentracija 
4-hidroksibenzaldehida uočena je u cirkulaciji ubrzo nakon ingestije radioizotopski 
obeleženog cijanidin-3-glukozida, što ukazuje na to da ovo jedinjenje verovatno nastaje 
razgradnjom antocijana u gornjem delu gastrointestinalnog trakta. U skladu sa 
navedenim, endotelne ćelije tretirane su antocijanima ili 4-hidroksibenzaldehidom tokom 
3 sata, a metabolitima mikroflore debelog creva (protokatehuinskom, ferulinskom, 
hipurnom i vanilinskom kiselinom) tokom 18 sati. Nakon pomenutih tretmana, 
inflamacija i aktivacija endotelnih ćelija indukovana je pomoću proinflamatornog 
citokina, faktora nekroze tumora alfa (TNFα). Po dodavanju monocita, njihova adhezija 
za endotelne ćelije merena je metodom protočne citometrije. Rezultati ovih ispitivanja 
pokazali su da je, sa izuzetkom 4-hidroksibenzaldehida, tretman endotelnih ćelija 
antocijanima i njihovim metabolitima doveo do značajnog smanjenja adhezije monocita 
za TNFα-aktivirane endotelne ćelije. Odnos doze i efekta ispitivanih jedinjenja uglavnom 
nije bio linearan, što je u skladu sa prethodno opisanim dejstvom polifenola na endotelne 
i druge tipove ćelija. Među ispitivanim antocijanima, delfinidin-3-glukozid doveo je do 
najvećeg smanjenja adhezije monocita za aktivirane endotlene ćelije, dok je među 
metabolitima najizraženiji efekat zabeležen nakon tretmana protokatehuinskom 
kiselinom. Uočeno dejstvo metabolita debelog creva bilo je slično dejstvu antocijana, što 
ukazuje na to da delovanjem bakterijske flore nastaju metaboliti koji mogu ispoljiti 
podjednako povoljan uticaj na endotelne ćelije kao i jedinjenja od kojih su potekli. 
Dodatno, ovi rezultati ukazuju na to da pored antocijana i njihovi metaboliti mogu 
doprineti kardioprotektivnom delovanju namirnica bogatih antocijanima. Pozitivno 
dejstvo antocijana na adheziju monocita za endotelne ćelije opisano je u ranijim 
istraživanjima. Ipak, ova istraživanja su koristila ekstrakate bogate antocijanima, ili 
aglikone i glikozide u visokim, fiziološki irelevantnim koncentracijama, sa dugim 
tretmanima ćelijama. Shodno tome, rezultati ove doktorske disertacije predstavljaju prve 
fiziološki relevantne podatke o uticaju ispitivanih antocijana na adheziju monocita za 
aktivirane endotelne ćelije. Uočeno pozitivno dejstvo protokatehuinske i ferulinske 
kiseline u skladu je sa prethodno opisanim uticajem ovih jedinjenja na adheziju monocita, 
dok je dejstvo hipurne i vanilinske kiseline uočeno po prvi put. 
U cilju ispitivanja mogućeg kumulativnog delovanja jedinjenja istovremeno prisutnih 
u cirkulaciji, pripremljene su dve smeše jedinjenja: smeša A (jedinjenja kratko prisutna u 
cirkulaciji) i smeša B (jedinjenja dugo prisutna u cirkulaciji). Smeša A sadržala je 
cijanidin-3-glukozid, cijanidin-3-arabinozid, cijanidin-3-galaktozid, delfinidin-3-
glukozid, peonidin-3-glukozid i 4-hidroksibenzaldehid. Finalna koncentracija jedinjenja 
smeše koja je dodavana endotelnim ćelijama iznosila je 0.1 µM za antocijane i 0.5 µM za 
4-hidroksibenzaldehid. Smeša B sadržala je protokatehuinsku, vanilinsku, ferulinsku i 
hipurnu kiselinu u finalnoj koncentraciji od 0.2 µM, 2 µM, 1 µM i 2 µM, redom. 
Koncentracije komponenata ovih smeša izabrane su tako da najbliže odgovaraju 
koncentracijama ovih jedinjenja zabeleženim u plazmi u studijama biološke 
raspoloživosti antocijana u ljudskom organizmu. Dodatno, tretman endotelnih ćelija 
smešom A, a potom smešom B (nazvan smeša A+B) kreiran je kako bi se što 
verodostojnije oponašali uslovi kojima su endotelne ćelije izložene tokom dužeg vremena 
nakon dijetarnog unosa antocijana. Rezultati ispitivanja dejstva smeša jedinjenja na 
adheziju monocita za aktivirane endotelne ćelije pokazali su takođe smanjenje adhezije. 
Ipak, aditivni efekat pojedinačnih komponenata smeša nije uočen. Ovi rezultati su u 
skladu sa prethodno opisanim odsustvom aditivnog efekta različitih polifenola i mogu se 
objasniti kompeticijom između komponenata smeše za isto mesto delovanja. 
Smeše antocijana i njihovih metabolita su potom korišćene za ispitivanje uticaja ovih 
jedinjenja na transendotelijalnu migraciju monocita. Rezultati ovih istraživanja pokazali 
su da je tretman endotelnih ćeilija pomenutim smešama jedinjenja doveo do značajnog 
smanjenja transendotelijalne migracije monocita indukovane hemoatraktantom, 
monocitinim hemotaksnim proteinom 1 (MCP-1). Ovi rezultati predstavljaju prve 
fiziološki relevantne dokaze pozitivnog dejstva antocijana i njihovih crevnih metabolita 
na transendotelijalnu migraciju monocita. 
Shodno navedenom, rezultati istraživanja dejstva antocijana i njihovih metabolita na 
adheziju i transendotelijalnu migraciju monocita ukazuju na to da ova jedinjenja mogu 
uticati na početne faze razvoja ateroskleroze. Ovo potencijalno anti-aterogeno dejstvo 
ispitivanih jedinjenja podržano je rezultatima studija na animalnim modelima 
ateroskleroze u kojima je uočeno smanjenje formiranja aterosklerotičnih lezija nakon 
suplementacije antocijanima bogatim ekstraktima. 
U cilju razmatranja mehanizama u osnovi uočenog pozitivnog dejstva antocijana i 
njihovih metabolita na adheziju monocita i njihovu transedneotelijalnu migraciju, ispitan 
je uticaj smeša ovih jedinjenja na ekspresiju gena u endotelnim ćelijama. Ova ispitivanja 
podrazumevala su upotrebu makroareja (еngl. Taqman Low Density Array) koji su 
omogućili istovremenu analizu nivoa ekspresije 93 različita gena. Analiza genske 
ekspresije u endotelnim ćelijama tretiranim navedenim smešama jedinjenja pokazala je 
promene u ekspresiji gena uključenih u regulaciju adhezije ćelija, reorganizacije 
aktinskog citoskeleta, fokalne adhezije i transmigracije leukocita. Stoga, zabeležena 
modulacija ekspresije gena u endotelnim ćelijama može predstavljati jedan od 
mehanizama preko kojih ispitivana jedinjenja ispoljavaju pozitivno dejstvo na procese 
adhezije i transendotelijalne migracije monocita. 
Ekspresija gena može biti regulisana transkripcionim faktorima čija je aktivnost pod 
uticajem signalnih puteva. Bioinformatička analiza rezultata genske ekspresije 
sprovedena je kako bi se otkrili transkripcioni faktori koji bi mogli doprineti uočenom 
delovanju ispitivanih jedinjenja na ekspresiju gena, kao i signalni proteini koji regulišu 
aktivnost ovih transkripcionih faktora. Dodatno, in silico analiza molekulskog uklapanja 
(molekulski doking) izvedena je kako bi se ispitale moguće interakcije antocijana i 
njihovih metabolita (liganada) sa ovim signalnim proteinima i transkripcionim faktorima. 
Molekulski doking predstavlja kompjutersku metodu koja se sve češće primenjuje u 
ispitivanju molekularnih mehanizama delovanja biološki aktivnih jedinjenja. U ovoj 
disertaciji izvedeno je molekulsko uklapanje liganada sa 62 makromolekula koji su 
uključeni u regulaciju različitih ćelijskih procesa poput inflamacije, ćelijske proliferacije, 
migracije i preživljavanja. Rezultati ovih analiza pokazali su da antocijanini i njihovi 
metaboliti mogu ostvariti interakcije sa signalnim proteinima. Takođe, pokazano je da 
antocijani mogu ostvariti snažnije interakcije sa ispitivanim signalnim proteinima nego 
njihovi metaboliti. U okviru grupe ispitivanih antocijana ili njihovih metabolita uočen je 
sličan afinitet vezivanja za ciljane makromolekule, što ide u prilog hipotezi da je 
nedostatak aditivnog efekta pojedinačnih jedinjenja smeša rezultat njihove kompeticije 
za isto mesto delovanja. Rezultati molekulskog dokinga ukazuju na to da antocijani i 
njihovi metaboliti mogu ostvariti interakcije sa katalitičkim domenom nekoliko 
proteinskih kinaza (npr. FAK1, MEK2, IKKα, JAK3, p38β) i da potencijalno mogu 
uticati na njihovu kinaznu aktivnost i aktivaciju nishodnih signalnih molekula. Podaci iz 
literature pokazuju da vezivanje različitih inhibitora za katalitički domen ovih proteinskih 
kinaza dovodi do inhibicije njihove aktivnosti koja potom može dovesti do smanjenja 
adhezije i transendotelijalne migracije leukocita za endotelne ćelije. U cilju potvrde 
rezultata molekulskog dokinga u in vitro uslovima, uticaj antocijana i njihovih metabolita 
na signalne puteve ispitan je imunobloting (engl. Western blot) analizom. Tretman 
endotelnih ćelija smešom A doveo je do smanjenja fosforilacije signalnog proteina 
ERK1/2 kao i transkripcionog faktora NF-κB-p65, dok je smeša B uticala na smanjenje 
fosforilacije NF-κB-p65. Shodno navedenom, rezultati istraživanja uticaja antocijana i 
njihovih metabolita na signalne puteve ukazuju na to da ova jedinjenja vezivanjem za 
različite signalne proteine mogu uticati na njihovu aktivnost, i aktivaciju nishodnih 
signalnih molekula i transkripcionih faktora, dovodeći do promena u nivou ekspresije 
gena koje mogu uticati na procese adhezije i transedotelne migracije monocita.  
Pored regulacije na transkripcionom nivou, ekspresija gena može biti regulisana i na 
posttranskripcionom nivou pomoću mikro-RNK. Ovi nekodirajući molekuli RNK 
uključeni su u kontrolu različitih ćelijskih procesa, a promene profila njihove ekspresije 
uočavaju se kod različitih oboljenja, uključujući kardiovaskularne bolesti. Sposobnost 
antocijana ili njihovih metabolita da utiču na ekspresiju mikro-RNK uočena je u nekoliko 
in vivo studija, dok su in vitro ispitivanja i dalje ograničena. U ovoj doktorskoj disertaciji 
dejstvo antocijana i njihovih metabolita na ekspresiju mikro-RNK ispitano je pomoću 
mikro-RNK mikroareja. Rezultati ovih ispitivanja pokazali su, po prvi put, sposobnost 
antocijana i njihovih metabolita da, pri fiziološki relevantnim koncentracijama, 
moduliraju ekspresiju mikro-RNK u aktiviranim endotelnim ćelijama. Ispitivana 
jedinjenja posebno su uticala na promenu ekspresije mikro-RNK povezanih sa nastankom 
endotelne disfunkcije i ateroskleroze (npr. let-7f, miR-181b, miR-125a i miR-26a), 
doprinoseći uočenim promenama endotelne funkcije. Stoga, navedeni rezultati ukazuju 
na to da modulacija ekspresije mikro RNK predstavlja još jedan mehanizam pomoću kog 
ova jedinjenja mogu ispoljiti svoje povoljno dejstvo na kardiovaskularno zdravlje. 
Pored ispitivanja uticaja antocijana i njihovih metabolita na funkciju endotelnih ćelija, 
u okviru ove doktorske disertacije, istraženo je i njihovo dejstvo na funkciju trombocita. 
Ova istraživanja imala su zadatak da ispitaju uticaj pomenutih jedinjenja na aktivaciju 
trombocita i njihovu agregaciju sa leukocitima, indukovanu dodavanjem adenozin-
difosfata. Adenozin-difosfat je fiziološki agonist deponovan u gustim granulama 
trombocita iz kojih se oslobađa po njihovoj aktivaciji. Rezultati prospektivnih studija 
ukazuju na vezu između stepena reaktivnosti trombocita kao odgovora na niske 
koncentracije adenozin-difosfata i kardiovaskularnog rizika. Ovim se racionalizuje 
ispitivanje uticaja antocijana i njihovih metabolita na aktivaciju i agregaciju trombocita 
indukovanu ovim agonistom kao potencijalnog ciljanog mehanizma za prevenciju 
kardiovaskularnih bolesti. Uzorci pune krvi dobijene venepunkcijom sedam zdravih 
volontera muškog pola inkubirani su sa antocijanima u finalnoj koncentraciji od 0.1µM, 
kao i 4-hidroksibenzaldehidom, protokatehuinskom, vanilinskom, ferulinskom ili 
hipurnom kiselinom u finalnoj koncentraciji od 0.5 µM, 0.2 µM, 2 µM, 1 µM i 2 µM, 
redom. Nakon ovoga, uzorci su aktivirani dodavanjem adenozin-difosfata, obeležavani 
odgovarajućim antitelima i analizirani primenom protočne citometrije. Uticaj navedenih 
jedinjenja na funkciju trombocita određivan je merenjem ekspresije aktivacionih markera 
P-selektina i GPIIb/IIIa, kao i agregata trombocita sa neutrofilima i monocitima. P-
selektin je adhezioni molekul, prisutan u alfa granulama trombocita, koji nakon aktivacije 
trombocita dospeva na njihovu površinu i posreduje u agregaciji sa neutrofilima i 
monocitima vezivanjem za svoj ligand PSGL-1 na površini ovih ćelija. Aktivacija 
trombocita povezana je i sa konformacionom aktivacijom GPIIb/IIIa, receptora za 
glikogen, koji osim što ima važnu ulogu u agregaciji trombocita sa drugim trombocitima,  
doprinosi i formiranju agregata sa leukocitima. Primena protočne citometrije u analizi 
uzoraka pune krvi omogućila je visok stepen osetljivosti u merenju pomenutih markera,  
te dobijanje pouzdanih rezultata koji se mogu isključivo pripisati direktnom dejstvu 
ispitivanih jedinjenja na funkciju trombocita. Rezultati ovih istraživanja pokazali su da 
sa izuzetkom vanilinske kiseline, kako antocijani tako i njihovi metaboliti ispoljavaju 
značajno dejstvo na bar jedan od ispitivanih parametara tj. aktivaciju trombocita ili 
njihovu agregaciju sa leukocitima. Ovi rezultati ukazuju na to da prethodno opisani, 
povoljni efekti namirnica bogatih antocijanima mogu biti posledica zajedničkog 
delovanja antocijana i njihovih metabolita na funkciju trombocita. Među ispitivanim 
antocijanima, najizraženije delovanje na funkciju trombocita ispoljio je cijanidin-3-
arabinozid, koji je značajno smanjio procenat trombocita koji eksprimiraju P-selektin, 
gustinu ovog receptora na trombocitima, kao i agregaciju trombocita sa neutrofilima. 
Nasuprot ovome, peonidin-3-glukozid, delfinidin-3-glukozid i cijanidin-3-glukozid 
ispoljili su značajano dejstvo na aktivaciju trombocita preko smanjenja ekspresije P-
selektina ili GPIIb/IIIa, dok je cijanidin-3-galaktozid značajno uticao samo na agregaciju 
leukocita sa trombocitima. Među metabolitima antocijana, 4-hidroksibenzaldehid 
delovao je na najveći broj ispitivanih parametara, izazivajući značajno smanjenje 
aktivacije trombocita i njihove agregacije sa neutrofilima i monocitima. Ovaj metabolit 
predstavlja jedino ispitivano jedinjenje koje nije ispoljilo značajano dejstvo na adheziju 
monocita za aktivirane endotelne ćelije. Shodno tome, ovi rezultati ukazuju na to da, iako 
ne utiče na funkciju endotelnih ćelija, 4-hidroksibenzaldehid preko delovanja na 
trombocite može indirektno uticati na smanje interakcija leukocita sa endotelnim ćelijama 
i na taj način štititi od razvoja ateroskleroze. Ograničen broj dostupnih literaturnih 
podataka o dejstvu antocijana i njihovih metabolita na aktivaciju trombocita i njihovu 
agregaciju sa leukocitima u in vitro uslovima doprinosi značaju rezultata dobijenih u ovoj 
doktorskoj disertaciji. Delovanje antocijana poput peonidin-3-glukozida, cijanidin-3-
galaktozida i cijanidin-3-arabinozida, kao i metabolita 4-hidroksibenzaldehida i 
vanilinske kiseline na aktivaciju trombocita, nije ranije ispitivano. Pored ovoga, posebno 
je značajno što je u okviru ovih istraživanja po prvi put pokazano dejstvo antocijana i 
njihovih metabolita na agregaciju trombocita sa leukocitima, koja u odnosu na aktivaciju 
trombocita predstavlja još osetljiviji pokazatelj rizika od nastanka kardiovaskularnih 
bolesti. 
Na osnovu izloženih rezultata ove disertacije može se doneti nekoliko zaključaka. 
Antocijani i njihovi metaboliti dovode do značajnog smanjenja adhezije monocita i 
njihove transendotelijalne migracije, procesa koji predstavljaju inicijalne korake u 
nastanku ateroskleroze, na taj način doprinoseći održanju integriteta endotela prilikom 
zapaljenskog procesa. Uočeno dejstvo na funkciju endotelnih ćelija posledica je složenih 
molekularnih mehanizmima delovanja, poput sposobnosti ispitivanih jedinjenja da utiču 
na ekspresiju mikro RNK, kao i da se vežu za ćelijske signalne proteine i utiču na njihovu 
aktivnost i aktivaciju transkripcionih faktora, dovodeći do promena na nivou ekspresije 
gena. Pored efekta na endotelne ćelije, ispitivana jedinjenja ispoljavaju povoljno dejstvo 
i na funkciju trombocita, izraženo smanjenjem aktivacije trombocita i njihove agregacije 
sa leukocitima, kao procesa koji značajno doprinose nastanku kardiovaskularnih bolesti. 
U skladu sa izloženim, ova doktorska disertacija pokazala je pozitivan uticaj antocijana i 
njihovih metabolita, u fiziološki relevantnim koncentracijama, na funkciju endotelinih 
ćelija i trombocita, i time, pružila nova saznanja o mehanizmima njihovog 
kardioprotektivnog delovanja. 
 Ključne reči: antocijani, metaboliti, endotelna disfunkcija, adhezija monocita za 
endotelne ćelije, transendotelna migracija, aktivacija trombocita, agregacija trombocita 
sa leukocitima. 
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 1 
1.& INTRODUCTION 
1.1.& Cardiovascular diseases 
Cardiovascular diseases (CVD) are a group of disorders that affect heart and blood 
vessels. They include coronary heart disease, cerebrovascular disease and peripheral 
artery disease and represent the leading cause of mortality worldwide (Mendis et al. 
2011). The latest statistics show that in Europe CVD account for 3.9 million deaths each 
year or 45% of the total number of deaths. The incidence and prevalence of CVD are 
significant with around 11 million new cases per year and more than 85 million CVD 
cases reported in European population in 2015 (Wilkins et al. 2017). There are several 
risk factors connected with the development of CVD. They include non-modifiable risk 
factors such as age, sex, ethnicity and genetic background, and factors that can be treated 
or changed such as high blood pressure (hypertension), high cholesterol levels 
(dyslipidemia), diabetes, obesity, smoking, harmful use of alcohol, physical inactivity 
and unhealthy diet (Mendis et al. 2011). Of these risk factors, modifiable factors such as 
hypertension and dietary factors make the most significant contribution to CVD 
morbidity and mortality (Yusuf et al. 2004; Cassidy et al. 2016; Wilkins et al. 2017). 
Atherosclerosis presents the common underlying pathology for most of the CVD. 
This chronic inflammatory condition is characterised by atherosclerotic lesions formed 
by accumulation of lipids, cellular and fibrous elements in the wall of large and medium-
sized arteries. The early atherosclerotic lesions (i.e. fatty streak) consist of subendothelial 
accumulations of cholesterol-loaded macrophages, named foam cells, while more 
advanced lesions are composed of smooth muscle cells and lipid-rich necrotic debris (i.e. 
fibrous lesions). Over the years, these lesions can become increasingly complex, 
disturbing the blood flow and in the most severe cases, the plaque rupture and thrombosis 
can result in myocardial infarction (MI) or stroke (Lusis 2000; Libby et al. 2011). 
The development of atherosclerosis is the result of the complex interplay between the 
endothelium of the blood vessel wall and circulating leukocytes and platelets. The role of 
these cells and their interactions will be detailed in the following sections. 
1.1.1.& The role of endothelium in CVD 
Endothelium presents a single layer of endothelial cells lining the blood vessels and 
maintaining vascular homeostasis. It plays a pivotal role in preserving the vascular tone 
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by balancing the release of vasodilators (e.g. nitric oxide) and vasoconstrictors (e.g. 
endothelins) and regulates blood flow and coagulation process by secreting factors that 
affect platelet activity, blood clotting and fibrinolysis (Widlansky et al. 2003). It also 
controls inflammatory processes through the expression of various cytokines and 
adhesion molecules that mediate the recruitment of circulating inflammatory cells. This 
endothelial activation is required for adequate neutralisation of pathogens. Under 
homeostatic conditions, vascular endothelium provides a non-adhesive and non-
coagulant blood-tissue barrier and secrets no or little proinflammatory molecules. 
However, during chronic inflammation and oxidative stress (i.e. the imbalance between 
reactive oxygen species (ROS) production and antioxidant defence) that are initiated by 
cardiovascular risk factors such as dyslipidemia, hypertension, or hyperglycemia, the 
endothelium becomes continuously activated. This activated endothelium is characterised 
by reduced vasodilatation (decrease in nitric oxide), prothrombic and proinflammatory 
properties and altered permeability (Bonetti et al. 2003; Brevetti et al. 2008). Increased 
endothelial permeability promotes the entry and retention of cholesterol-containing low-
density lipoprotein (LDL) particles in the vessel wall, where they can undergo chemical 
modification (oxidation) and further stimulate endothelial cells to express 
proinflammatory factors (Osterud & Bjorklid 2003; Libby et al. 2011). Activated 
endothelium expresses inflammatory cytokines such as monocyte chemoattractant 
protein-1 (MCP-1), tumour necrosis factor alpha (TNFα) and interleukins (e.g. IL-1β, IL-
6) as well as the adhesion molecules that promote the adhesion of circulating leukocytes 
and their subsequent transmigration into the blood vessel wall (Figure 1). In the 
subendothelium, monocytes (the most numerous recruited leukocytes) differentiate into 
macrophages, take up modified LDL and form foam cells. These cells also release 
proinflammatory agents that additionally promote leukocyte recruitment, transmigration, 
and foam cell formation, subsequently leading to the development of early atherosclerotic 
lesions (Libby et al. 2011). 
 3 
 
Figure 1. Early events in the development of atherosclerosis, from Libby et al. 2002. 
These data show that the alteration of endothelial cell function and the consequent 
repetitive recruitment of circulating leukocytes into the vascular wall are the dominant 
features of atherosclerosis development that contribute to the progression of CVD. Due 
to their unique role as sensors and contributors to disturbed vascular homeostasis and 
associated diseases, the endothelial cells present the interesting target for exploring 
prevention of CVD. 
1.1.1.1.&Leukocyte adhesion and transendothelial migration 
The processes of adhesion of leukocytes to activated endothelial cells and their 
transmigration into the subendothelial space are mediated by different adhesion 
molecules and cytokines. They begin with the capture of circulating white blood cells and 
their subsequent rolling on the endothelium of the vascular wall, both mediated by 
selectins (Figure 2). The inflamed endothelium expresses P-selectin and E-selectin, the 
most significant capture and rolling adhesion molecules, while most of the leukocytes 
express L-selectin. All of these molecules bind to glycosylated P-selectin glycoprotein 
ligand 1 (PSGL1), and E-selectin can additionally bind to glycosylated E-selectin ligand 
1 (ESL1) and CD44 glycoprotein on leukocytes. Binding interactions between selectins 
and their ligands have remarkably fast on and off rates (i.e. bond association and 
dissociation rates) that allow the initial capture of circulating leukocytes and their labile 
rolling interactions with the endothelium (Ley et al. 2007). The purpose of rolling is to 
bring leukocyte in contact with the different chemotactic cytokines (chemokines) such as 
MCP-1 and IL-8, associated with proteoglycans located on the surface of endothelial cells 
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(Gerszten et al. 1999; Muller 2013). Binding of chemokines to their receptors on the 
leukocyte surface (G protein-coupled receptors) triggers the complex intracellular 
signalling that leads to rapid activation of leukocyte integrins and subsequent arrest of 
leukocyte rolling. Integrins belonging to the β1-integrin and β2-integrin subfamilies, such 
as the late antigen 4 (VLA-4) and lymphocyte function-associated antigen 1 (LFA-1) are 
the most relevant for the leukocyte arrest. Their intracellular activation results in a 
conformational change that favours tight binding of their ligands, i.e. immunoglobulin 
superfamily members such as vascular cell adhesion molecule 1 (VCAM-1) and 
intercellular adhesion molecule 1 (ICAM-1) that are expressed in a significant number on 
the surface of activated endothelial cells (Ley et al. 2007). The tight binding of VCAM-
1 to VLA-4 and ICAM-1 to LFA-1, arrests monocytes on the endothelial surface, 
allowing them to subsequently spread, polarise and move laterally to find preferred sites 
of transmigration (Gerhardt & Ley 2015). 
Figure 2. Multistep process of leukocyte adhesion and transendothelial migration. Adapted 
from Ley et al. 2007. 
Transmigration can occur either through the cytoplasm of endothelial cells 
(transcellular transmigration) or between endothelial cells (paracellular transmigration), 
with the majority of transmigration events happening paracellularly. Unique finger-like 
endothelial cell projections, rich in clustered ICAM-1 and VCAM-1 adhesion molecules, 
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actin and actin-binding proteins, are believed to strengthen leukocyte-endothelial 
interactions and play a guiding role in leukocyte transmigration (Schnoor 2015). These 
structures named docking structures or transmigratory cups are created in response to 
initial endothelial binding to LFA-1 and VLA-4, partially wrapping the migrating 
leukocytes. Binding of leukocytes to clustered ICAM-1 and VCAM-1 activates several 
cell signalling proteins involved in cytoskeleton reorganisation such as Rac family small 
GTPase 1 (RAC1), SRC proto-oncogene, non-receptor tyrosine kinase (SRC) and Ras 
homolog gene family member A (RHOA) that promote loosening of endothelial cell 
junctions and paracellular transmigration (van Buul & Hordijk 2004; Hordijk 2006). 
Endothelial junctions include tight junctions, adherens junctions and gap junctions 
that are crucial for maintaining the endothelial integrity and regulation of vascular 
permeability. Gap junctions mediate the direct exchange of ions and small molecules 
between two cells, while tight and adherens junctions, formed by a complex and dynamic 
network of transmembrane proteins, allow the regulated leukocyte passage (Bazzoni 
2004). On its paracellular transmigration route leukocyte first faces tight junctions formed 
by transmembrane proteins like claudins, occludins and proteins belonging to a family of 
junctional adhesion molecules (JAM) that establish close contact between cells. 
Activation of RHOA, induced by ICAM-1 and VCAM-1 interactions with their leukocyte 
ligands, leads to the formation of actin-myosin fibres (stress fibres) and cell contraction 
that loosens cell junctions, increases inter-cellular space and promotes transmigration. 
The family of JAM proteins have been shown to actively participate in the leukocyte 
transendothelial migration by interacting with corresponding integrins on the leukocyte 
surface. Furthermore, vascular endothelial cadherin also known as cadherin 5 (CDH5), a 
transmembrane protein of adherens junction, is shown to be highly important for 
leukocyte transmigration by acting as a gatekeeper. This protein interacts in a homophilic 
way (i.e. the molecule on one cell interacts with the identical molecule on the other cell) 
attaching the cell membranes to intracellular networks of catenins and actin 
microfilaments. Activation of RAC1 and SRC signalling proteins leads to 
phosphorylation of CDH5, its subsequent dissociation from catenins and removal from 
the junction allowing leukocyte passage. Other junctional molecules such as platelet 
endothelial cell adhesion molecule (PECAM-1) and CD99 glycoprotein have also been 
shown to participate in transmigration. These proteins, enriched at endothelial cell 
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junctions and expressed diffusely on the leukocyte surface, facilitate transmigration by 
homophilic binding between the molecules on the two cells (Muller 2011; Muller 2013; 
Gerhardt & Ley 2015). It was recently shown that binding of PECAM-1 could also 
activate a unique transmigration complex that is actively transported to the site of 
transmigration by kinesin-microtubule motors. This transmigration complex named the 
lateral border recycling compartment (LBRC) is composed of subjunctional, intracellular 
endothelial membrane reticulum, rich in PECAM-1, CD99 and JAM proteins, 
surrounding the transmigrating cell. Homophilic binding of PECAM-1 triggers rapid, 
recycling of PECAM-1-bearing membrane to the transmigration site, supplying the 
migrating cell with functional molecules required to allow its transmigration (Gerhardt & 
Ley 2015). However, the physiological relevance of LBRC still needs to be shown in 
vivo. 
Cell-cell interactions play an essential role in transendothelial migration. Specialized 
structures named focal adhesions are formed at these contact points. In these structures, 
actin filaments attach to integrin transmembrane receptors through a complex of various 
junctional proteins. Some of the proteins of focal adhesions present the structural 
connections between membrane receptors and the actin cytoskeleton, such as vinculin, 
talin, tensin, and paxillin, while others are signalling molecules like focal adhesion kinase 
(FAK) and protein kinase C (PKC). Binding to cell integrins results in a conformational 
change in their extracellular domains and activation of associated signalling molecules 
that lead to reorganisation of the actin cytoskeleton and consequent changes in the cell 
shape that allow cell movement (van Buul & Hordijk 2004; Hordijk & van Buul 2009). 
Taken together, the recruitment of circulating monocytes, their adhesion to activated 
endothelium and subsequent transendothelial migration present the complex multistep 
processes that involve various adhesion molecules, chemokines, and signalling pathways 
and constitute the initial, key steps in the atherosclerosis development. 
1.1.2.&The role of platelets in CVD 
Platelets are anuclear, discoid cell fragments formed from the cytoplasm of bone 
marrow megakaryocytes that in the resting state circulate in the bloodstream with the 
lifespan of seven to ten days. They contribute to the preservation of vascular integrity 
through their essential role in hemostasis, i.e. a natural process of preventing blood loss 
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at sites of mechanical blood vessel injury. This process involves rapid adhesion of 
platelets to the exposed endothelial cell matrix of an injured blood vessel, their activation 
and aggregation and a formation of a platelet plug that seals the damaged vessel wall. By 
contrast, in pathological conditions, such as atherosclerosis, platelet activity can lead to 
thrombosis, an exaggerated hemostatic response that obstructs the blood flow and can 
lead to stroke and myocardial infarction (Willoughby et al. 2002). In addition to the late 
stage thrombotic complications of atherosclerosis, platelets also play a key role as 
inflammatory mediators in the development of early atherosclerotic lesions. This function 
is achieved by interactions of activated platelets with monocytes, neutrophils, and 
endothelial cells, either directly, through their surface adhesion molecules, or indirectly, 
through various proinflammatory factors secreted from activated platelets (van Gils et al. 
2009; Aukrust et al. 2010). 
Platelet function in physiological and pathological conditions is based on their 
specific morphological characteristics. As anuclear cell fragments, platelets possess a 
large number of pre-synthesised molecules and some specialised structures that allow 
them to respond to altered environmental conditions and achieve their function rapidly. 
These molecules of high importance for hemostatic and inflammatory processes are 
stored in platelets’ alpha and dense granules. Alpha granules are rich in membrane 
glycoproteins (e.g. P-selectin, integrin αIIb3, PECAM-1), adhesion molecules (e.g. Von 
Willebrand factor (vWF), fibrinogen, fibronectin), various chemokines and cytokines 
(e.g. MCP-1, platelet factor 4 (PF-4), macrophage inflammatory protein 1α, C-C Motif 
Chemokine Ligand 5 (CCL5), IL-1 and IL-8), clotting and fibrinolytic factors and their 
inhibitors (e.g. factor V, plasminogen and plasminogen activator inhibitor 1) as well as 
growth factors (e.g. platelet-derived growth factor, transforming growth factor  β1, 
insulin-like growth factor-1, and vascular endothelial growth factor), while dense 
granules contain platelet agonist adenosine diphosphate (ADP), other nucleotides and 
calcium ions (Nurden 2011; Schnoor 2015). Binding of platelet agonist such as ADP, 
thrombin, prostaglandins or chemokines to their receptors on the surface of resting 
platelets triggers cell signalling that leads to platelet activation characterised by changes 
in platelet shape (formation of multiple pseudopodia), expression of specific surface 
receptors and release of platelet granule content. The specific receptors such as P-selectin 
or an active form of glycoprotein IIb/IIIa (GPIIb/IIIa, synonym integrin αIIbβ3) appear 
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on the surface of activated platelets and allow their direct interactions with leukocytes 
and endothelium. P-selectin is a glycoprotein that is stored in the α granules of resting 
platelets. Upon platelet activation, P-selectin is translocated from α granules to the 
platelet surface where it binds to its ligand PSGL-1 expressed on leukocytes and 
endothelial cells, thus mediating the initial contact with these cells. Additionally, platelet 
activation is associated with a conformational change in the GPIIb/IIIa, an integrin family 
member exclusively expressed by platelets. On the surface of resting (non-activated) 
platelets, this protein is present in the inactive state. However, binding of platelet agonist 
induces cell signalling that leads to its activation and increased affinity and avidity for its 
ligands fibrinogen and vWF. Aside from its role in platelet-platelet aggregation during 
hemostasis, this protein is also important in mediating the firm platelet adhesion to 
leukocytes and endothelial cells (Jennings 2009; Aukrust et al. 2010). 
In inflammatory conditions, the interaction between platelets and activated 
endothelium is usually initiated by the endothelial release of platelet binding and 
stimulating agents, such as ADP and vWF that promote platelet activation and adhesion 
to endothelium. Stable complex of platelets and activated endothelial cells stimulates 
secretion of platelet-derived molecules such as PF4, CCL5 and IL-1β. These molecules 
further induce the inflammatory responses in endothelial cells such as the expression of 
adhesion molecules (e.g. E-selectin, VCAM-1, ICAM-1) and various chemokines and 
cytokines (e.g. MCP-1, IL-8 and IL-6) that promote leukocyte adhesion to endothelium 
and their transmigration (Gawaz et al. 2000; Gawaz et al. 2005; Yu et al. 2005). 
Additionally, adhered platelets contribute to these processes by their direct involvement 
in leukocyte rolling and arrest. This is achieved by binding of P-selectin on the adhered 
platelets with its leukocyte ligand PSGL-1 (Kuijper et al. 1998) as well as by deposing 
platelet-derived chemokines on the endothelial cell surface, which induces leukocyte 
arrest and strengthens its adhesion to endothelium (von Hundelshausen et al. 2001). 
Inflammatory conditions also promote aggregation of activated platelets with 
circulating leukocytes. The extent of formation of these aggregates is dependent on the 
extent of platelet activation. The platelet-leukocyte aggregates (PLA) have been reported 
in clinical conditions such as hypertension, acute or stable coronary syndromes, MI, 
stroke and diabetes (Furman et al. 2001; Nomura et al. 2002; McCabe et al. 2004; Elalamy 
et al. 2008). They present a sensitive marker for in vivo platelet activation and are 
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increasingly considered as the biomarker of CVD (van Gils et al. 2009). The binding of 
activated platelets to leukocytes as well as the deposition of platelet-derived molecules 
on leukocyte surface leads to increased expression and activation of leukocyte integrins 
(CD11b/CD18 and VLA-1) and secretion of proinflammatory agents like TNFα, IL-8, 
and MCP-1, further promoting inflammation and leukocyte recruitment (van Gils et al. 
2009). Binding of platelets to leukocytes decreases the velocity of rolling on activated 
endothelium thus increasing the probability of leukocyte arrest and firm adhesion. These 
aggregates also show increased transmigration when compared to platelet-free leukocytes 
(Martins 2005; van Gils et al. 2008). During the transmigration, platelets are removed 
from leukocytes by mechanical stress and deposed on the endothelium, suggesting that 
the lifespan of PLA is at least partly associated with the leukocyte adhesion and 
transmigration process. 
These data show that platelet activation and aggregation are important features of the 
development of atherosclerosis and CVD (Figure 3). Therefore, in addition to endothelial 
cells, platelets present the attractive targets for exploring susceptibility to CVD and their 
prevention. 
 
Figure 3. A summary of platelet effects that contribute to the development of atherosclerosis, 
from Lievens and von Hundelshausen 2011. 
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1.2.& Diet and cardiovascular health 
Diet is an important factor in the promotion and maintenance of health. It plays a 
major role in the development and progression of CVD, but can also, together with 
physical activity, present an important lifestyle modification for the prevention and 
management of CVD (Perk et al. 2012; Eckel et al. 2014). The evidence on the association 
between diet and CVD arises mainly from epidemiological cohort studies investigating 
the relationship between dietary patterns (overall diet) or specific foods and CVD 
outcomes, as well as from randomised controlled trials (RCT) usually assessing the effect 
on surrogate markers of CVD risk (e.g. endothelial dysfunction, hypertension, lipid 
profiles). Results from two recent meta-analyses of prospective cohort studies have 
shown an increased risk of CVD for a Western-type diet, i.e. a diet characterised by high 
intake of red and processed meat, refined grains, salty snacks, sweets and high-fat dairy 
products (Hou et al. 2015; Zhang et al. 2015). Also, these studies showed an inverse 
association between CVD risk and a healthy diet, i.e. a diet rich in fruit, vegetables and 
fish, moderate in alcohol and low in meat and dairy products (Figure 4). 
Figure 4. Meta-analysis of studies examining the associations of healthy diet with CVD risk, 
from  Zhang et al. 2015. 
Regarding healthy diets, the Mediterranean diet (i.e. characterised by high intake of fruits, 
vegetables, vegetable oils, whole grains, moderate alcohol consumption and low intake 
of animal products) has been associated with a reduced risk of cardiovascular mortality 
and decreased endothelial dysfunction and inflammation (Schwingshackl & Hoffmann 
2014; Grosso et al. 2017). Furthermore, other healthy diets such as the Nordic diet, based 
on bilberries, whole grains, and fish, have also been reported to improve endothelial 
function and decrease inflammation (De Mello et al. 2011). 
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The important constituents of these healthy diets are fruits and vegetables. The 
consumption of these foods has been associated with the lower incidence of CVD and 
stroke based on evidence from numerous epidemiological studies and several meta-
analyses (Dauchet et al. 2006; Gan et al. 2015; Sala-Vila et al. 2015). Two recent meta-
analyses of cohort studies (Hu et al. 2014; X. Wang et al. 2014) reported a 5% and 4% 
reduction in risk of CVD mortality for each additional serving/day of fruits and 
vegetables, respectively, as well as the reduced risk of stroke by 32% for each 200 g/day 
increase in fruit consumption or by 11% for the same increase in vegetable consumption. 
Also, several dietary interventions have shown that specific fruits, vegetables and derived 
products such as berries, citrus fruits, cocoa, leafy vegetables, juices and wine, may exert 
beneficial effects on different markers of CVD (Dohadwala & Vita 2009; Galleano et al. 
2009; Basu, Rhone, et al. 2010; Zheng et al. 2017). These observations underline the 
general recommendations for consuming at least 400 g of fruits and vegetables per day 
(FAO/WHO 2004). 
Despite convincing evidence of beneficial health effects of fruits and vegetables, their 
key constituents and the precise mechanisms by which these foods exert health effects 
are still not well established. Health-promoting properties of fruits and vegetables could 
be attributed not only to their low-calorie value but also to the high levels of fibre, 
essential micronutrients and bioactive compounds like polyphenols. Increasing body of 
evidence suggests that polyphenols can indeed underlie or contribute to cardiovascular 
health benefits associated with diets rich in fruits and vegetables (Morand et al. 2011; 
Rodriguez-Mateos et al. 2014; Medina-Remón et al. 2017). 
1.2.1.&Dietary polyphenols 
Polyphenols are the biggest and widely distributed group of phytochemicals, 
abundantly present in the human diet. In plants, these molecules are involved in 
pollination and seed dispersal as well as protection against herbivores, microorganisms 
and ultraviolet radiation (Chalker-Scott 1999). In plant-food, polyphenols contribute to 
organoleptic characteristics, such as smell, taste (e.g. bitterness, astringency) and colour 
(Pandey & Rizvi 2009). They are regularly consumed in fruits, vegetables, cereals and 
plant-derived beverages such as wine, fruit juices, herbal tea, and coffee, with an 
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estimated intake of more than 1 g/day (Pérez-Jiménez et al. 2011; Zamora-Ros et al. 
2016). 
Polyphenols are structurally highly diverse compounds, with more than 8000 different 
phenolic structures identified in plants. They are characterised by the presence of phenolic 
rings, i.e. aromatic rings with one or more hydroxyl groups attached (Tsao 2010). 
Depending on the number of phenolic rings and structural elements connecting these 
rings, polyphenols are classified into four major groups: phenolic acids, lignans, stilbenes, 
and flavonoids (Figure 5). Of these, phenolic acids and flavonoids are the most abundant 
polyphenols in the human diet, accounting for almost one-third and two-thirds of total 
polyphenol intake, respectively (Scalbert & Williamson 2000). By contrast, stilbenes and 
lignans are in the human diet present only in low quantities, due to their low contents in 
foods or a limited number of food sources. 
Figure 5. Major polyphenol groups 
Phenolic acids are a polyphenol group that includes hydroxybenzoic and 
hydroxycinnamic acids and their derivatives (Figure 5). Hydroxycinnamic acids (e.g. 
caffeic, ferulic and p-coumaric acids) occur in high quantities in many regularly 
consumed foods (0.5- 2.4 g/kg FW), such as fruits, especially pomes and berries, coffee 
and cereals, therefore presenting the most abundant polyphenols in the human diet (El-
Seedi et al. 2012). Hydroxybenzoic acids (e.g. gallic, vanillic, protocatechuic acid 
(PCA)), both free and esterified, are in plant foods present in low quantities, except in 
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certain berry fruits (e.g. raspberries, blackberries and blackcurrants), black radish and 
onions (Del Rio et al. 2013). 
Flavonoids present the largest and most studied polyphenol group, widely distributed 
in plants. Chemically these compounds are characterised by two benzene rings (rings A 
and B) linked with a heterocyclic pyrane ring (ring C) (Figure 5). Depending on the level 
of oxidation and substitution pattern of the C-ring these compounds can be further 
classified as isoflavones (abundant in cereal grains), flavones (parsley, celery, broccoli), 
flavonols (broccoli, onion, tomato, tea), flavanones (citrus fruits and beverages), 
flavanols (cocoa, tea, fruits, wine) and anthocyanins (berry fruits and wines) (Figure 6). 
 
Figure 6. Flavonoids and their dietary sources, from Pan et al. 2010. 
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1.2.2.&Dietary polyphenols and CVD 
The effects of polyphenols, especially flavonoids, on cardiovascular health have been 
intensively studied, and still present an active field of scientific research. Data from 
numerous epidemiological, clinical, animal and mechanistic in vitro studies support the 
protective role of these compounds against the development of CVD (Chanet et al. 2012; 
Del Rio et al. 2013; Rodriguez-Mateos et al. 2014). It has been shown that polyphenols 
can exert anti-inflammatory, antioxidant and antithrombotic activates that can contribute 
to their cardioprotective effects (Pandey & Rizvi 2009; A.N. Li et al. 2014). This range 
of polyphenol biological activities could be explained by their ability to act trough 
different complex non-specific and/or specific mechanisms. First are based on the ability 
of polyphenols to interact with plasma membranes, leading to changes in their structure 
and physical characteristics that could affect cell function. Second concern the particular 
structural and conformational characteristics of specific polyphenols and their biological 
targets, including their ability to modulate enzyme activities and interact with receptors 
or transcription factors affecting gene expressions (Fraga et al. 2010; Krga et al. 2016). 
Since this thesis focuses on anthocyanins, the characteristics of this group of 
polyphenols and their effects on cardiovascular health are further detailed. 
1.3.& Anthocyanins and cardiovascular health 
Anthocyanins (of the Greek anthos = flower and kyáneos = blue) are water-soluble 
plant pigments, responsible for the red, purple and blue colouration of many fruits, 
flowers and leaves. Additionally, they can be found in other plant tissues such as stems, 
roots, bulbs and tubers (Andersen & Jordheim 2010). 
The interest in these compounds has dramatically increased over the past two decades 
due to diverse health-promoting effects associated with the consumption of anthocyanin-
rich plant foods. Anthocyanins have been associated with the prevention of CVD, 
neurodegenerative diseases and cancer as well as vision improvements (Jing et al. 2008; 
Wallace 2011; Arfan et al. 2012; Subash et al. 2014). 
Good knowledge of anthocyanin chemistry, dietary sources and fate in the human 
body (i.e. absorption, distribution, and metabolism) is a prerequisite for understanding 
the role of anthocyanins in the prevention of CVD, their biological effects and underlying 
mechanisms of action. An overview of these aspects is given in the following sections. 
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1.3.1.&Chemical structure and characteristics of anthocyanins 
Anthocyanins are glycosylated, polyhydroxy or polymetoxy derivatives of flavylium 
cation (2-phenylchromenylium). To date, there are 702 different anthocyanins and 27 
anthocyanidins (the sugar-free, aglycone forms of anthocyanins) identified in nature. 
However, only six anthocyanidins: cyanidin, delphinidin, pelargonidin, peonidin, 
malvidin and petunidin are widely distributed, accounting for more than 90% of all 
known anthocyanins (Andersen & Jordheim 2013) (Figure 7). 
 
Figure 7. Structure and approximate distribution of six main anthocyanidins. Adapted from 
Fang 2014. 
The diversity of anthocyanin structure is achieved by differences in 1) the number 
and position of hydroxy groups and a degree of their methylation, 2) the nature, number 
and position of sugar attached to the aglycone and 3) the nature and number of aliphatic 
and aromatic acids linked to these sugars (Kong et al. 2003). Glucose, galactose, rutinose 
(rhamnosyl-glucose), rhamnose, arabinose and xylose are commonly found attached to 
anthocyanidins as mono-, di-, or trisaccharide forms. They are mainly bound to C3-
position on the C-ring or C5 or C7-position on the A-ring (Fang 2014). These attached 
sugars can also be acylated with aromatic acids such as p-coumaric, ferulic, caffeic and 
p-hydroxybenzoic acids and/or aliphatic acids like malonic, acetic, malic and oxalic acids 
(Francis & Markakis 1989). 
Anthocyanins are highly soluble in water and alcoholic solutions due to the presence 
of phenolic hydroxyl groups (de Pascual-Teresa & Sanchez-Ballesta 2008). They are 
reactive and very unstable compounds, which stability can be affected by pH, 
temperature, light, as well as the presence of oxygen, enzymes, other flavonoids, proteins 
and metal ions (Castañeda-Ovando et al. 2009). In aqueous solution, anthocyanins can 
form several structural isoforms, which relative abundance at equilibrium varies with pH 
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and anthocyanidin structure (Mazza & Brouillard 1987). Anthocyanins are the most 
stable at low pH (1-3) where they occur as flavylium cations that are red coloured. As the 
pH increases, the most of the flavylium cations transform to blue quinoidal forms (pH 2-
4) or colourless carbinol pseudo-base and pale yellow chalcone (pH 5-6) (Fossen et al. 
1998). The stability of glycosylated and acylated forms is significantly increased over 
aglycones (Zhao et al. 2014). 
1.3.2.&Dietary consumption of anthocyanins 
Anthocyanins are important constituents of the human diet. They are regularly 
consumed in many fruits and fruit-derived products (e.g. wines, juices and jams) and 
some dark-coloured vegetables and cereals (e.g. eggplant, red onion, red cabbage, black 
rice). Furthermore, they are present in the diet as the colouring agent E163 that is 
increasingly used as an additive in the food industry for various foods and beverages 
(Heinonen 2001). Among fruits, the most commonly eaten anthocyanin sources are berry 
fruits belonging to Vitaceae family (species Vitis vinifera), Rosaceae family (e.g. 
strawberries, raspberries, blackberries, cherries, apples, plums) and genera Ribes (e.g. 
blackcurrants) and Vaccinium (e.g. bilberries, blueberries, cranberries) of Ericaceae 
family (Andersen & Jordheim 2013). In these dietary sources anthocyanin concentration 
usually reaches several hundreds of mg in 100 g of fresh weight (FW), providing 
substantial anthocyanin doses in a single serving (Table 1). In several foods such as 
elderberry, chokeberry and purple corn anthocyanin concentrations are even higher, 
reaching up to 1816, 1480 and 1642 mg/100 g FW, respectively (de Pascual-Teresa & 
Sanchez-Ballesta 2008) (Table 1). However, it should be noted that in foods anthocyanin 
concentrations can vary considerably as a consequence of genetic, environmental and 
agronomic factors such as light, temperature, humidity, fertilisation, but also on 
conditions of processing and storage (Biesiada & Tomczak 2012). 
 17 
Table 1. Anthocyanin concentrations in foods. Adapted from de Pascual-Teresa and Sanchez-
Ballesta 2008. 
 
The daily anthocyanin intakes vary greatly depending on dietary habits of the studied 
population that are influenced by socioeconomic, demographic and lifestyle factors 
(Burton-Freeman 2010). They are still poorly established, mainly due to the absence of 
available information in food composition databases and variations in results depending 
on the used dietary assessment. They range from 2.7 to 82 mg/day, with estimated 
habitual anthocyanin intake of 58 mg/day in France (Pérez-Jiménez et al. 2011), 82 
mg/day in Finland (Heinonen 2001), 12.5 mg/day in the US (Wu et al. 2006), 7.6 mg/day 
in Belgium (Mullie et al. 2007), 5-9 mg/day in the UK (Clifford & Brown 2006) and 2.7 
mg/day in Germany (Watzl et al. 2002). 
1.3.3.&Anthocyanin bioavailability 
To be able to exert their effect in the human body, ingested dietary anthocyanins need 
to be available in the circulation and tissues. Bioavailability is defined as a portion of the 
ingested dose of a compound that reaches the general circulation and specific sites where 
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it can exert its action (Porrini & Riso 2008). Anthocyanin bioavailability has been 
previously reported to be very low, with the recovery of less than 1% of the ingested 
anthocyanin dose (Kay et al. 2005). However, recent human bioavailability study, using 
isotope-labelled anthocyanin cyanidin-3-glucoside (cy-3-glc), has reported the extensive 
anthocyanin metabolism and a recovery of 12.4% (Czank et al. 2013). This suggests that 
the anthocyanin bioavailability is much greater than previously thought due to their new 
identified metabolites. Therefore, a good understanding of the faith of dietary 
anthocyanins in the human body following their intake, i.e. their absorption, distribution, 
metabolism and excretion (ADME) is of great importance for assessing their possible 
biological effects. However, there are still gaps in the knowledge concerning this topic. 
In foods, anthocyanins are present as glycosides. Following the consumption, they 
enter and move through different regions of the gastrointestinal tract (GIT) (Figure 8). 
There, the specific pH, composition of the dissolved gases and metabolic activity can lead 
to anthocyanin degradation and metabolism (He et al. 2005). Anthocyanins that are 
absorbed along GIT are transported through the portal vein into the liver, where they can 
be further metabolised. Subsequently, these compounds can return to the GIT through the 
bile (enterohepatic-recycling) or enter the general circulation before being eliminated 
from the body by the urinary route (Lila et al. 2016). Anthocyanins that are not absorbed 
in the GIT are eliminated through faeces. 
 
Figure 8. Scheme of anthocyanin absorption and metabolism 
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1.3.3.1.&  Anthocyanin absorption and metabolism 
In the stomach, the low pH (1.5-4) provides favourable conditions for the anthocyanin 
stability, allowing them to persist in glycoside form. The presence of anthocyanin 
glycosides in the circulation within minutes of consumption in humans (Matsumoto et al. 
2001; Rechner et al. 2002; Frank et al. 2003) suggests that the ingested anthocyanins, 
unlike other flavonoids, can be absorbed intact from the stomach (Talavéra et al. 2004). 
Since anthocyanins cannot pass the cell membranes by passive diffusion, a transporter 
system needs to be involved. An organic anion membrane carrier named bilitranslocase, 
expressed in the gastric mucosa, as well as in the liver, kidneys and vascular endothelium 
(Passamonti et al. 2002; Passamonti et al. 2005; Vanzo et al. 2008; Maestro et al. 2010), 
has been proposed to mediate anthocyanin transport. Its normal transport activity was 
found to be competitively inhibited by anionic quinoidal forms of different anthocyanins 
in vitro, suggesting that this transporter could be responsible for their quick transport into 
the portal and general circulations (Passamonti et al. 2002). The involvement of glucose 
transporter 1 (GLUT1) in the transport of anthocyanin glucosides has also been suggested 
(Oliveira et al. 2015). However, these proposed mechanisms of anthocyanin gastric 
absorption are based only on findings from in vitro studies and their relevance to the 
absorption and metabolism in humans is still uncertain.  
The important site for anthocyanin absorption is the small intestine. There, similarly 
to other flavonoids, anthocyanins undergo deglycosylation (i.e. cleavage of the glycoside) 
that releases lipophilic aglycones that can enter the epithelial cells by passive diffusion 
(Del Rio et al. 2013). Deglycosylation can be mediated by β-glucosidase in the intestinal 
lumen and lactase-phloridzin hydrolase in the brush border of the intestinal epithelial cells 
(Day et al. 2000). Alternatively, absorption could involve the active transport of intact 
glycosides into the epithelial cells by the sodium-dependent glucose transporter 1 
(SGLT1) (Hollman et al. 1999; Gee et al. 2000) or glucose transporter 2 (GLUT2) (Day 
et al. 2000; Manzano & Williamson 2010) and their subsequent deglycosylation by 
cytosolic β-glucosidase (Németh et al. 2003). However, due to some contradictory results 
(Walton et al. 2006; Kottra & Daniel 2007; Felgines et al. 2008), the involvement of 
SGLT1 in the anthocyanin absorption is still uncertain. 
Anthocyanin aglycones that enter the intestinal epithelial cells may be metabolised 
there to some extent before reaching portal circulation. This involves the 
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biotransformation typical for many xenobiotics, which increases their hydrophilicity and 
facilitates elimination from the body through bile and urine. This metabolism includes 
the phase I metabolism (oxidation, reduction, hydrolysis reactions) and phase II 
metabolism (conjugation reaction). In the intestine, anthocyanins can undergo 
methylation, sulphation, and glucuronidation, mediated by phase II metabolising 
enzymes catechol-O-methyltransferase (COMT), sulfotransferase (SULT) and uridine-
5’-diphospho-glucuronosyltransferase (UGT), respectively (Del Rio et al. 2013). These 
reactions can also take place in the liver (i.e. the most important site of xenobiotic 
metabolism) and kidneys (Talavéra et al. 2005). Consequently, following the intake of 
anthocyanin-rich foods, the methylated, sulphated and glucuronidated anthocyanins are 
detected in human plasma and urine (Kay et al. 2005; Mullen et al. 2008; Azzini et al. 
2010; de Ferrars, Czank, et al. 2014). 
Prior to conjugation, anthocyanin aglycones can alternatively undergo degradation to 
phenolic acids and aldehydes within the intestinal lumen or epithelial cells. Anthocyanin 
degradation can also be a result of the activity of colonic microbiota. Anthocyanins that 
reach the colon are there exposed to 300-500 different bacterial species, with Bacteroides, 
Eubacterium, Bifidobacterium and Clostridium presenting the most abundant genera 
(Salminen et al. 1998). Gut microbiota releases many deglycosylation enzymes that 
cleave the sugar moiety, giving rise to aglycones that further degrade to phenolic acids 
(e.g. PCA, ferulic, hippuric acids) or aldehydes (Faria et al. 2014; Hribar & Ulrih 2014). 
Consequently, the portion of ingested anthocyanin forms decreases along the GIT, 
whereas the portion of phenolic acids increases. The products of anthocyanin degradation 
may also be absorbed from the intestines and further metabolised in the liver or kidneys 
(Czank et al. 2013). 
Taken together, the results from the available studies assessing anthocyanin 
absorption and metabolism show that the dietary anthocyanins may be absorbed from the 
different regions of GIT (stomach, small intestines and colon) and extensively 
metabolised before eliminated from the body. The involved metabolic reactions may 
include microbial degradation as well as phase I and phase II metabolism. 
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1.3.3.2.&Anthocyanins in the circulation 
The available data on anthocyanin ADME in humans shows that anthocyanins and 
their aglycone conjugates, formed by phase II biotransformation, appear rapidly in the 
circulation. They peak at around 100 nM within 1.5 hours after the doses ≤ 2400 mg of 
anthocyanins (Table 2), and disappear from the bloodstream by 6 hours post-consumption 
(Rechner et al. 2002; Stalmach et al. 2012). The maximal plasma concentrations (Cmax) 
of total anthocyanins reported in these studies were in the range of 1.4-591 nM (Table 2), 
while Cmax of individual anthocyanins in human plasma varied from 0.06 to 367 nM 
(Kay et al. 2005; Kuntz, Rudloff, et al. 2015).   
Table 2. Summary of anthocyanin concentrations in plasma from selected human bioavailability 
studies with anthocyanin rich-sources 
a Administrated anthocyanin dose. b Sampling duration. c Cmax - maximum concentration in plasma. d Tmax - time to reach Cmax. * 
mg/kg body weight. 
Anthocyanin source Dosea Durationb 
(h) 
Cmaxc 
(nM) 
Tmaxd 
(h) 
Reference 
Elderberry 720 mg 24 97.4 1.2 (Cao et al. 2001) 
Red wine 68 mg 6 1.4 0.3 (Bub et al. 2001) 
Blackcurrant juice 1000 mg 6 85.3 1 (Rechner et al. 2002) 
Blackcurrant concentrate 2380 mg 8 147.4 1.5 (Matsumoto et al. 2001) 
Blueberry powder 1200 mg 4 29 4 (Mazza et al. 2002) 
Red grape juice 283.6 mg 7 165.4 0.5 (Frank et al. 2003) 
Red wine 279.6 mg 7 100.2 1.5  
Chokeberry extract 1300 mg 2 591.7 2 (Kay et al. 2004) 
Chokeberry extract 721 mg 24 96.1 2.8 (Kay et al. 2005) 
Strawberries 222 µmol 24 274 1.1 (Mullen et al. 2008) 
Red grape extract 183.8 mg 24 7.9 2 (Garcia-Alonso et al. 2009) 
Chokeberry juice 0.8* 24 32.7 1.3 (Wiczkowski et al. 2010) 
Cranberry juice 94.7 mg 4 13.6 1.5 (Milbury et al. 2010) 
Concord grape juice 238 µmol 24 5.9 2.15 (Stalmach et al. 2012) 
Bilberries 919 µmol 6 108 1.31 (Sakakibara et al. 2014) 
Elderberry drink 500 mg 3 33 2.3 (de Ferrars, Cassidy, et al. 
2014) 
Grape/blueberry juice 277.4 mg 2 5.6 1.2 (Kuntz, Rudloff, et al. 2015) 
Grape/blueberry 
smoothie 
324.5 mg 2 5.4 1.4  
Strawberry drink 34.7 mg 10 44.2 1.8 (Sandhu et al. 2016) 
Chokeberry extract 45.1 mg 24 300 2.1 (Xie et al. 2016) 
Red cabbage 6 mg 24 86.4 2 (Wiczkowski et al. 2016) 
Bilberry extract 2400 mg 8 91.2 2.6 (Mueller et al. 2017) 
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It should be noted that the plasma anthocyanin levels in most of the available 
bioavailability studies were proportional to their levels in tested food (Milbury et al. 2010; 
Kuntz, Rudloff, et al. 2015). For example, in one study the maximum levels of cy-3-glc 
and peonidin-3-glucoside (pn-3-glc) measured in plasma of healthy subjects after the 
consumption of grape/blueberry juice or smoothie, providing 13.6±0.2 and 19.1±0.7 mg 
of cy-3-glc and 54.5±0.7 and 53.8±2.0 mg of pn-3-glc, were eight times higher for pn-3-
glc (0.8 nM) than for cy-3-glc (0.1 nM) (Kuntz, Rudloff, et al. 2015). Therefore, the 
reasonable physiological levels of glycosides reached after their dietary intake in 
substantial doses could be much higher than reported. 
In addition to anthocyanins and their phase II conjugates, several anthocyanin 
bioavailability studies have also reported the presence of other compounds in plasma (e.g. 
different phenolic acids) that may be a result of anthocyanin metabolism (Rechner et al. 
2002; Azzini et al. 2010; Stalmach et al. 2012). However, since their origin was hard to 
trace, these compounds were ascribed to anthocyanin food source used in studies. In 
recent studies investigating ADME of isotopically labelled cy-3-glc administrated to male 
subjects in a 500 mg single oral dose, also detected different phenolic acids (e.g. PCA, 
vanillic, ferulic, hippuric acids) and their phase I and phase II metabolites in the 
circulation (Czank et al. 2013; de Ferrars, Czank, et al. 2014). The use of isotope-labelling 
allowed authors to define the origin of these phenolic compounds and report them as 
anthocyanin-derived metabolites. Interestingly, unlike their parent anthocyanin that 
reached Cmax of 141 nM by 1.8 hours and disappeared from the bloodstream by 6 hours, 
metabolites picked (0.2-2 µM) at around 10 hours and were detectable in the circulation 
up to 48 hours post-ingestion. Furthermore, metabolites displayed biphasic serum 
profiles, with the first peak between 0 and 5 hours and a second, more pronounced peak 
between 6 and 48 hours that corresponded to absorption of anthocyanin bacterial 
metabolites from the colon (Figure 9). Therefore, these studies provided evidence of the 
extensive anthocyanin metabolism in the human body. Furthermore, they demonstrated 
that metabolites, especially those derived from microbial metabolism, present the 
dominant anthocyanin form in the circulation and suggested that these compounds could, 
at least partly, contribute to the beneficial health effects associated with the consumption 
of anthocyanin-rich sources. 
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Figure 9. Biphasic serum profiles of anthocyanin forms in humans following the consumption of 
500 mg of isotopically labelled cy-3-glc, from Warner et al. 2017. 
In summation, following the ingestion of dietary anthocyanins these compounds 
appear rapidly in the circulation where they are present for a short period of time at 
nanomolar concentrations, unlike their gut metabolites that appear later in the 
bloodstream and are present for significantly longer time and at higher, micromolar 
levels. 
1.3.4.&Cardiovascular health benefits of anthocyanins 
Accumulating evidence suggests the protective effects of anthocyanin consumption 
against CVD. The overview of the data from epidemiological, clinical, preclinical and in 
vitro studies is provided in the following sections. 
1.3.4.1.&  Evidence from epidemiological studies 
Data from several epidemiological studies have reported an inverse correlation 
between anthocyanin intake and risk of CVD or CVD-related mortality. In a prospective 
study, following 34489 healthy postmenopausal women (55-69 years old) for 16 years, 
the anthocyanin intake (none versus any intake) was associated with a 12% and 9% lower 
risk of coronary heart disease (CHD) and CVD mortality, respectively (Mink et al. 2007). 
Similarly, a study of 38180 men and 60289 women (mean age of 70 and 69 years) with 
7-year follow-up, observed a 21% reduction in risk of CHD mortality and 14% in CVD 
mortality in men and women when comparing higher (≥ 16.7 mg/day) with lower (< 5.5 
mg/day) anthocyanin intakes (McCullough et al. 2012). Higher habitual anthocyanin 
intakes were also inversely associated with reduced risk of total MI in premenopausal 
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women (Cassidy et al. 2013) and non-fatal MI in men (Cassidy et al. 2016). The 
magnitude of this effect of anthocyanin consumption was higher in the study following 
93600 premenopausal women (25-42 years old) for 18 years, with observed 32% decrease 
in MI risk when comparing extremes of anthocyanin intake (2.5 mg/day with 25.1 
mg/day). Additionally, a food-based analysis in this study showed that combined intake 
of strawberries and blueberries tended to be associated with the reduced risk of MI. A 
34% lower risk of MI was observed in women that consumed more than three portions 
per week compared with those that rarely consumed these anthocyanin-rich fruits 
(Cassidy et al. 2013). 
Several cross-sectional and prospective studies have also shown the inverse 
association between anthocyanin intake and biomarkers of CVD risk, providing possible 
mechanistic support for the reported reduction in risk of CHD or CVD-related mortality. 
In a cross-sectional study investigating 1898 women aged between 18 and 75 years, 
higher anthocyanin intake was associated with significantly lower central blood pressure, 
mean arterial pressure and pulse wave velocity (PWV) that are direct measures of 
atherosclerosis and arterial stiffness (Jennings et al. 2012). In this study, a 44-mg increase 
in anthocyanin intake was associated with a reduction in PWV by 3.9% and a decrease of 
3 mmHg in systolic blood pressure, suggesting that these effects could be easily achieved 
by incorporating around 1 to 2 portions of berries in an everyday diet. In several cross-
sectional studies, higher anthocyanin intakes were also inversely correlated with different 
inflammatory biomarkers (e.g. IL-18 and C-reactive protein) and the overall 
inflammation score that combined several cytokines, markers of acute inflammation and 
oxidative stress (Chun et al. 2008; Jennings et al. 2014; Cassidy et al. 2015). Furthermore, 
a large prospective study following 156957 subjects for 14 years reported that the higher 
anthocyanin intake, mainly from strawberry and blueberry consumption, was associated 
with an 8% reduction in risk of hypertension (Cassidy et al. 2011). This reduction was 
the most pronounced in premenopausal women, which was in line with the most 
significant decrease in risk of MI also observed in this age group (Cassidy et al. 2013). 
Taken together, results from the available epidemiological studies are promising 
regarding the role of anthocyanins against CVD, showing the inverse associations 
between anthocyanin consumption and CVD incidence, mortality or different biomarkers 
of CVD risks. 
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1.3.4.2.&  Evidence from clinical studies 
The hypothesis created from epidemiological studies has initiated a number of clinical 
studies with the aim to provide cause-effect relationships that could explain the role of 
anthocyanins in the CVD prevention. 
Several RCTs have investigated the effects of the consumption of different 
anthocyanin-rich sources on surrogate markers of CVD risk, such as hypertension, lipid 
profiles, endothelial dysfunction and platelet function. Results from short-term 
intervention studies have shown that the consumption of anthocyanin-rich berries and 
extracts can decrease both systolic and diastolic blood pressure and improve lipid profiles 
mainly in subjects at risk for CVD (Table 3). Few of these studies have also reported the 
improvements in arterial stiffness and endothelial function through a decrease in PWV 
and an increase in flow-mediated vasodilatation (FMD) of the brachial artery, 
respectively (Table 3). A double-blinded crossover RCT that investigated the acute effect 
of the consumption of a wild blueberry beverage containing 310 to 724 mg of 
anthocyanins on FMD in healthy men has reported the significant increase in FMD at 1, 
2 and 6 hours post-consumption (Rodriguez-Mateos, Rendeiro, et al. 2013). Also, no 
significant difference in the effect between higher and lower anthocyanin doses was 
observed. Interestingly, the observed biphasic improvements in endothelial function 
correlated with the increased plasma levels of anthocyanins at around 2 hours and of their 
gut metabolites at 6 hours following the consumption of this blueberry drink. These 
results suggested that both anthocyanins and their gut metabolites could contribute to the 
reported beneficial effect of this anthocyanin-rich beverage. Several three- or six-month 
intervention trials that used purified anthocyanins have also reported the improvements 
in endothelial function, lipid profiles and inflammatory biomarkers in subjects with CVD 
risks (Table 3) therefore providing evidence that anthocyanins are at least partly 
responsible for the effects observed using anthocyanin-rich fruits and extracts. 
To date, only a limited number of RCTs have investigated the effect of anthocyanins on 
platelet function. However, the available data do suggest that short-term dietary 
interventions with anthocyanin-rich foods and extracts can affect platelet function by 
decreasing platelet activation and platelet aggregation with other platelets and leukocytes 
and lowering the potential for clot formation and fibrinolysis (Sikora et al. 2012; Song et 
al. 2014; Santhakumar, Kundur, Fanning, et al. 2015; Santhakumar, Kundur, Sabapathy, 
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et al. 2015; Zhang et al. 2016; Thompson, Hosking, et al. 2017; Thompson, Pederick, et 
al. 2017). 
In summation, evidence from clinical studies shows that anthocyanin-rich foods, 
extracts and purified anthocyanins can improve different markers of CVD risk. However, 
more well-designed long-term investigation trials that are focused on the effect of pure 
anthocyanins in both healthy and subjects with CVD risk are needed to strengthen the 
available evidence and establish the role of this compounds in the prevention of CVD. 
Table 3. Summary of the effect of anthocyanin-rich foods, extracts and purified anthocyanins 
reported in RCTs 
RCT 
design 
Participants Intervention 
(per day) 
Dose* 
(mg/day) 
Duration 
(weeks) 
Significant 
findings 
Reference 
DB, 
PC, C 
44 subjects, 
aged 62± 8y, 
with CHD 
480 ml 
cranberry 
juice 
94 4 ↓carotid-femoral 
PWV (6%) 
(Dohadwala et 
al. 2011) 
DB, 
PC, P 
54 subjects, 
≥18 y, with 
hyperlipidemia 
3x500 mg 
whortleberry 
extract 
90 4 ↓TG (30%) 
↓TC (15.2%) 
↓LDL (8.6%) 
(Soltani et al. 
2014) 
DB, 
PC, C 
21 healthy 
subjects, 
aged 21-45y 
200 ml 
plum juice 
202 4 ↓platelet 
aggregation 
(2.7-5%) 
↓platelet activation 
(17.2%), 
↓plasma-
fibrinogen (7.5%) 
(Santhakumar, 
Kundur, 
Fanning, et al. 
2015) 
DB, 
PC, P 
44 subjects, 
age 65.9±8.3y, 
post-MI 
3×85 mg 
chokeberry 
extract 
63.8 6 ↓SBP (8.32%) 
↓DBP (8.34%) 
↓hsCRP (23%) 
↓IL-6 (30%) 
↓MCP-1 (29%) 
↓sVCAM-1(28%) 
↓sICAM-1 (15%) 
↓ox-LDL (29%) 
(Naruszewicz 
et al. 2007) 
SB, 
PC, P 
72 subjects, 
aged 57.5±6.3y, 
with CVD risk 
bilberries, 
lingonberries 
black 
currants 
strawberry 
chokeberry, 
raspberries 
515 8 ↑HDL (5.2%) 
↓SBP (1.2%) 
↓platelet 
aggregation (11%) 
(Erlund et al. 
2008) 
SB, 
PC, P 
27 subjects, 
aged 47 ± 3y, 
with MtS 
50g 
freeze-dried 
strawberries 
154 8 ↓TC (11%) 
↓LDL (10%) 
↓small LDL 
particles (16%) 
↓VCAM-1 (18%) 
(Basu, Fu, et 
al. 2010) 
SB, 
PC, P 
48 subjects, 
aged 50± 3y, 
with MtS 
50 g 
freeze-dried 
blueberries 
742 8 ↓SBP (6%) 
↓DBP (4%) 
↓ox-LDL (28%) 
(Basu, Du, et 
al. 2010) 
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Table 3. (Continued) 
RCT 
design 
Participants Intervention 
(per day) 
Dose* 
(mg/day) 
Duration 
(weeks) 
Significant 
findings 
Reference 
DB, 
PC, P 
105 subjects, 
aged 20-60y, 
with primary 
hyperlipidemia 
3x350 mg 
whortleberry 
extract 
7.4 8 ↓TG (19.2%) 
↓TC (27.6%) 
↓LDL (26.3) 
↑HDL (37.5%) 
(Kianbakht et 
al. 2014) 
DB, 
PC, P 
48 women, 
aged 45-60y, 
with pre- and 
stage 1 
hypertension 
22g 
freeze-dried 
blueberry 
powder  
101.2 8 ↓SBP (5.1%) 
↓DBP (6.3%) 
↓brachial-ankle 
PWV(6.5%) 
(Johnson et al. 
2015) 
DB, 
PC, P 
32 subjects, 
aged 65± 1y, 
with T2D 
3x500 mg 
cranberry 
extract 
NR 12 ↓TC (8%) 
↓LDL (12%) 
↓TC:HDL (7.5 %) 
(Lee et al. 
2008) 
PC, P 120 healthy 
subjects, aged 
40–74y 
Purified** 
anthocyanins 
300 3 ↓IL8 (45%), 
↓CCL5(15%), 
↓IFNα (40%) 
(Karlsen et al. 
2007) 
DB, 
PC, C 
16 subjects, 
mean age 38 y, 
sedentary, 
healthy  
Purified** 
anthocyanins 
320 4 ↓platelet 
aggregation 
(29%) 
↓platelet-leukocyte 
aggregation (39%), 
↓platelet activation 
(10-14%) 
(Thompson, 
Hosking, et al. 
2017) 
DB, 
PC, P 
120 subjects, 
aged 40–65y, 
with 
dyslipidemia 
Purified** 
anthocyanins 
320 12 ↓LDL (13.6%) 
↑HDL (13.7%) 
(Qin et al. 
2009) 
DB, 
PC, P 
150 subjects, 
aged 40–65y,  
with hyper-
cholesterolemia 
Purified** 
anthocyanins 
320 12 ↑FMD (28.4%) 
↑HDL (12%)  
↓LDL (10%) 
↑cGMP (12.6%) 
↓sVCAM-1 (12%) 
(Zhu et al. 
2011) 
DB, 
PC, P 
150 subjects, 
aged 40–65y,  
with hyper-
cholesterolemia 
Purified** 
anthocyanins 
320 24 ↑HDL (14%)  
↓LDL (10%) 
↓hsCRP (21.6%) 
↓sVCAM-1 (12%) 
↓IL1β (12.8%) 
(Zhu et al. 
2013) 
DB, 
PC, P 
 
 
 
 
 
 
 
 
 
58 subjects, 
aged 56–67 y, 
with T2D 
Purified** 
anthocyanins 
320 24 ↓LDL (7.9%) 
↓HDL (19.4%)  
↓TC (3.75%)  
↓TG (23%) 
↓apoB-48 (16.5%) 
↓apoC-III (11.0%) 
↓fasting plasma 
glucose (8.5%) 
↓TNFα (8.6%) 
↓IL6 (31.6%) 
(Li et al. 
2015)  
*anthocyanin dose administrated in the study, ** purified from bilberry and black currant, DB-double-blinded, SB-
single blinded, PC-placebo-controlled, P-parallel, C-crossover design, MtS-metabolic syndrome, T2D-type 2 diabetes, 
NR-not reported, SBP-systolic blood pressure, DBP-diastolic blood pressure, ox-LDL-oxidized LDL, TC-total 
cholesterol, HDL-high density lipoprotein, TG-triglycerides, hsCRP-high-sensitivity C reactive protein. 
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1.3.4.3.&  Evidence from animal studies 
Findings from several animal studies also support the beneficial effects of 
anthocyanins on cardiovascular health. Several nutritional interventions performed with 
apolipoprotein E knockout (ApoE−/−) mice that spontaneously develop atherosclerosis 
have reported that anthocyanin-rich extracts or pure compounds, administrated at 
nutritionally relevant doses, reduced the formation of atherosclerotic lesions in the aorta 
of these mice (Miyazaki et al. 2008; Mauray et al. 2009; Wang et al. 2010; Wu et al. 2010; 
Y. Wang et al. 2012). Furthermore, anthocyanin supplementation has been reported to 
increase survival following induced MI, decrease thrombus development and improve 
blood pressure, lipid profiles and endothelium-dependent vasorelaxation in several 
studies using different animal models of CVD (Ahmet et al. 2009; Suh et al. 2011; Yang 
et al. 2011; Rodriguez-Mateos, Ishisaka, et al. 2013; Zhang et al. 2013). 
1.3.5.& Molecular mechanisms of action of anthocyanins underlying their 
cardiovascular health properties 
A number of in vitro and in vivo studies have been performed to identify mechanisms 
by which anthocyanins exert their cardioprotective effects. These health benefits were 
previously associated with their direct antioxidant properties, i.e. ability to transfer 
hydrogen (electron) to ROS and neutralise them. It was proposed that by exerting the 
direct antioxidant effect against ROS, which production is increased in the dysfunctional 
endothelium, anthocyanins could prevent LDL oxidation and associated inflammatory 
responses, and thus affect the development and progression of atherosclerosis (Tsuda et 
al. 1996; Yi et al. 2010). However, more recent studies have reviled the implication of 
more complex molecular mechanisms of action including modulation of gene expression, 
cell signalling and micro RNA expression that will be detailed in the following sections. 
1.3.5.1.&Effect on gene expression 
Several in vitro studies have reported the ability of anthocyanins and their metabolites 
to reduce oxidative stress by modulating the expression of genes coding for antioxidant 
and detoxifying enzymes. Oxidative stress is an important promoter of inflammatory 
reactions and one of the hallmarks of endothelial dysfunction and atherosclerosis (Hajjar 
& Gotto 2013). Anthocyanin-mediated upregulation of the expression of genes encoding 
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enzymes involved in antioxidant defence, such as nicotinamide adenine dinucleotide 
phosphate (NADPH) quinone oxidoreductase 1, heme oxygenase-1 and superoxide 
dismutase (SOD), has been reported in different types of endothelial cells (Sorrenti et al. 
2007; Cimino et al. 2013; Speciale et al. 2013; Fratantonio et al. 2015; Huang et al. 2016). 
Also, few studies have shown that anthocyanins can downregulate the expression of genes 
coding for different subunits of NADPH oxidase, which represents a major source of 
oxygen radical production (Lazzè et al. 2006; Chen et al. 2011; Speciale et al. 2013). 
These nutrigenomic effects were concomitant with reduced production of ROS and 
increased cell viability observed in these studies. Similar to in vitro evidence, the 
upregulation of the expression of genes encoding antioxidant enzymes like glutathione 
reductase, thioredoxin reductase 1 and SOD 1 and 2 has been observed in the aorta of 
ApoE−/− mice after 20-week long dietary supplementation with blueberries. These effects 
were accompanied by significant decreases in atherosclerotic lesion area in the aortic 
sinus and descending aorta of these mice (Wu et al. 2010). Results from these mechanistic 
studies suggest that the ability of anthocyanins to reduce oxidative stress by increasing 
the antioxidant defence and inhibiting lipid peroxidation can present one of the 
mechanisms underlying their observed anti-atherogenic effects. 
In addition to the effect on oxidative stress, anthocyanins have been reported to 
modulate the expression of genes involved in the regulation of vascular tone. 
Anthocyanins at concentrations ranging from 0.1 to 100 µM have been shown to increase 
the expression of nitric oxide synthase 3 (NOS3) and decrease the expression of 
endothelin 1 (EDN1) in endothelial cells (Lazzè et al. 2006; Paixão et al. 2012; Edwards 
et al. 2015). Endothelin 1 is an endothelium-derived vasoactive peptide that contributes 
to the regulation of vascular tone and maintenance of cardiovascular homeostasis through 
the constriction of vascular smooth muscle. NOS3 encodes an enzyme that produces the 
vasoactive nitric oxide (NO) from L-arginine, leading to a NO-dependent relaxation of 
vascular smooth muscle (Krga et al. 2016). Decreased bioavailability of endothelial-
derived NO, the upregulation of EDN1 and subsequently increased contractibility are 
important characteristics of endothelial dysfunction and pathogenesis of CVD (Böhm & 
Pernow 2007). Therefore, the increase in NOS3 expression and NO synthesis, as well as 
downregulation of EDN1 expression, could also represent a mechanism by which 
anthocyanins improve endothelial function and contribute to cardiovascular health. 
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Other available mechanistic studies have also shown the ability of anthocyanin 
extracts or pure compounds to affect the expression of genes involved in the regulation 
of inflammation, monocyte adhesion and transmigration (Chen et al. 2011; Chao, Lin, et 
al. 2013; Chao, Huang, et al. 2013; Huang, Liu, et al. 2014). As previously detailed, 
proinflammatory cytokines such as the interleukins and TNFα are produced in 
endothelial cells during the inflammatory insult, stimulating the expression of cell 
adhesion molecules on the surface of activated endothelium. The inflamed endothelium 
also promotes the production of chemotactic cytokines such as MCP-1 or IL-8 that guide 
leukocytes into the subendothelial space. Anthocyanins at concentrations ranging from 
0.1 to 100 µM have been reported to modulate the expressions of genes coding for the 
adhesion molecules such as VCAM-1, ICAM-1 and E selectin and cytokines like IL-6, 
IL-8 and MCP-1 in different types of endothelial cells subjected to inflammatory 
mediators or oxidative stress (Speciale et al. 2010; Huang, Liu, et al. 2014; Huang, Wang, 
et al. 2014; Amin et al. 2015; Kuntz, Asseburg, et al. 2015). These effects were 
accompanied by a decrease in monocyte adhesion to activated endothelial cells observed 
in the cell adhesion experiments (Wang et al. 2010; Chen et al. 2011; Chao, Lin, et al. 
2013; Chao, Huang, et al. 2013; Kuntz, Asseburg, et al. 2015). Similar to in vitro 
evidence, the inhibition of aortic expression of several proinflammatory factors and 
adhesion molecules involved in the recruitment of inflammatory cells (e.g. VCAM-1, 
ICAM-1, TNFα and inducible nitric oxide synthase) have also been reported in studies 
with ApoE−/− mice that consumed diet enriched in anthocyanin-based extracts or pure 
compounds (Xia et al. 2006; Wang et al. 2010; Xie et al. 2011). Furthermore, 
downregulation of aortic expression of scavenger receptors (scavenger receptor-A and 
CD36) responsible for the incorporation of modified LDL into macrophages, as well as 
decreased foam cell formation, were reported following a 20-week dietary 
supplementation with blueberries in ApoE−/− mice (Seymour et al. 2009). In addition to 
these studies that used targeted-based approach (focused on the impact on specific genes), 
there is one study that used a microarray-based holistic approach that allowed 
simultaneous investigation of the effect on several thousand genes. This microarray 
analysis of the gene expression in the aorta of ApoE−/− mice that consumed diet enriched 
in anthocyanin-rich bilberry extract during two weeks revealed changes in the expression 
of 1261 genes implicated in different cellular processes such as inflammation, cell 
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adhesion and transmigration (Mauray et al. 2012), proposing the multi-targeted mode of 
action of anthocyanins. 
Taken together, mechanistic evidence suggests that anthocyanin-mediated 
modulations of the expression of different genes implicated in processes such as oxidative 
stress, inflammation, monocyte adhesion and transendothelial migration (Figure 10) 
could present the important mechanism in anthocyanin protection against the 
development of atherosclerosis and associated cardiovascular complications. 
 
Figure 10. Summary of genes linked to vascular dysfunction, which expression has been 
identified as modulated by different polyphenols, from Krga et al. 2016. 
1.3.5.2.&Regulation of cell signalling pathways 
Cellular responses to changes in their environment require rapid and precise 
transmission of signals from the cell surface to the nucleus. These cell signalling 
pathways depend on protein phosphorylation and eventually lead to the activation of 
transcription factors, which induce the expression of target genes (Viatour et al. 2005). It 
has been suggested that the observed anthocyanin nutrigenomic effects are associated 
with their ability to affect cell signalling pathways such as the nuclear factor-κB (NF-κB) 
and mitogen-activated protein kinases (MAPK) pathways that play an essential role in 
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initiation and regulation of inflammatory processes. NF-κB presents the transcription 
factor that is closely associated with the development of atherosclerosis due to its 
important role in the regulation of multiple cellular processes such as inflammation, 
immune response, proliferation and apoptosis (Warboys 2011). This transcription factor 
functions as a dimer with the p50/p65 heterodimer as the most abundant form. Under 
normal physiological conditions, NF-κB heterodimer is bound to the inhibitor of kappa 
B (IκB) that keeps it in an inactive state in the cytoplasm. However, diverse extracellular 
stimuli, including oxidised LDL (ox-LDL) or cytokines such as TNFα can activate NF-
κB signalling pathway in endothelial cells leading to stimulation of the IκB kinase (IKK) 
complex that triggers the phosphorylation of IκB, eventually causing its ubiquitination 
and proteasomal degradation (De Winther et al. 2005). Consequently, activated NF-κB 
dimer translocates freely to the nucleus where it regulates the expression of 
proinflammatory genes, such as the genes encoding adhesion molecules E-selectin, 
ICAM-1 and VCAM-1 or cytokines like TNFα, IL-1 and MCP-1, inducing the 
inflammatory response and promoting the leukocyte adhesion (Warboys 2011). In a few 
studies, anthocyanin-rich extracts or pure compounds have been shown to suppress ox-
LDL or cytokine-stimulated NF-κB activation in endothelial cells through the inhibition 
of IκB phosphorylation and translocation of p65 subunit into the nucleus (Xia et al. 2007; 
Speciale et al. 2010; Yi et al. 2012; Chao, Lin, et al. 2013). This anthocyanin effect was 
associated with the observed decrease in the expression of genes encoding inflammatory 
mediators and adhesion molecules. Additionally, anthocyanins at concentrations ranging 
from 10 µM to 100 µM have also shown the ability to affect MAPK signalling pathways. 
This group of serine (Ser)/threonine (Thr) protein kinases includes the extracellular 
signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK) that play an 
important role in many cellular processes including inflammation, proliferation and 
apoptosis. Usually, activation of MAPK pathways is initiated by proinflammatory factors 
through the activation of cell surface receptors, activating a phosphorylation cascade that 
includes MAPK kinase kinases and MAPK kinases (Warboys 2011). Activated 
(phosphorylated) MAPK can then activate different transcription factors (e.g. NF-κB, 
activator protein 1 (AP-1), cyclic AMP-responsive element-binding protein 1 (CREB1)) 
that regulate transcription of proinflammatory genes. In a few studies, the anthocyanin-
mediated decrease in the expression of proinflammatory genes in activated endothelial 
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cells has been associated with their ability to reduce JNK and p38 phosphorylation (Xia 
et al. 2009; Yi et al. 2012). Similarly, the effect of anthocyanins on MAPK and NF-κB 
pathways have also been shown in others cells involved in the pathogenies of 
atherosclerosis such as macrophages and smooth muscle cells (Hou et al. 2005; L. Li et 
al. 2014; Sogo et al. 2015). 
These observations suggest that the ability of anthocyanins to affect cell signalling 
pathways and consequently modulate the expression of genes involved in inflammatory 
responses, thus maintaining endothelial cell function, could present one of the 
mechanisms underlying the cardioprotective effects of anthocyanins reported in clinical 
trials and animal studies. 
1.3.5.3.&Modulation of microRNA (miRNA) expression 
Modulation of miRNA expression has recently emerged as a possible mechanism by 
which polyphenols, including anthocyanins, may exert their beneficial health effects. 
These endogenous, non-coding, single-stranded RNAs of around 22 nucleotides act as 
the post-transcriptional regulators of gene expression (Bartel 2004). They are initially 
transcribed by RNA polymerase II (primary miRNA) and treated with the RNase III 
enzymes Drosha and Dicer, to generate 18- to 24-nucleotides mature miRNAs, which can 
then regulate the gene expression depending on the degree of complementarity with its 
target (Milenkovic et al. 2013). These mature miRNAs that perfectly base-pair with their 
mRNA targets induce their cleavage, while imperfect binding blocks protein translation. 
Therefore, by changing mRNA availability and consequently protein synthesis, these 
single-stranded RNAs can control various processes in cells such as cell differentiation, 
growth, proliferation and apoptosis (Miska 2005). The changes in miRNA expression 
profiles have been associated with the development of cancer, neurodegeneration and 
CVD, thus presenting an interesting target for the prevention of these multifactorial 
diseases. 
More than 100 miRNAs involved in the regulation of different cellular processes 
were identified as being modulated by different polyphenols (Milenkovic et al. 2012; 
Milenkovic et al. 2013). However, the effect of anthocyanins on miRNA expression is 
still largely unknown. One in vivo study has reviled that the supplementation of diet with 
anthocyanins or ferulic acid, at nutritionally relevant doses, modulated the expression of 
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45 and 28 miRNAs, respectively, in the liver of ApoE−/− mice compared to non-
supplemented mice (Milenkovic et al. 2012). The ability of anthocyanin extracts or pure 
compounds to modulate miRNA expression in different cell types such as mesenchymal 
stem cell, macrophages and myoblast have been recently reported (Du et al. 2017; Murata 
et al. 2017; Su et al. 2017). However, the in vitro evidence is still limited. Therefore, more 
studies are necessary to fully understand weather anthocyanin-mediated modulation of 
miRNA expression present one of the mechanisms underlying their cardioprotective 
properties. 
1.3.5.4.&Limitations of studies investigating the mechanisms of anthocyanin 
action and recommendation for future research 
Although the available mechanistic studies have shown the ability of anthocyanins to 
affect cell processes involved in the development of CVD by acting on cell signalling 
pathways, miRNA expression and gene expression, the majority of them present several 
limitations. Most of these studies are in vitro studies that did not consider the extensive 
metabolism of anthocyanins within the body. They predominantly used parent 
compounds or extracts rather than circulating metabolites, at high, supraphysiological 
concentrations (up to 200 µM) and long periods of cell exposure (up to 24 hours), thus, 
producing results with no physiological relevance. Furthermore, mechanistic studies 
mostly use targeted-based approach, focussing on the impact on a few specific targets, 
which is not suitable for the assessments of the proposed complex multi-target mode of 
action of polyphenols. 
In contrast to the relatively large number of studies investigating the effect of 
anthocyanins on endothelial cell function, the number of studies examining their effects 
on platelet function is limited. These in vitro studies mostly focus on the ability of 
anthocyanin-rich extracts, pure anthocyanins or their metabolites to affect platelet 
activation, platelet granule secretion and platelet aggregation with endothelial cells and 
other platelets (Kim et al. 2012; Yang et al. 2012; Song et al. 2014; Olas 2016), not rarely 
lacking the physiological relevance. Also, the effect of anthocyanins and their metabolites 
on the agonist-induced platelet aggregation with leukocytes still needs to be established. 
Taken together, results from mechanistic studies propose several mechanisms of 
action of anthocyanins that could underlie the reported beneficial effects of anthocyanin-
 35 
rich food consumption on cardiovascular health. These mechanisms include their ability 
to regulate the activity of cell signalling proteins and transcription factors and modulate 
gene expression thereby lowering inflammation and improving endothelial function. 
However, in vitro studies with physiologically relevant design that use omic approaches 
investigating the effect of anthocyanins and their metabolites on gene, protein and 
miRNA expressions are needed to fully understand the role of anthocyanins in CVD 
prevention. Aside from endothelial and immune cells, platelets also contribute to 
disturbed vascular homeostasis and present an interesting target for exploring the CVD 
prevention. Thus, future studies should focus on the assessments of anthocyanins and 
their metabolites on platelet activation and aggregation with immune cells. 
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2.& THE AIM OF THE THESIS 
Accumulating evidence suggests that anthocyanins, plant-food constitutes abundantly 
present in the human diet, could play an essential role in the cardioprotective effects 
associated with the consumption of anthocyanin-rich foods. These health benefits may be 
attributed to the ability of anthocyanins to affect endothelial or platelet function. 
Additionally, given the extensive metabolism of anthocyanins in the human body, it is 
also possible that their metabolites can at least partly contribute to observed 
cardioprotective effects of anthocyanin-rich foods. However, the underlying molecular 
mechanisms of action of anthocyanins and their metabolites are not fully understood. 
Therefore, this doctoral thesis aimed to examine the effect of anthocyanins and their 
metabolites, at physiologically relevant conditions, on endothelial cell and platelet 
function and to decipher, using the integrated omic approaches, the underlying molecular 
mechanisms of action. 
 
Accordingly, the following research objectives included: 
 
1.* Investigations of the effect of anthocyanins and their metabolites on endothelial 
cell function and integrity by evaluating adhesion of monocytes to activated 
endothelial cells and their subsequent transendothelial migration. 
2.* Clarification of the molecular mechanism of action of anthocyanins and their 
metabolites in the endothelial cells by assessing their effects on gene expression, 
miRNA expression, and cell signalling pathways. The investigations of the cell 
signalling comprised in silico docking evaluation of the possible interactions 
between cell signalling proteins and anthocyanins and their metabolites as well as 
the western blot analysis of the impact on the phosphorylation of cell-signalling 
proteins and transcription factors. 
3.* Investigations of the effect of anthocyanins and their metabolites on the agonist-
induced platelet activation and platelet-monocyte and platelet-neutrophil 
aggregation in human whole blood. 
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3.& MATERIALS AND METHODS 
3.1.& Materials 
All chemicals, antibodies, solutions, and kits that were used in the experimental work 
are listed in Table 4 to 10. 
Table 4. Anthocyanins and their metabolites tested in the experimental work 
 Compound Chemical structure Manufacturer 
A
nt
ho
cy
an
in
s 
Cyanidin-3-O-arabinoside 
(cy-3-arab) 
 
Extrasynthese  
(Genay, France) 
Cyanidin-3-O-galactoside 
(cy-3-gal) 
 
Cyanidin-3-O-glucoside 
(cy-3-glc) 
 
Delphinidin-3-O-glucoside 
(del-3-glc) 
 
Peonidin-3-O-glucoside 
(pn-3-glc) 
 
M
et
ab
ol
ite
s 
4-hydroxybenzaldehyde 
(4-HBAL) 
 
Sigma-Aldrich 
(St. Louis, USA) 
 
 
Protocatechuic acid 
(PCA) 
 
Vanillic acid 
 
Ferulic acid 
 
Hippuric acid 
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Table 5. Chemicals and commercially prepared solutions used in the experimental work 
Name Manufacturer 
Ethanol  
(≥99.8%, for molecular biology) Sigma-Aldrich (St. Louis, USA) 
 Hydrochloric acid (HCl) 
Chloroform  VWR Prolabo Chemicals (Radnor, USA) 
Bovine serum albumin (BSA) Euromedex (Strasbourg, France) 
Recombinant TNFα* R&D Systems (Minneapolis, USA) 
Human MCP-1* 
Miltenyi Biotec 
(Bergisch Gladbach, Germany) 
ADP Sigma-Aldrich (St. Louis, USA) 
Phosphate buffered saline (PBS 1X) Dominique Dutscher (Brumath, France) 
Trypsin/Ethylenediaminetetraacetic acid (EDTA) 
(0.05%/0.02%; w/o Ca, Mg, sterile, filtered) 
Pan Biotech (Aidenbach, Germany) 
Coulter ISOTON II electrolyte solution Beckman Coulter (Fullerton, USA) 
FCR-blocking reagent, human 
Miltenyi Biotec 
(Bergisch Gladbach, Germany) 
MS-SAFE protease and phosphatase inhibitor 
Cocktail 
Sigma Aldrich (St. Louis, USA) 
 
Radio-immunoprecipitation assay buffer (RIPA 
buffer) 
Sodium dodecyl sulphate (SDS) 
Ammonium persulfate (APS) 
Tetramethylethylenediamine (TEMED) 
40% Acrylamide/bisacrylamide solution 
(37.5/1) 
Euromedex (Strasbourg, France) 
Ponceau S solution Sigma Aldrich (St. Louis, USA) 
BD FACS Lysing Solution 10X 
BD Biosciences (Franklin Lakes, USA) CellFIX 10X 
BD FACS Flow Sheath Fluid 
 * dissolved in PBS with 0.2% BSA 
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Table 6. The cell culture media and supplements used in the cell-based assays 
Name Manufacturer 
Endothelial cell basal medium 
(w/o phenol red)  
Lonza 
(Basel, Switzerland) Endothelial cell growth medium SingleQuots™ 
RPMI 1640 
(L-glutamine, 2g/L NaHCO3, phenol red) Pan Biotech 
(Aidenbach, Germany) 
Penicillin/ streptomycin 
Fetal bovine serum (FBS) 
(inactive, Sterile, filtered) 
Dominique Dutscher (Brumath, France) 
 
Table 7. List of commercially available kits and their components used in the experimental work 
Name Components Manufacturer 
miRNeasy Micro Kit 
QIAzol Lysis Reagent 
RNeasy MinElute Spin Columns 
Buffer RWT 
Buffer RPE 
RNase-Free Water 
Qiagen 
(Hilden, Germany) 
High Capacity cDNA RT kit 
10X RT Buffer 
10X RT Random Primers 
25X dNTP Mix (100 mM) 
MultiScribe Reverse Transcriptase 
RNase Inhibitor 
Applied 
Biosystems  
(Foster City, USA) 
TaqMan Fast Advanced 
Master Mix 
AmpliTaq® Fast DNA Polymerase 
Uracil-N-glycosylase (UNG) 
dNTPs (with dUTP) 
ROX™ dye (passive reference) 
optimised buffer 
Power SYBR Green PCR 
Master Mix 
SYBR® Green 1 Dye 
AmpliTaq Gold DNA Polymerase LD 
dNTPs with dUTP/dTTP blend 
Passive Reference 1 
optimised buffer  
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Table 7 (Continued) 
Name Components Manufacturer 
miRNA Complete Labelling 
and Hyb Kit 
10X Gene Expression Blocking Agent 
2X Hi-RPM Hybridisation Buffer 
T4 RNA Ligase 
10X T4 RNA Ligase Buffer 
Calf Intestinal Phosphatase 
10X Calf Intestinal Phosphatase Buffer 
Dimethyl sulfoxide (DMSO) 
nuclease-free water 
Cyanine 3-pCp 
Agilent 
Technologies 
(Santa Clara, USA) 
MicroRNA Spike-In Kit 
Labelling Spike-In 
Hyb Spike-In 
Dilution Buffer 
Gene Expression Wash 
Buffer Kit 
Gene Expression Wash Buffer 1 
Gene Expression Wash Buffer 2 
Triton X-102 (10%) 
Bicinchoninic acid (BCA) 
Protein Quantitation Kit 
BSA Standard stock solution (2 
mg/ml) 
Reagent A 
Reagent B 
Interchim 
(Montluçon, 
France) 
LumiGLO reserve 
chemiluminescent substrate 
Reagent A (luminol solution) 
Reagent B (reaction buffer) 
(1:2 v/v) 
KPL 
(Gaithersburg, 
USA) 
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Table 8. Solutions used in the experimental work 
* All chemicals used to prepare solutions were from Sigma-Aldrich (St. Louis, USA) unless differently stated  
Name  Composition* 
0.2% Gelatin solution   
0.2% (w/v) Gelatin  
MiliQ water 
Crystal violet solution  
0.5% (w/v) Crystal violet 
20% (v/v) Methanol 
Solubilizing solution 0.1 M Sodium citrate (pH 7.4) 50% (v/v) Methanol 
4% Paraformaldehyde (PFA) solution 
4 % (w/v) PFA  
NaOH 5N 
10X PBS  
MiliQ water 
Flow cytometry analysis buffer 
0.5% (w/v) BSA 
2mM EDTA (pH 7.4) 
1X PBS  
1X Running buffer 
0.25 M Tris-base 
1.92 M Glycine  
0.1% (w/v) SDS 
MiliQ water 
4X Cracking buffer 
0.166 M Tris-HCl, pH6.8  
33.3 % (v/v) Glycerol  
6.6 % (v/v) SDS   
0.16% (v/v) β-mercaptoethanol 
0.05% (w/v) Bromophenol blue 
1X Transfer Buffer 
0.25 M Tris-base 
0.95 M Glycine 
20% (v/v) Ethanol 
MiliQ water 
1X Tris-Buffer-Tween20  
(TBS-T)  
0.032M Tris-base 
0.168M Tris-HCl 
1.5M NaCl 
2% Tween20 
MiliQ water 
pH 7.4 
Blocking buffer 
5% (w/v) Milk Powder  
1X TBS-T 
Modified HEPES-Tyrode’s buffer (HTB) 
 
10 mM HEPES 
137 mM NaCl 
2.8 mM KCl 
1 mM MgCl2 
12 mM NaHCO3 
0.4 mM Na2HPO4 
0.35% (w/v) BSA 
5.5 mM glucose 
pH 7.4 
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Table 9. The antibodies used in flow cytometry analysis 
Name Antigen Isotype Manufacturer 
Fluorescein isothiocyanate-
conjugated Anti-Human CD45 
antibody (CD45-FITC) 
CD45 Mouse IgG2a, κ 
Miltenyi Biotec 
(Bergisch Gladbach, 
Germany) 
Fluorescein isothiocyanate-
conjugated Mouse Anti-Human 
CD61 antibody (CD61-FITC) 
GPIIIa 
(part of GIIb/IIIa 
complex) 
Mouse 
IgG1, κ 
BD Biosciences 
(Franklin Lakes, 
USA) 
 
Fluorescein isothiocyanate-
conjugated Mouse Anti-Human 
PAC-1 antibody (PAC1-FITC) 
GPIIb/IIIa  
(on activated platelets) 
Mouse 
IgM, κ 
Phycoerythrin-conjugated 
Mouse Anti-Human antibody 
(CD62P-PE) 
CD62P 
(syn. P-selectin) 
Mouse 
IgG1, κ 
Phycoerythrin-conjugated 
Mouse Anti-Human CD11b 
antibody (CD11b-PE) 
CD11b (syn. MAC1) 
(part of CD11b/CD18 
heterodimer) 
Mouse 
IgG2, κ 
Peridinin Chlorophyll Protein 
Complex-conjugated CD61 
antibody (CD61-PerCP) 
GPIIIa (part of 
GIIb/IIIa complex) 
Mouse 
IgG1, κ 
Peridinin Chlorophyll Protein 
Complex-conjugated CD14 
antibody (CD14-PerCP) 
CD14 Mouse IgG2, κ 
Isotype controls 
Fluorescein isothiocyanate-conjugated Mouse IgG2a 
antibody (IgG2a -FITC) 
Mouse 
IgG2a, κ 
Miltenyi Biotec 
(Bergisch Gladbach, 
Germany) 
Fluorescein isothiocyanate-conjugated Anti-Human IgG1 
antibody (IgG1-FITC) 
Mouse 
IgG1, κ 
BD Biosciences 
(Franklin Lakes, 
USA) 
 
Fluorescein isothiocyanate-conjugated Anti-Human IgM 
antibody (IgM-FITC) 
Mouse 
IgM, κ 
Phycoerythrin-conjugated Anti-Human IgG1 antibody 
(IgG1-PE) 
Mouse 
IgG1, κ 
Phycoerythrin-conjugated Anti-Human IgG2 antibody 
(IgG2-PE) 
Mouse 
IgG2, κ 
Peridinin Chlorophyll Protein Complex-conjugated Anti-
Human IgG1 antibody (IgG1-PerCP) 
Mouse 
IgG1, κ 
Peridinin Chlorophyll Protein Complex-conjugated Anti-
Human IgG2 antibody (IgG2-PerCP) 
Mouse 
IgG1, κ 
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Table 10. Antibodies used in Western blot analysis 
Name Species type Working dilution* Manufacturer 
p44/42 MAPK (ERK1/2) Rabbit 
monoclonal 1/1000 
Cell Signaling 
(Danvers, USA) Phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) 
Rabbit 
monoclonal 
1/2000 
NF-κB p65 Rabbit 
polyclonal 1/1000 
Genetex  
(Irvine, USA) 
Phospho-NF-κB p65 (Ser536) Rabbit 
monoclonal 1/1000 
Cell Signaling 
(Danvers, USA) 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (FL-335) 
Rabbit 
polyclonal 1/1000 
Santa Cruz 
Biotechnology 
(Santa Cruz, USA) 
Horseradish peroxidase-conjugated 
Anti-Rabbit IgG antibody  
(IgG-HRP) 
Goat 
Polyclonal 1/4000 
Abbiotec 
(San Diego, USA) 
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3.2.& Methods 
To achieve the aim of this thesis, two in vitro studies were performed: 
−* a study of the impact of anthocyanins and their metabolites on endothelial cell 
function, conducted at the French National Institute for Agricultural Research in 
Saint-Genès-Champanelle, France 
−* a study of the effect of these compounds on platelet function, performed at the 
Centre of Research Excellence in Nutrition and Metabolism in Belgrade, Serbia. 
3.2.1.&Investigations of the effects of anthocyanins and their metabolites on 
endothelial cell function 
The impact of anthocyanins and their metabolites on endothelial cell function was 
assessed by examining the adhesion of monocytes to activated endothelial cells as well 
as monocyte transendothelial migration. Further investigations of the effect of these 
bioactive compounds on gene expression, miRNA expression and cell signalling in 
endothelial cells were performed to identify the underlying molecular mechanisms of 
action. 
3.2.1.1.&Preparation of compounds 
Each of the commercially available anthocyanins was dissolved in 70% ethanol with 
1% HCl and metabolites in 70% ethanol, to obtain stock solutions of 10 mM and 20 mM, 
respectively. Aliquots of these solutions were stored at -80 °C until used. 
3.2.1.2.&Cell culturing 
For the investigations of the effect of anthocyanins and their metabolites on 
endothelial cell function and endothelial-monocyte interactions, primary human 
umbilical vein endothelial cells (HUVECs) and THP1 monocytic cell line were used. 
Pooled donor HUVECs obtained from Lonza (Basel, Switzerland) were cultured in a 
phenol red-free endothelial growth medium supplemented with 2% FBS, 0.1% human 
epidermal growth factor, 0.1% vascular endothelial growth factor, 0.4 % human fibroblast 
growth factor, 0.1% insulin-like growth factor, 0.1% heparin, 0.1% ascorbic acid, 0.04% 
hydrocortisone and 0.1% gentamicin/amphotericin-B. THP1 cell line purchased from 
ATCC (Manassas, USA) was cultured in the basic growth medium RPMI 1640 
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supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were 
cultured at 37 °C in a humid air atmosphere with 5% carbon dioxide. 
3.2.1.3.&Cell viability assay 
The available literature shows that anthocyanins and their metabolites do not exert a 
cytotoxic effect on endothelial cells when tested at up to 100 µM levels (Xie et al. 2012; 
Edwards et al. 2015). Therefore, only the effect of solvents (70% ethanol/1% HCl and 
70% ethanol) on endothelial cell viability was tested. HUVECs at passage four were 
seeded in a 0.2% gelatin-coated 24-well plate (Becton Dickinson, Le Pont de Claix, 
France) at a density of 15000 cells/well. At 80% of confluence, cells were exposed for 3 
and 24 hours to 70% ethanol/1% HCl or 70% ethanol, diluted in the cell culture medium 
to a final concentration of 0.1% (v/v). Cells treated only with the culture medium were 
used as a control. Following the treatment, cell viability was determined using the 
previously reported, adapted crystal violet staining assay (Cao et al. 2012). Briefly, cells 
were rinsed using 1X PBS and stained with 200 µl/well of crystal violet staining solution 
(Table 8) for 15 minutes at room temperature. Cells were then washed with water for four 
times and air-dried at room temperature overnight. Subsequently, 150 µl of solubilising 
solution (Table 8) was added per well to solubilise the colourant. Coloured solutions from 
each well were transferred to a 96-well plate (Becton Dickinson, Le Pont de Claix, 
France) and the optical density was measured at 550 nm using the Infinite 200 PRO 
NanoQuant microplate reader (TECAN, Zurich, Switzerland). Viability was presented as 
a percentage relative to the control. 
3.2.1.4.& Experimental conditions: compound concentrations and time of 
exposure 
To test whether anthocyanins (cy-3-glc, cy-3-gal, cy-3-arab, cy-3-glc, del-3-glc, pn-
3-glc) and their metabolites (4-HBAL, PCA, vanillic, ferulic or hippuric acids) can affect 
monocyte-endothelial cell interactions and if they exert a dose-response effect, all 
compounds were tested over a range of concentrations: 0.1 µM, 0.2 µM, 0.5 µM, 1 µM 
and 2 µM. The chosen concentration range was in accordance with the plasma levels of 
these compounds reported after the consumption of anthocyanin-rich sources (Table 11). 
The selected time of the exposure of cells with tested compounds was 3 hours for 
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anthocyanins and their degradation product 4-HBAL, and 18 hours for anthocyanin gut 
metabolites (PCA, vanillic, ferulic or hippuric acids). The chosen duration of the cell 
exposure was in agreement with the plasma residence time of tested compounds observed 
in anthocyanin bioavailability studies in humans (Figure 9) (Table 11). 
Table 11. Summary of the maximum concentration in human plasma and the time to reach peak 
concentration of compounds used in this study 
*Cmax - maximum concentration in plasma. **Tmax - time to reach Cmax, GIT-gastrointestinal tract 
For the investigations of the possible synergistic effect of anthocyanins and their 
metabolites at their circulating plasma concentrations, two mixtures of compounds were 
created. The first mixture, named mix A, was prepared with compounds that are present 
in the circulation from 1 to 5 hours after the consumption of anthocyanin-rich foods. This 
mixture contained cy-3-glc, cy-3-gal, cy-3-arab, del-3-glc, pn-3-glc and 4-HBAL. The 
final concentration of compounds in this mixture that was added to endothelial cells was 
0.1 µM for anthocyanins and 0.5 µM for 4-HBAL. The second mixture, named mix B, 
contained metabolites that can be detected in the circulation for around 15 hours 
following the anthocyanin intake. This mixture consisted of PCA, vanillic acid, ferulic 
acid and hippuric acid, administrated to endothelial cells at the final concentration of 0.2 
µM, 2 µM, 1 µM and 2 µM, respectively. The chosen concentrations of compounds of 
Compound 
Anthocyanin 
form in the 
circulation 
Cmax 
(µM)* 
Tmax 
(h)** Reference 
cy-3-arab Intact  0.013 1.5 (Milbury et al. 2010) 
cy-3-gal Intact  0.098 2 (Kay et al. 2004) 
cy-3-glc Intact  0.14 1.8 (Czank et al. 2013) 
del-3-glc Intact  0.023 1.5 (Matsumoto et al. 2001) 
pn-3-glc Intact 0.059  0.5 (Frank et al. 2003) 
4-HBAL Upper GIT metabolite 0.67 5.6 
(de Ferrars, Czank, et al. 
2014) 
PCA Gut metabolite 0.15 3.3 (de Ferrars, Czank, et al. 2014) 
Vanillic acid Gut metabolite 1.85 12.5 (de Ferrars, Czank, et al. 2014) 
Ferulic acid Gut metabolite 0.94 11.3 (Czank et al. 2013) 
Hippuric acid Gut metabolite 1.96 15.7 (Czank et al. 2013) 
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these mixtures were closest to those previously reported in human plasma following the 
anthocyanin consumption (Table 11). Endothelial cells were exposed to the mix A for 3 
hours and the mix B for 18 hours. In addition to this, an experimental condition named 
mix A+B, where the cells were first exposed to the mix A for 3 hours and then mix B for 
18 hours, was designed to mimic as closely as possible the profiles of anthocyanin forms 
present in circulation after the intake of anthocyanin-rich sources (Figure 9). 
3.2.1.5.&Cell adhesion assay 
HUVECs at passage four were seeded in 0.2% gelatin-coated 24-well plates at a 
density of 50000 cells/well. At 80% of confluence, cells were exposed to cy-3-gal, cy-3-
arab, cy-3-glc, del-3-glc, pn-3-glc or 4-HBAL for 3 hours and to PCA, vanillic, ferulic or 
hippuric acids for 18 hours. Each compound was tested over a physiologically relevant 
range of concentrations from 0.1 µM to 2 µM. A series of dilutions of stock solutions of 
compounds were prepared using 70% ethanol/1% HCl or 70% ethanol and subsequently 
diluted in cell culture medium to reach working concentrations, right before application 
to cells. Cells exposed to 70% ethanol/1% HCl or 70% ethanol, diluted to a final 
concentration of 0.1% (v/v) in the culture medium were used as a control. Following the 
incubation, the medium containing treatments was discarded, and inflammation induced 
by stimulating cells with the fresh media containing 1 ng/ml TNFα for 4 hours. Cells 
treated only with the culture medium were used as the negative control ((-) TNFα 
condition). Subsequently, 400 µl of cell suspension containing 250000 THP1 cells was 
added to each well and cells were co-incubated for 15 minutes. Wells were then rinsed 
for three times with 1X PBS to remove non-adhering THP1 cells, and the remaining cells 
were detached by incubation with 100 µl/well of trypsin/EDTA solution for 3 min at 
37°C. Afterwards, 200 µl of 1X PBS containing 10% FBS was added per well to 
neutralise trypsin. Samples of collected cells were then fixed with 100 µl/well of 4% PFA 
solution (1% final concentration) and stored at 4 °C until analysis by flow cytometry the 
following day. These cell adhesion assays were performed in triplicates for both 
treatments and controls. The schematic representation of this experimental design is given 
in Figure 11. 
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Figure 11. Schematic representation of the in vitro investigations of the effect of individual 
anthocyanins and their metabolites on monocyte adhesion to HUVECs 
To further investigate the possible synergic effect of anthocyanins and their 
metabolites on monocyte adhesion, endothelial cells were exposed to mixtures of these 
compounds (section 3.2.1.4.). The adhesion assay was performed as described above 
except that the HUVECs were exposed to the mix A for 3 hours or mix B for 18 hours as 
well as to their corresponding controls (Figure 12). For the mix A+B, HUVECs were 
exposed to the mix A for 3 hours after which medium was replaced with the fresh one 
containing the mix B for 18 hours. Cells treated with the culture media containing 70% 
ethanol/1% HCl for 3 hours and 70% ethanol for further 18 hours, were used as a control 
for this experimental condition. These cell adhesion assays were performed in 
quintuplicates for both treatments and controls. 
Figure 12. Schematic representation of the in vitro investigations of the effect of mixtures on 
monocyte adhesion to HUVECs 
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3.2.1.6.&Quantification of monocyte adhesion to endothelial cells by flow 
cytometry methodology 
The flow cytometry was used to measure the adhesion of THP1 monocytes to 
HUVECs. This technique allows distinction between different cell types in the same 
sample based on their morphological characteristics and presence of specific surface 
antigens. The morphological characterisation is based on light scattering that occurs when 
each cell is illuminated by the laser beam. The resulting forward scatter (FSC) is 
proportional to the size of the cell while the side scatter (SSC) gives information about 
cell granularity. Additionally, the use of antibodies conjugated to fluorescent dyes that 
bind to antigens expressed only on the surface of specific cell type allows to detect these 
cell markers and further distinguish between different cells (Brown & Wittwer 2000). 
Differentiation between THP1 monocytes and HUVECs and their quantification in 
the samples collected from the adhesion assays was achieved with the use of the human 
CD45-FITC antibody that binds to CD45-antigen expressed on the surface of monocytes. 
In addition to samples obtained from cell adhesion assays, samples containing only THP1 
cells or HUVECs were also prepared and fixed for the flow cytometry analyses to control 
the specific binding of antibodies. All cell samples were immunostained as recommended 
by the manufacturer. Briefly, samples were centrifuged for 10 minutes at 300 x g and 
incubated with FcR blocking reagent (dilution 1:8) for 10 minutes in the dark to inhibit 
nonspecific binding of antibodies. Subsequently, cell samples were incubated with the 
human CD45-FITC antibody (dilution 1:10) for 30 minutes in the dark. Mouse IgG2a-
FITC antibody (dilution 1:10) was used as isotype control for determining nonspecific 
antibody binding. Both FcR blocking and antibody dilutions were prepared with the flow 
cytometry analysis buffer (Table 8). Following the immunostaining, 500 µl of this buffer 
was added to each sample. Samples were immediately measured and analysed on the 
FACSCalibur flow cytometer (BD Bioscience, San Jose, USA) using the integrated 
CellQuest Pro software, version 5.1.1. Following the acquisition set to 20000 events, the 
number of monocytes (i.e. CD45-positive cells) and HUVECs (i.e. unstained cells) in 
each sample were determined by the analysis of CD45-FITC/FSC diagrams. Monocyte 
adhesion was calculated as a ratio of quantified monocytes to HUVECs and expressed in 
comparison to positive control (TNFα-stimulated HUVECs) that was normalised to 
100%. 
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3.2.1.7.&Transmigration assay 
The effects of mixtures on monocyte transendothelial migration were assessed using 
a transmigration model with Transwell® inserts (Corning, NY, USA) (Figure 13). These 
inserts of 6.5 mm in diameter contained 5 µm pores at a density of 4x105 pores/cm2 that 
allowed cell migration. 
Fourth-passage HUVECs were seeded onto 0.2% gelatin-coated inserts at a density 
of 15000 cells/insert and cultured until reached confluence. Subsequently, the endothelial 
cell monolayer was exposed either to mix A for 3 hours, mix B for 18 hours or to mix 
A+B for 21 hours and their matching controls (as described in the section 3.2.1.5). Each 
of these treatments was added to both upper and lower chambers of the transwell system 
(100 µl and 500 µl, respectively). At the end of the exposure time, treatments were 
discarded, and 100 µl of THP1 cell suspension containing 0.5 x 106 cells/ml was added 
to the upper chambers. 500 µl of medium containing chemoattractant MCP-1 at a final 
concentration of 50 ng/ml was added to the lower chambers. The same volume of 
chemoattractant-free medium was used as a negative control. Cells were then co-
incubated for 4 hours to allow the transmigration of monocytes. Following the incubation, 
samples of transmigrated THP1 cells were taken from the lower chambers and quantified 
with a Z1 Coulter particle counter system using the ISOTON II electrolyte solution as 
recommended by the manufacturer (Beckman Coulter, Fullerton, USA). This system uses 
the electrical sensing zone technology that allows accurate counting and sizing of cells 
based on quantifiable changes in electrical resistance produced by cells that are suspended 
in an electrolyte solution (Henriquez et al. 2004). Samples were measured for three times 
in a random order. Monocyte transmigration assays were performed in quadruplicates for 
both treatments and controls. The results were reported as a percentage of transmigrated 
monocytes relative to positive control (the (+) MCP-1 condition). 
 
Figure 13. The in vitro model of transendothelial migration using transwells 
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3.2.1.8.&Impact on gene expression 
3.2.1.8.1.#RNA extraction 
For the investigations of the effect of anthocyanins and their metabolites on the gene 
expression, fourth-passage HUVECs were seeded in 0.2% gelatin-coated Petri dishes at 
a density of around 106 cells/ dish and cultured until reaching 80% confluence. Cells were 
then treated with the mix A, mix B, mix A+B and their matching controls as described in 
the section 3.2.1.5. Subsequently, inflammation was induced by incubation with 1 ng/ml 
TNFα for 4 hours, while the cell culture medium was used as negative control. The 
extraction of total RNA, including miRNA was performed using the Qiagen miRNeasy 
Micro Kit (Table 7). According to manufacturer’s instructions, HUVECs were washed 
twice with 1X PBS before lysis with QIAzol lysis reagent for 5 minutes at room 
temperature. Collected lysates were separated into three phases by incubation with 
chloroform at room temperature for 2 minutes and subsequent centrifugation at 12000 x 
g at 4°C for 15 minutes. The RNA-containing aqueous phase was collected and mixed 
with 1.5 volume of 100% ethanol. These mixtures were transferred onto RNAeasy 
MinElute columns and centrifuged at 8000 x g for 30 seconds at room temperature to 
allow the binding of total RNA to the column’s membrane. Membranes were then washed 
with RWT buffer, RPE buffer and 80% ethanol, respectively. Each wash was followed 
by quick centrifugation at 8000 x g to remove the impurities. Total RNA was eluted from 
each column using 30 µl of RNase-free water. Aliquots of total RNA samples were stored 
at -80°C. 
RNA quality and quantity were determined by agarose gel electrophoresis and 
NanoDrop ND-1000 spectrophotometer using the ND-1000 software, version 3.8.1 
(Thermo Fisher Scientific, Wilmington, USA). The electrophoresis on the 1% agarose 
gel stained with ethidium bromide allowed the RNA quality assessments by visualisation 
of bands corresponding to 28S and 18S ribosomal RNA. RNA was considered to be of 
high quality if the ratio of 28S:18S bands was around 2.0 or higher. The evaluation of 
RNA quality using NanoDrop spectrophotometer was based on the ratio of absorbance at 
260 nm and 280 nm. Additionally, a ratio of absorbance at 260 nm and 230 nm was used 
as a secondary measure of quality. An RNA with the 260/280 ratio of around 2.0 and 
260/230 values in the range of 2.0-2.2 was considered as pure. Only the RNA samples 
that passed these quality criteria were used for later experiments. 
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3.2.1.8.2.#Reverse transcription of total RNA 
Reverse transcription of total RNA samples was performed using the High Capacity 
cDNA RT kit. 10 µl of each total RNA sample (200 µg/µl) was mixed with the reaction 
solution containing 2 µl of 10X RT buffer, 0.8 µl of 25X dNTP Mix (100 mM), 2 µl of 
10X RT random primers, 1 µl MultiScribe reverse transcriptase (50U/µl), 1 µl of RNase 
inhibitor and 3.2 µl of nuclease-free water. Reverse transcription was performed using a 
thermal cycler (Bibby Scientific, Stone, UK) under the following conditions: 10 minutes 
at 25 °C, 2 hours at 37 °C and 5 minutes at 85 °C. The obtained cDNAs were stored at -
20 °C. 
3.2.1.8.3.#Quantitative real-time PCR analysis 
The impact of mixtures of anthocyanins and their metabolites on the gene expression 
in HUVEC was investigated using the 384 Wells TaqMan Array Micro Fluidic Cards 
(TLDA cards) (Applied Biosystems, Foster City, USA) that allowed simultaneous 
assessments of gene expression levels of multiple genes. These TLDA cards consisted of 
eight loading ports, each connected to 48 wells preloaded with TaqMan probes and 
primers specific for target genes. TLDA cards were custom designed for investigation of 
expression of 91 different genes involved in regulation of endothelial function 
(Supplementary Table 1).  
Before the investigations of gene expression with TLDA cards, a real-time PCR 
quantification of the expression of vascular cell adhesion molecule 1 (VCAM1) and 
selectin E (SELE) genes was performed with (-) TNFα and (+) TNFα cDNA samples to 
verify the efficiency of TNFα to induce inflammation and modulate the gene expression 
profiles in HUVECs. These gene show low levels of expression in basal conditions while 
their expression is markedly increased upon stimulation with the proinflammatory agents 
(Ley 1996). PCR reactions were prepared with 10 µl of Power SYBR Green PCR Master 
Mix, 0.4 µl of reverse and forward primers (both at 10 pm/µl concentration), and 2 µl of 
the cDNA in the final reaction volume of 20 µl. The primers that were used were: 
VCAM1-F: GGG AAG ATG GTC GTG ATC CTT, VCAM1-R: TCT GGG GTG GTC 
TCG ATT TTA; SELE-F: AGA GTG GAG CCT GGT CTT ACA; SELE-R: CCT TTG 
CTG ACA ATA AGC ACT GG; GAPDH-F: CTG GGC TAC ACT GAG CAC C, 
GAPDH-R: AAG TGG TCG TTG AGG GCA ATG. Real-time quantitative PCR 
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amplifications were performed in a MicroAmp Fast optical 96-well reaction plate 
(Applied Biosystems, Foster City, USA) using the 7900HT system (Applied Biosystems, 
Foster City, USA) with integrated Sequence Detection System software, version 2.4 
under the following conditions: 2 minutes at 50 °C, 10 minutes at 95 °C, 40 cycles of 15 
seconds at 95 °C and 1 minute at 60 °C. 
Gene expression analyses with TLDA cards were performed with (+) TNFα, mix A, 
mix B and mix A+B cDNA samples. According to manufacturer’s instructions, 1 000 ng 
of cDNA samples were diluted in nuclease-free water to a final volume of 105 µl and 
mixed with 105 µl of TaqMan Fast Advanced Master Mix. Each mixture was divided 
between the two loading ports of TLDA card. TLDA cards were centrifuged twice in 
Heraeus multifuge 3S centrifuge (Applied Biosystems, Foster City, USA) for one minute 
at 1200 rpm and subsequently sealed with a TLDA Sealer (Applied Biosystems, Foster 
City, USA) to prevent well-to-well contamination. Real-time quantitative PCR 
amplifications were performed by Applied Biosystems 7900HT system (Foster City, 
USA) under the same conditions as described above for the quantification of the VCAM1 
and SELE expression. The obtained raw data were analysed with the Relative 
Quantitation (RQ) web-based software from Thermo Fisher Scientific 
(https://www.thermofisher.com/fr/fr/home/cloud), which calculates relative gene 
expression using a comparative threshold cycle (Ct) method, also known as the 2-ΔΔCt 
method (Schmittgen & Livak 2008). Briefly, Ct data (i.e. the number of cycles required 
for the amplified target to cross the fixed threshold) were used to calculate ΔCt values by 
subtracting Ct value of endogenous control from Ct value of each gene of interest. ΔΔCt 
values were then calculated by subtracting the calibrator ((+) TNFα condition) from the 
ΔCt value of each gene of interest. The relative gene expression was calculated as 2-ΔΔCt 
and analysed using Student’s t-tests with the (+) TNFα samples as a reference biological 
group. 
3.2.1.9.&Investigations of miRNA expression using miRNA microarrays 
The investigations of the effect of mixtures of tested compounds on miRNA 
expression in HUVECs were performed using 8x15K miRNA microarrays (V3) from 
Agilent Technologies (Santa Clara, USA). This technology combines highly efficient 
direct labelling method and special probe design that allow accurate measurements of 
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miRNA profiles (Wang et al. 2006; Mestdagh et al. 2014). The array format used in these 
experiments included eight microarrays printed on a single glass slide. Each of the 
microarrays contained around 15000 probes that corresponded to 866 human and 89 
human viral miRNAs of the Sanger miRBase database, version 12.0. Labelling and 
hybridisation of total RNA samples were performed using miRNA complete labelling 
and hybridisation kits (Table 7) obtained from Agilent Technologies (Santa Clara, CA, 
USA). Agilent’s miRNA Spike-in Kit was used to monitor the labelling and hybridisation 
efficiencies and therefore distinguish significant biological data from processing issues. 
This kit contained in vitro synthesised RNAs that were added to samples during the 
labelling and hybridisation steps as a control. 
Following the manufacturer's instructions, 100 ng of each of the previously extracted total 
RNA samples (50 ng/µl) was dephosphorylated by incubation with calf intestinal 
phosphatase for 30 minutes at 37 °C. Samples were further denatured using 100% DMSO 
for 5 minutes at 100 °C and immediately transferred to ice-water bath to prevent 
reannealing. Subsequently, samples were labelled with cyanine 3-pCp fluorescent dye by 
incubation with T4 RNA ligase for 2 hours at 16 °C and vacuum dried for 1.5 hours at 55 
°C to remove residual DMSO that could interfere with hybridisation process. Dried 
pellets were then suspended in nuclease-free water and incubated with the hybridisation 
mixture containing blocking reagent and hybridisation buffer for 5 minutes at 100 °C. 
Afterwards, samples were loaded onto microarray slides and hybridised to microarray 
probes using the SureHyb microarray hybridisation chamber (Agilent Technologies, 
Santa Clara, USA) set to 20 rpm and 55 °C for 20 hours. Following the hybridisation, 
microarrays were washed with the Gene expression washing buffer kit (Table 7) and 
scanned with the Agilent G2505 microarray scanner system (Santa Clara, USA). Feature 
Extraction software version 11.0. (Agilent Technologies, Santa Clara, USA) was used to 
extract the raw data from microarray images. Raw data were normalised to the 50th 
percentile and analysed with moderated t-tests corrected by Westfall-Young permutation 
using the Gene Spring GX software version 14.5 (Agilent Technologies, Santa Clara, 
USA). 
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3.2.1.10.& Bioinformatics analysis 
Gene and miRNA expression data were examined using different bioinformatics 
tools:  
−* Kyoto Encyclopedia of Genes and Genomes (KEGG) database 
(http://www.genome.jp/kegg/tool/map_pathway2.html) was used for pathway 
analysis. 
−* MetaCore software (GeneGo, St Joseph, USA; https://portal.genego.com/) was 
used to identify the most significant transcription factors involved in the 
regulation of the genes identified as differentially expressed in the gene 
expression experiments. Identification of upstream cell signalling proteins 
involved in the regulation of these potential transcription factors was performed 
using KEGG database. 
−* Hierarchical clustering and heatmap visualisation of the miRNA expression 
profiles were carried out using PermutMatrix, version 1.9.3. (Caraux & Pinloche 
2005). 
−* miRWalk 2.0 (Dweep & Gretz 2015), a comprehensive database that provides 
information on predicted and experimentally verified miRNA-mRNA interactions 
was used to identify possible gene targets of differentially expressed miRNA. 
−* BioVenn (http://www.cmbi.ru.nl/cdd/biovenn) and Venny 2.1.0. 
(http://bioinfogp.cnb.csic.es/tools/venny/) web applications were used to create 
Venn diagrams. 
3.2.1.11.& Investigations of the effect on cell signalling pathways 
3.2.1.11.1.#In silico docking analyses 
The molecular docking was used to predict the possible binding interactions between 
anthocyanins/their metabolites (ligands) and transcription factors and signalling proteins 
(targets) that were identified using Metacore and KEGG bioinformatics tools as described 
in the previous section. These bindings could hypothetically affect the activity of cell 
signalling proteins and transcription factors and explain the observed changes in gene 
expression and, ultimately, cellular response.  
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The in silico docking analyses were performed in collaboration with Dr Radu Tamaian 
from the National Institute for Research and Development for Cryogenic and Isotopic 
Technologies in Râmnicu Vâlcea, Romania. Before docking analyses, MarvinSketch 
chemical editor version 16.10.24.0 (ChemAxon, Budapest, Hungary, 
https://www.chemaxon.com) was used for drawing two-dimensional chemical structures 
of ligands, their three-dimensional (3D) optimisation and creation of input files for 
docking. Furthermore, MarvinSpace version 16.10.24.0 (ChemAxon, Budapest, 
Hungary, https://www.chemaxon.com/) was used to identify ligands’ pharmacophore 
points, i.e. steric and electronic features necessary for molecular recognition of a ligand 
by a biological macromolecule (Wermuth et al. 1998). The Universal Protein Resource 
(UniProt) (http://www.uniprot.org/) and RCSB Protein Data Bank (RCSB-PDB) 
(http://www.rcsb.org/) online databases were used to obtain the high-resolution, complete 
3D structure of targets needed for docking (i.e. a resolution higher than 2.0 Å and the 
coverage higher than 90%). High-resolution full-length 3D structures were available for 
only three targets, while for the rest of the targets the homologues models were 
constructed using the SWISS-MODEL (Supplementary Table 2), a fully automated 
protein structure homology-modelling server that is accessible through the ExPASy web 
server (https://swissmodel.expasy.org, Arnold et al. 2006). 
All docking runs were performed by Python Prescription Virtual Screening Tool, 
version 0.9.4 using AutoDock Vina (Trott & Olson 2010) as a docking software. This 
software uses the X-score-inspired scoring function tuned with a PDBbind dataset (Wang 
et al. 2004; Wang et al. 2005) to predict noncovalent binding of a macromolecule with a 
ligand, and automatically calculates the grid maps (Trott & Olson 2010). Search space 
was set to cover the targets entirely to reveal all possible ligand-protein interactions and 
the accuracy of computations was improved by increasing the default exhaustiveness (the 
number of calculation repeats) by ten times. Following the docking, the most relevant 
results concerning binding affinity (BA) were thoroughly examined using the Molegro 
Molecular Viewer software, version 2.5 (CLC Bio, Aarhus, Denmark). 
3.2.1.11.2.#Western blot analysis 
To associate results of molecular docking analyses with the in vitro effects on cell 
signalling, the phosphorylation of p65 (a subunit of NF-κB transcription factor) and 
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ERK1/2 cell signalling protein were examined by Western blot. 
For these investigations, the same cell treatments were used as described in the section 
3.2.1.5. Cells were washed twice with 1X PBS and lysed with 700 µl of RIPA buffer with 
1X MS-SAFE protease and phosphatase inhibitor cocktail (Table 5) by incubation on ice 
for five minutes. Plates were rapidly scraped and lysates were collected and frozen at -80 
°C overnight. The following day, lysates were centrifuged at 8000 x g for 10 minutes at 
4 °C, and supernatants containing the soluble proteins stored at -80 °C. Protein 
concentrations were determined by spectrophotometry using the BCA protein 
quantification kit (Table 7). Following the manufacturer’s instructions, a series of BSA 
solutions prepared in RIPA buffer were used to obtain the standard curve. 25 µl of each 
sample and standard dilution were added into the 96-well multiple well plate (in technical 
triplicate), mixed with 200 µl of BCA working reagent containing reagents A and B in a 
1:50 ratio, and then incubated for 30 minutes at room temperature in the dark. The 
absorbance was measured at 562 nm using the Infinite 200 PRO NanoQuant microplate 
reader (TECAN, Zurich, Switzerland). The protein concentrations in samples were 
calculated based on the BSA standard curve and the measured absorbance for each 
sample. 
Proteins from the collected samples were first separated based on their molecular 
weight by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
(Laemmli 1970). 20 µg of each protein sample were mixed with 4X cracking buffer 
(added in a 1:3 ratio) and denatured at 95 °C for 3 minutes. Samples were directly loaded 
onto polyacrylamide gels composed of a 4% stacking gel (containing 0.125 M Tris-HCl 
(pH 6.8), 4% acrylamide/bis, 0.1% SDS, 0.1% APS and 0.1% TEMED) and 10% or 12% 
resolving gel (containing 0.375 M Tris-base (pH 8.8), 10% or 12% Acrylamide/bis, 0.1% 
SDS, 0.1% APS solution and 0.1% TEMED). Electrophoresis was performed at 100 V 
for 90 minutes using the Mini-Protean Vertical Electrophoresis System (Biorad, 
Hercules, USA) and running buffer (Table 8). 
Following the separation, protein transfer ("blotting") onto the Hybond-P 
polyvinylidene difluoride (PVDF) membrane (GE Healthcare Europe, Velizy-
Villacoublay, France) was carried out at 100 V for 80 min using the Mini Trans-Blot 
System (Biorad, Hercules, USA) filled with transfer buffer (Table 8). The efficiency of 
the transfer was checked by incubating membranes with the PonsoS solution for several 
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seconds. Subsequently, membranes were blocked with the blocking buffer (Table 8) for 
one hour at room temperature and incubated with selected primary antibodies at 4 °C 
overnight. These antibodies included: p44/42 MAPK (ERK1/2), phospho-p44/42 MAPK 
(Thr202/Tyr204), NF-κB p65 and phospho-NF-κB p65 (Ser536) antibodies while 
GAPDH was used as a loading control. Following the incubation, membranes were 
washed for four times with 1X TBS-T solution (Table 8) and then incubated with a 
corresponding secondary antibody conjugated to horseradish peroxidase (HRP) for one 
hour at room temperature. The list of used antibodies and their dilutions is given in Table 
10. Following the incubation with secondary antibody, membranes were again washed 
with 1X TBS-T solution and incubated for one minute with the LumiGLO reserve 
chemiluminescent substrate solution (Table 7) to detect the proteins. Chemiluminescent 
signals were captured using the Syngene G-Box (Ozyme, Saint Quentin Yvelines, France) 
with integrated Syngene GeneSys image acquisition software, version 1.2.5., and proteins 
were quantified by ImageJ software (National Institutes of Health, Rockville Pike, USA, 
http://rsb.info.nih.gov). The obtained protein levels were normalised to GAPDH.  
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3.2.2.& Investigations of the effects of anthocyanins and their metabolites 
on platelet function 
The investigations of the impact of anthocyanins and their metabolites on platelet 
function included the evaluation of their in vitro effect on platelet activation and platelet-
leukocyte aggregation responses to ADP as platelet agonist. These investigations were 
performed using whole blood flow cytometry in accordance with the standardised 
protocols with slight modifications (Krueger et al. 2002; Barnard et al. 2003). 
3.2.2.1.&Volunteers and blood collection 
The whole blood samples were taken from seven apparently healthy, non-smoking 
non-obese men, aged between 28 to 34 years. Their health status was estimated based on 
their medical history. Volunteers visited the research centre twice, with one visit 
corresponding to investigations of the effect of anthocyanins on platelet function and the 
other one to the evaluation of the impact of anthocyanin metabolites. There was at least 
a three-week wash out between these visits. Volunteers were asked to refrain from the 
consumption of alcohol, berry fruits, berry-derived products (e.g. juices and jams) and 
regularly consumed polyphenol-rich drinks such as tea and coffee for 72 hours before 
each blood collection to reduce the impact of bioactives from background diet on platelet 
function. Blood was drawn in the morning after an overnight fast of at least 12 hours and 
at least 20 minutes of seated rest. Blood collection was performed by venepuncture using 
the 21-gauge needle and no tourniquet, discarding the first 2 ml of drawn blood. This 
procedure was in accordance with previously published standardised protocols for blood 
sampling in platelet analyses (Krueger et al. 2002; Gerrits et al. 2016). The whole blood 
collected in Vacutainer tubes, with sodium citrate (3.2%) as an anticoagulant (BD 
Diagnostics, Franklin Lakes, USA), was used straightaway for the examinations of 
platelet function. Additional blood samples were taken for the assessments of 
haematological and biochemical parameters. 
3.2.2.2.&Whole blood treatments 
Right after the blood collection, aliquots of whole blood were incubated with tested 
compounds for 10 min at 37 °C (Figure 14). This short incubation needed to fit into a 
narrow time frame between the blood collection and flow cytometry measurements, 
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determined as the maximum one hour (Krueger et al. 2002; Barnard et al. 2003). This 
short time frame was required to minimise the impact of extracorporeal platelet activation 
and influence of other factors affecting investigated parameters such as the effect of 
leukocytes activated by platelets. 
Compounds were tested at following concentrations: anthocyanins at 0.1 µM, 4-
HBAL at 0.5 µM, PCA at 0.2 µM, vanillic acid at 2 µM, ferulic acid at 1 µM and hippuric 
acid at 2 µM concentration. These chosen concentrations were closest to the plasma levels 
of these compounds reported after the consumption of anthocyanin-rich sources (de 
Ferrars, Cassidy, et al. 2014; de Ferrars, Czank, et al. 2014). Dilutions of anthocyanins 
and their metabolites were prepared from stock solutions (section 3.2.1.1.) using HTB 
and added to whole blood samples to reach the aforementioned working concentrations. 
The whole blood treated with 70% ethanol with 1% HCl or 70% ethanol in matched 
concentration was used as a blank for anthocyanins and metabolites, respectively. These 
blanks did not affect platelet activation and aggregation. 
 
Figure 14. Schematic representation of the whole blood treatments used for the investigations 
of the in vitro effect of anthocyanins and their metabolites on platelet function. 
3.2.2.3.&Assessments of platelet activation 
Platelet activation was assessed based on the expression of P-selectin and GPIIb/IIIa 
on the surface of activated platelets. 
 Whole blood samples, treated with tested compounds or blank, were diluted with 
HTB (1:10) (Table 8). 20 µl of diluted whole blood samples were then activated with a 
suboptimal, 0.5 µM concentration of platelet agonists ADP and labelled with 5µl of 
antiCD61-PerCP (platelet identifier), antiCD62P-PE and PAC1-FITC antibody (Table 9) 
for 20 minutes at room temperature in the dark. Diluted blank blood, labelled with 
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monoclonal antibodies and treated with an optimal, 20 µM concentration of ADP was 
used to control the optimal response (Krueger et al. 2002; Barnard et al. 2003). Diluted 
and labelled blank blood without the addition of agonist and with the addition of an equal 
volume of HTB, was used to monitor platelet extracorporeal activation. At the end of the 
incubation time, samples were fixed with 400 µl of 1X CellFix solution for 15 minutes at 
room temperature in the dark and immediately analysed by FACSCalibur flow cytometer 
(BD Biosciences, Franklin Lakes, USA) and integrated CellQuest software, version 6.0. 
Schematic representation of a workflow is given in Figure 15. 
Figure 15. Schematic representation of the platelet analyses workflow 
Anti-human IgG1-FITC, IgG1-PE and IgM-FITC antibodies (Table 9) were used as 
isotype controls for determining nonspecific antibody binding. Platelets were 
distinguished from leucocytes and red blood cells based on their specific forward and side 
light scatter and their CD61-PerCP fluorescence. The expression of the analysed markers 
of activation was expressed as a percentage or a mean fluorescence intensity (MFI) of P-
selectin or GPIIb/IIIa positive platelets (CD62P+CD61+ or PAC1+CD61+) in a population 
of 20000 platelets (CD61+ cells). The former represented the percentage of activated 
platelets in the total platelet population and later corresponded to a mean density of P-
selectin or GPIIb/IIIa on activated platelets. 
3.2.2.4.&Assessments of platelet aggregation with monocytes and neutrophils 
The whole blood samples treated with tested compounds or blank were used for the 
assessments of platelet-leucocyte aggregates. 25µl of whole blood samples were treated 
with a suboptimal, 0.5µM concentration of platelet agonists ADP and labelled with 5µl 
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of antiCD61-FITC (platelet identifier), antiCD14-PerCP (monocyte identifier) and 
antiCD11b-PE antibody (neutrophil identifier) (Table 9) by incubation for 15 minutes at 
room temperature in the dark. Labelled blank blood, treated with 20 µM ADP was used 
to control the optimal response. Labelled blank blood without the addition of agonist and 
with the addition of an equal volume of HTB, was used to monitor platelet extracorporeal 
activation. Following the incubation, samples were treated with 1.2 ml of 1X Lysing 
solution at room temperature in the dark for 12 minutes to lyse erythrocytes. Samples 
were then washed twice in HTB, fixed with 300 µl of 1X CellFix solution and 
immediately analysed on the flow cytometer (Figure 15). Anti-human IgG1-FITC, IgG2-
PE, and IgG2-PerCP antibodies (Table 9) were used as isotype controls for determining 
nonspecific antibody binding. Platelet aggregation with monocytes and neutrophils was 
expressed as a percentage of platelet-monocyte aggregates (CD14+CD61+ events) in the 
population of 1000 monocytes (CD14+ cells) and platelet-neutrophil aggregates (CD11b+ 
CD61+ events) in the population of 10000 neutrophils (CD11b+ cells). 
3.2.2.5.&Assessments of biochemical and haematological parameters 
The biochemical and haematological analyses were performed to confirm volunteers’ 
good health. 
For the biochemical analysis, blood was collected in Vacutainer SSTTM II Advance 
tubes (BD Diagnostics, Franklin Lakes, USA), clotted at room temperature for l5-20 
minutes and then centrifuged at 2000 rpm for 10 minutes to separate serum. 500 µl of 
serum was used for evaluation of defined biochemical parameters using the Cobas c111 
clinical chemistry analyser (Roche Diagnostics, Basel, Switzerland) and appropriate 
Cobas reagent kits, as recommended by the manufacturer. The analysed parameters 
included: lipid status, glucose level, the activity of liver enzymes, levels of urea, uric acid, 
creatinine and iron. 
For the haematological analysis, blood was collected in Vacutainer tubes containing 
K2EDTA as an anticoagulant (BD Diagnostics, Franklin Lakes, USA). Haematological 
parameters were evaluated using the ABX micros 60 haematology analyser (Horiba, 
Kyoto, Japan). 
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3.2.2.6.&Measurements of anthropometric parameters and blood pressure in 
healthy volunteers 
Evaluated anthropometric parameters included body height, hip and waist 
circumferences as well as body weight measured using the TANITA UM-072 body 
composition analyser (Arlington Heights, USA). 
The obtained values of body weight and height were used to calculate the body mass 
index (BMI) with the following equation: BMI = Weight (kg) / (Height (m))2. 
Systolic and diastolic blood pressure and heart rate were measured using the 
professional IntelliSense HEM-907XL blood pressure monitor (Omron, Bannockburn, 
USA) and expressed as an average value of three successive measurements. 
3.2.3.& Statistical analysis 
Data from the cell adhesion and transmigration assays and Western blot experiments 
were analysed by one-way analysis of variance (ANOVA) followed by Dennett’s post-
hoc multiple comparison tests using Prism software, version 6.0.c for Mac OS X 
(GraphPad, La Jolla, CA, USA). For the assessments of the expression of platelet 
activation and aggregation markers, the obtained data was first examined by the Shapiro-
Wilk normality test and then analysed by the paired samples t-test using the SPSS 
software, version 20.0. (SPSS, Chicago, USA), with the p-value<0.05 considered as 
significant. All of these data were graphically presented using the Prism software as mean 
with standard deviation (SD). 
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4.& RESULTS 
4.1.& Investigations of the effect of anthocyanins and their metabolites 
on endothelial cell function 
4.1.1.&Cell viability assay 
The results from the available literature show that anthocyanins and their metabolites 
do not significantly affect endothelial cell viability when tested at up to 100µM 
concentrations. Therefore, in this thesis, the cytotoxic effect of solvents that were used to 
dissolve anthocyanins and their metabolites was assessed prior to investigations of the 
impact of these compounds on endothelial cell function. Results from the cell viability 
assay using crystal violet revealed that both 3 and 24-hour exposure of HUVECs to either 
70% ethanol or 70% ethanol with 1% HCl diluted to a final concentration of 0.1% (v/v) 
in the culture medium did not significantly affect the cell viability (Figure 16).  
 
Figure 16. The effect of solvents (70% ethanol or 70% ethanol with 1% HCl, diluted to a final 
concentration of 0.1% (v/v)) on endothelial cell viability. Viability is represented in comparison 
to control (HUVECs treated with culture medium) that is normalised to 100%. Results are 
reported as mean ± SD of four replicates for both control and experimental treatments. 
4.1.2.&The effect of anthocyanins and their upper GIT metabolite 4-HBAL 
on monocyte adhesion to TNFα-activated endothelial cells 
To test whether anthocyanins and their upper GIT metabolite 4-HBAL alter monocyte 
adhesion to inflamed endothelial cells, cell adhesion assays were performed as described 
in the section 3.2.1.5. Following the co-incubation with unstimulated endothelial cells, 
monocyte exhibited low, basal levels of adhesion (Figure 17). This was significantly 
changed upon stimulation of HUVECs with TNFα when a 9.2-fold increase in monocytes 
adhesion was observed compared to unstimulated cells. Pretreatment of HUVECs for 3 
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hours with different anthocyanins displayed the ability of these compounds to reduce the 
TNFα-induced increase in monocyte adhesion (Figure 17). Cy-3-gal at 0.1µM, 0.2µM 
and 2µM concentrations significantly diminished monocyte adhesion by 21.0%, 15.4% 
and 22.8 %, respectively, while pre-exposure of endothelial cells with cy-3-arab at 0.1µM 
and 2µM levels decreased adhesion by 30.4% and 23.5%, respectively. Cy-3-glc 
significantly attenuated monocyte adhesion only at the highest tested concentrations, with 
a reduction of 26.3% and 29.9% observed at 1 µM and 2 µM concentrations, respectively.  
By contrast, pn-3-glc significantly decreased monocyte adhesion by 26 % at the lowest, 
0.1 µM concentration, with no significant effect at other tested concentrations. Of all 
examined anthocyanins only del-3-glc displayed a significant effect on monocyte 
adhesion at all tested concentrations, with the highest decrease of 33.1 % observed at 0.1 
µM concentration. Unlike anthocyanins, pretretement of HUVECs to the anthocyanin 
upper GIT metabolite 4-HBAL for 3 hours did not significantly affect monocyte adhesion 
to activated endothelial cells at any tested concentration (12.2 % reduction at 0.5 µM and 
19.7% at 2 µM level) (Figure 17). 
Figure 17. The effect of pretreatment of endothelial cells with anthocyanins and their upper 
GIT metabolite 4-HBAL on monocyte adhesion to TNFα-stimulated HUVECs. Monocyte 
adhesion is represented in comparison to positive control (TNFα-stimulated HUVECs) that is 
normalised to 100%. Results are reported as mean ± SD of three replicates. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
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4.1.3.& The impact of gut metabolites on monocyte adhesion to TNFα-
stimulated endothelial cells 
Similar to anthocyanins, all of the tested gut metabolites exhibited the ability to affect 
monocyte adhesion to activated endothelial cells (Figure 18). Pretreatment of HUVECs 
for 18 hours with vanillic acid at 0.2 µM and 2 µM concentrations significantly decreased 
monocyte adhesion by 25.8% and 19.0%, respectively. Both hippuric and ferulic acids 
significantly attenuated monocyte adhesion only at the highest tested concentrations, with 
a decrease of 18.1% observed with 2 µM hippuric acid and 21.3% and 31.5% with 1 µM 
and 2 µM ferulic acid, respectively. PCA showed the greatest ability to affect monocyte 
adhesion to TNFα-activated endothelial cells, causing the significant 31.9%, 28.7%, 
38.4% and 47% reductions in monocyte adhesion at 0.2 µM, 0.5 µM, 1µM and 2 µM 
concentrations, respectively (Figure 18). 
Figure 18. The effect of pretreatment of endothelial cells with gut metabolites on monocyte 
adhesion to TNFα-stimulated HUVECs. Monocyte adhesion is represented in comparison to 
positive control (TNFα-stimulated HUVECs) that is normalised to 100%. Results are shown as 
mean ± SD of three replicates. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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4.1.4.&The impact of mixtures of anthocyanins and their metabolites on 
monocyte adhesion to TNFα-stimulated endothelial cells 
With the aim to investigate the possible synergic effect of anthocyanins and their 
metabolites that are present in the circulation at the same time following the anthocyanin 
intake, HUVECs were pretreated with different mixtures of compounds, and monocyte 
adhesion to TNFα-activated endothelial cells was assessed. Pre-exposure of endothelial 
cells for 3 hours with the mixture of anthocyanins and their upper GIT metabolite 4-
HBAL (mix A) significantly lowered monocyte adhesion by 26.4% (Figure 19A). The 18 
hour-treatment with the mixture of anthocyanin gut metabolites (mix B) also significantly 
decreased monocyte adhesion by 18.7%, although to a lesser extent than mix A (Figure 
19B). Pre-exposure of HUVECs with the mix A for 3 hours and then mix B for 18 hours, 
i.e. the experimental condition that mimicked the anthocyanin pharmacokinetic profiles 
in the circulation following the consumption of anthocyanin-rich foods (mix A+B), also 
significantly attenuated monocyte adhesion by 30.6% (Figure 19C). 
 
Figure 19. The effect of pre-exposure of HUVECs with the mix A (A), mix B (B) and mix A+B 
(C) on monocyte adhesion to TNFα-stimulated HUVECs. Monocyte adhesion is represented in 
comparison to positive control (TNFα-stimulated HUVECs), normalised to 100%. Results are 
displayed as mean ± SD of three replicates. **p<0.01, ****p<0.0001. 
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4.1.5.&The effect of mixtures of anthocyanins and their metabolites on 
monocyte transendothelial migration 
The effect of mixtures on monocyte transendothelial migration was examined using 
a transwell system as described in the section 3.2.1.7. As shown in Figure 20, the addition 
of chemoattractant cytokine MCP-1 to the lower compartments of transwell system 
resulted in a significant 3.2-fold increase in monocyte migration through HUVEC 
monolayer compared to condition with no added MCP-1. Pre-exposure of endothelial 
cells with different mixtures significantly attenuated the MCP-1 induced increase in 
monocyte transendothelial migration (Figure 20). Mix A displayed the ability to decrease 
the transmigration by 43.9%, mix B by 50.5% and mix A+B by 41.2%. 
 
Figure 20. The effect of pre-exposure of HUVECs with the mix A (A), mix B (B) and mix A+B 
(C) on MCP-1-induced monocyte transendothelial migration. The values are represented in 
comparison to positive control (MCP-1-stimulated HUVECs), normalised to 100%. Results are 
displayed as mean ± SD of four replicates. **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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4.1.6.&The effect of mixtures of anthocyanins and their metabolites on gene 
expression in endothelial cells 
The impact of anthocyanins and their metabolites on gene expression in endothelial 
cells was examined with an aim to identify the mechanisms by which these compounds 
could induce the observed effects on monocyte adhesion and transendothelial migration. 
In the test experiments performed before the gene expression macroarray analysis 
using TLDA cards, the ability of TNFα to induce the inflammation and modulate the 
expression of inflammatory genes VCAM1 and SELE in the endothelial cells was 
confirmed. This experiment showed that the low, basal expression of these genes in 
TNFα-non-activated endothelial cells was significantly increased upon the 4 hour-
treatment with TNFα (Figure 21). 
 
Figure 21. The effect of TNFα on the relative expression of genes encoding cell adhesion 
molecules VCAM-1 and E-selectin in HUVECs. Relative gene expression was normalised to 
housekeeping gene GAPDH and shown as fold-change over TNFα-activated HUVECs. Results 
are displayed as mean ± SD of three replicates, *p<0.05, **p<0.01, student t-tests. 
The impact of mixtures of tested compounds on the expression of 91 genes involved 
in endothelial cell function was evaluated using macroarrays. These results revealed that 
the pre-exposure of endothelial cells to the mix A, mix B and mix A+B resulted in 
significant alterations in gene expression when compared to TNFα-stimulated cells 
nonexposed to mixtures (Table 12). Mix A significantly affected the expression of 7 genes 
such as ICAM1, CXCL12 or IKBKB that encode proteins involved in the regulation of 
cell adhesion or NF-κB signalling pathway. Mix B significantly altered the expression of 
10 genes, including genes like CDH5, CLDN1, CAPN1 and ITGA5. These genes are 
involved in pathways that regulate leukocyte transendothelial migration cell adhesion, 
tight junction or focal adhesion. Pretreatment of endothelial cells with the mix A and then 
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mix B significantly modulated the expression of 7 genes, such as GJA4, ITGA5, CXCL12 
and CAPN1 that are involved in the pathways regulating leukocyte transendothelial 
migration, actin cytoskeleton organisation or focal adhesion. 
Table 12. Genes identified as differentially expressed between endothelial cells pre-exposed to 
the mix A, mix B or mix A+B and stimulated with TNFα and those treated only with TNFα 
Gene symbol Gene Name FC 
Mix A 
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta 0.44 
CXCL12 C-X-C motif chemokine ligand 12 0.52 
CLDN1 claudin 1 0.31 
IGF1R insulin-like growth factor 1 receptor 0.44 
ICAM1 intercellular adhesion molecule 1 0.51 
F11R F11 receptor 0.49 
FABP4 fatty acid binding protein 4 0.22 
Mix B 
CDH5 cadherin 5 15.12 
JAM3 junctional adhesion molecule 3 1.55 
CALM1 calmodulin 1 3.01 
CASK calcium/calmodulin-dependent serine protein kinase 4.01 
RHOC ras homolog gene family member C 0.37 
ITGA5 integrin subunit alpha 5 0.59 
CAV1 caveolin 1 4.18 
CLDN1 claudin 1 5.45 
CALD1 caldesmon 1 9.14 
CAPN1 calpain 1 0.45 
Mix A+B 
GJA4 gap junction protein alpha 4 12.88 
CDH5 cadherin 5 7.20 
ITGA5 integrin subunit alpha 5 0.37 
EZR ezrin 2.06 
CXCL12 C-X-C motif chemokine ligand 12 0.21 
TLN1 talin 1 0.39 
CAPN1 calpain 1 0.38 
Results are expressed as fold change (FC) over TNFα-activated HUVECs, p<0.05. 
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4.1.7.&The effect of anthocyanins and their metabolites on endothelial cell 
signalling 
Gene expression is controlled at the transcriptional level by transcription factors 
which activity is regulated by signalling pathways. Therefore, differentially expressed 
genes from gene expression experiments were analysed to find possible transcription 
factors and signalling proteins that could mediate the observed nutrigenomic effect of 
tested compounds. The most significant transcription factors that were identified by 
Metacore included CREB1, SP1, c-Jun and NF-κB (Supplementary Table 3). Afterwards, 
the KEGG database was used to determine the upstream signalling proteins that are 
involved in regulation of the activity of these transcription factors. A network of 62 
proteins (including transcription factors and their regulatory cell signalling proteins) was 
identified (Figure 22) and further analysed by molecular docking to investigate whether 
anthocyanins and their metabolites can bind to these proteins and possibly affect their 
activity, which could be associated with the observed modulations in gene expression. 
Figure 22. Schematic representation of 62 proteins identified from gene expression data using 
Metacore and KEGG bioinformatics tools, 
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Before docking, the chemical structures of anthocyanins and their metabolites were 
drawn (Figure 23) and their pharmacophore points examined.  
 
Figure 23. The chemical structures of anthocyanins and their metabolites 
 
The pharmacophore search (Figure 24) showed that the phenolic ring system of 
anthocyanins is planar and electron-rich. Their planar benzene ring is hydrophobic, but 
their phenolic hydroxyl group that is also present in their metabolites confers polarity and 
solubility in water as well as the capacity to form hydrogen (H) bonds with proteins. 
Additionally, hippuric acid has an electron donor (-NH-) and may form additional H- 
bonds with proteins. Only a few amino acid (AA) residues of investigated protein targets 
such as asparagine (Asn), glutamine (Gln), histidine (His), Ser, glutamic acid (Glu), 
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aspartic acid (Asp) or tyrosine (Tyr) can make H-bonds with the ligands. Extended 
hydrophobic regions of all ligands allow them to interact with the regions of targets that 
are rich in hydrophobic AA residues like alanine (Ala), leucine (Leu), isoleucine (Ile), 
valine (Val), methionine (Met), tryptophan (Trp) cysteine (Cys), phenylalanine (Phe) or 
proline (Pro). 
 
Figure 24. Pharmacophore points of the examined ligands. Ligands are represented as stick 
and balls. Yellow spheres show the hydrophobic points, red spheres the electron acceptor 
points, blue spheres the electron donor point and yellow arrows the direction of the 
pharmacophore effects. 
 
The molecular docking analyses revealed that anthocyanins and their metabolites 
present capacity to bind to the identified cell signalling proteins (Supplementary Table 
4). The BA of anthocyanins for the investigated targets ranged from -4.9 to -9.9 kcal/mol. 
Results show that anthocyanins can establish strong interactions (BA between -8.5 and -
9.9 kcal/mol) with some of the investigated signalling proteins (Supplementary Table 4). 
Among these proteins were those belonging to STE Ser/Thr protein kinase family (dual 
specificity mitogen-activated protein kinase kinase 2 (MEK2)), CMGC Ser/Thr protein 
kinase family (mitogen-activated protein kinase 8 (JNK1)), Tyr protein kinase family 
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(focal adhesion kinase 1 (FAK1)), AGC Ser/Thr protein kinase family (Rho-associated 
protein kinase 2 (ROCK2)) and Ser/Thr protein kinase family (inhibitor of nuclear factor 
kappa-B kinase subunit alpha (IKKα)) of protein kinases (Supplemental table 5).  
Results of molecular docking against MEK2 (Supplementary Table 5) revealed that 
tested anthocyanins interact only with the protein kinase domain of this target via 
adenosine triphosphate (ATP) binding site and Ser/Thr-protein kinase active site. Figure 
25 shows different views of the best docking pose of del-3-glc that forms strong H-bonds 
and steric interactions with Ser/Thr-protein kinase active site (located between positions 
190-202) and ATP binding site (located between positions 78-101) of MEK2, a binding 
pattern that may influence the protein kinase activity of this enzyme.  
 
Figure 25. Best docking pose of del-3-glc, the strongest binder of MEK2 (target presented as 
thin sticks with secondary structure drawn as cartoon backbone; ligand as sticks). The general 
view with H-bonds (light blue dashed lines) and energy grid (light blue-hydrogen acceptor 
favourable; green-steric favourable; yellow-hydrogen donor favourable; orange to red, dark 
blue-electrostatic interactions) (top image). Detailed view with H-bonds formed between ligand 
and target (bottom left). Target presented with molecular surface (cropped view) whit ligand 
deeply buried inside of the binding pocket (bottom right). 
 
Docking against JNK revealed that anthocyanins establish strong interactions with 
the protein kinase domain of this protein through H-bonds and steric interactions (Figure 
26, Supplementary Table 5). All tested anthocyanins can bind to JNK1 in a large binding 
pocket described between Ile32 and Asp169, which includes the conserved signature 
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region of MAP kinases (located between positions 61-163) and the Ser/Thr-protein kinase 
active site (located between positions 145-159), which may affect the kinase functions of 
this cell signalling protein. 
 
Figure 26. Best docking pose of cy-3-glc, the strongest binder of JNK1 (target presented as thin 
sticks with secondary structure drawn as cartoon backbone; ligand as sticks). The general view 
with H-bonds (light blue dashed lines) and energy grid (light blue-hydrogen acceptor 
favourable; green-steric favourable; yellow-hydrogen donor favourable; orange to red, dark 
blue-electrostatic interactions) (top image). Detailed view with H-bonds formed between ligand 
and target (bottom left). Target presented with molecular surface (cropped view) whit ligand 
deeply buried inside of the binding pocket (bottom right). 
Docking results against FAK1 showed that anthocyanins establish strong interactions 
with the protein kinase domain (cy-3-arb and cy-3-gal), FERM domain (pn-3-glc and cy-
3-glc) or both protein kinase and FERM domain (del-3-glc, Figure 27) of FAK1 trough 
H-bonds and steric interactions (Supplementary Table 5). Interaction of ligands with the 
FERM domain could affect the localisation of this protein to the plasma membrane, while 
interactions of anthocyanins with the protein kinase ATP binding site (located between 
positions 428-454) and Tyr-protein kinase active site (located between positions 542-554) 
of FAK1 may affect its kinase function. 
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Figure 27. Best docking pose of del-3-glc, the strongest binder of FAK1 (target presented as 
thin sticks with secondary structure drawn as cartoon backbone; ligand as sticks). The general 
view with H-bonds (light blue dashed lines) and energy grid (light blue-hydrogen acceptor 
favourable; green-steric favourable; yellow-hydrogen donor favourable; orange to red, dark 
blue-electrostatic interactions) (top image). Detailed view with H-bonds formed between ligand 
and target (bottom left). Target presented with molecular surface (cropped view) whit ligand 
deeply buried inside of the binding pocket (bottom right). 
Results of docking analyses against ROCK2 showed that investigated anthocyanins 
are deeply buried inside of the protein kinase domain (Ile98-Asp232), with ligands-
protein interactions formed by H-bonds and electrostatic interaction (Supplementary 
Table 5, Figure 28). Additionally, weak steric interactions are established with AGC-
kinase C-terminal domain (pn-3-glc, del-3-glc, cy-3-glc and cy-3-arab having steric 
interactions with Phe384, while cy-3-gal establishes steric interactions with Phe384 and 
Ile387). The binding pattern demonstrates that the bulky anthocyanins interplay 
concomitantly with Ser/Thr-protein kinase active site (located between positions 210-
222) and protein kinase ATP binding site (located between positions 98-121).  
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Figure 28. Best docking pose of cy-3-gal, the strongest binder of ROCK2 (target presented as 
thin sticks with secondary structure drawn as cartoon backbone; ligand as sticks). The general 
view with H-bonds (light blue dashed lines) and energy grid (light blue-hydrogen acceptor 
favourable; green-steric favourable; yellow-hydrogen donor favourable; orange to red, dark 
blue-electrostatic interactions) (top image). Detailed view with H-bonds formed between ligand 
and target (bottom left). Target presented with molecular surface (cropped view) whit ligand 
deeply buried inside of the binding pocket (bottom right). 
Docking results against IKKα showed that all investigated anthocyanins interact with 
the protein kinase domain (located between positions 15-302) and AAs of the α-helix that 
is located close to the Leucine-zipper (Figure 29, Supplementary Table 5). This indicates 
that tested anthocyanins do not interact with the protein kinase ATP binding site (located 
between positions 22-44) but establish strong interactions with Ser/Thr-protein kinase 
active site (located between positions 140-152) and surrounding area via H-bonds and 
steric interactions, which may affect Ser/Thr-protein kinase activity. 
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Figure 29. Best docking pose of cy-3-gal, the strongest binder of IKKα (target presented as thin 
sticks with secondary structure drawn as cartoon backbone; ligand as sticks). The general view 
with H-bonds (light blue dashed lines) and energy grid (light blue-hydrogen acceptor 
favourable; green-steric favourable; yellow-hydrogen donor favourable; orange to red, dark 
blue-electrostatic interactions) (top picture). Detailed view with H-bonds formed between 
ligand and target (bottom left). Target presented with molecular surface (cropped view) whit 
ligand deeply buried inside of the binding pocket (bottom right). 
Regarding anthocyanin gut metabolites, docking results showed that these 
compounds can also bind cell signalling proteins with some ligand-target interactions BA 
reached or overpassed -7.0 kcal/mol: ferulic acid against protein Janus kinase 3 (JAK3), 
myosin light-chain kinase (MLCK), mitogen-activated protein kinase 11 (p38β) and b-
Raf proto-oncogene (b-Raf), hippuric acid against p38β, b-Raf, Raf-1 proto-oncogene (c-
Raf) and ERK1, PCA against and b-Raf and CREB binding protein (CREBBP). However, 
in general, these metabolites are weaker binders than anthocyanins (Supplementary 
Figure 1), with BA mainly between -3.3 and -6.9 kcal/mol (Supplementary Table 4). 
Results of docking analyses against JAK3, a Tyr-protein kinase with two described 
catalytic regions (between positions 521-777 and 822-1095), showed that ferulic acid 
interacts with this kinase in a small binding pocket deeply inside of its second catalytic 
domain (Figure 30, Supplementary Table 6). Ferulic acid interacts with the Tyr-protein 
kinase catalytic domain via two strong H-bonds (with Leu905 and Asp967 (Figure 30)) 
and weak steric interactions (Supplementary Table 6). Additional weak steric interactions 
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are made with the two functional regions of the catalytic domain: the ATP binding site 
and the Tyr kinase active site. 
 
Figure 30. General view (top image) and detail (bottom image) of the best docking pose of ferulic 
acid (figured as ball-and-stick, CPK coloured) against JAK3. Target is depicted as thin sticks with 
secondary structure drawn as cartoon backbone and semi-transparent electrostatic molecular 
surface (cropped to the docking site for a better view in the top image). The bottom image shows 
ferulic acid binding mode (the cropped view showing only the nearest AAs residue-until a 10.0 Å 
distance from ligand), emphasizing two H-bonds (shown as dashed blue lines) established with the 
AAs of the Tyr-protein kinase catalytic domain (Leu905 and Asp967). The energy grid components 
are depicted as fading dots: green-steric favourable; light blue-hydrogen acceptor favourable; 
yellow-hydrogen donor favourable; red and dark blue-electrostatic interactions. 
Docking against MLCK revealed that ferulic acid interacts with the protein kinase 
domain (located at MLCK between positions 106-361). Ferulic acid makes five H-bonds 
and weak steric interactions within the binding pocket (Figure 31, Supplementary Table 
6). Weak H-bonds are established with glycine (Gly)114, Gly115 and lysine (Lys)135 of 
the ATP binding site and another two adjacent AAs (Glu181 and Val183). The binding 
pattern of this metabolite concomitantly blocks the access of substrate at the location of 
the active site of the Ser/Thr-protein kinase, by establishing weak steric interactions. 
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Figure 31. General view (top image) and detail (bottom image) of the best docking pose of ferulic 
acid (figured as ball-and-stick, CPK coloured) against MLCK. Target is depicted as thin sticks with 
secondary structure drawn as cartoon backbone and semi-transparent electrostatic molecular 
surface (cropped to the docking site for a better view in the top image). The bottom image shows 
ferulic acid binding mode (the cropped view showing only the nearest AAs residues-until a 10.0 Å 
distance from ligand), emphasizing five H-bonds (depicted as dashed blue lines) established with the 
AAs from ATP binding site (Gly114, Gly115 and Lys135) and protein kinase domain (Glu181 and 
Val183). The energy grid components are shown as fading dots: green-steric favourable; light blue-
hydrogen acceptor favourable; yellow-hydrogen donor favourable; red and dark blue-electrostatic 
interactions. 
Docking results also showed that PCA interacts with a good BA (7.2 kcal/mol) with 
b-Raf (Supplementary Table 4). PCA forms five H-bonds and multiple steric interactions 
(both weaker and stronger) with the catalytic domain of this target (Ser-Thr/Tyr-protein 
kinase domain, located at b-Raf between positions 458-712) (Figure 32, Supplementary 
Table 6). All interactions are made with AAs from the active site and surrounding 
residues. PCA does not interact with the ATP binding site of b-Raf (located between 
positions 463-483).  
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Figure 32. General view (top image) and detail (bottom image) of the best docking pose of PCA 
(figured as ball-and-stick, CPK coloured) against b-Raf. Target is depicted as thin sticks with 
secondary structure drawn as cartoon backbone and semi-transparent electrostatic molecular 
surface (cropped to the docking site for a better view in the top image). The bottom image shows 
PCA binding mode (the cropped view showing only the nearest AAs residues-until a 10.0 Å distance 
from PCA), emphasizing five H-bonds (depicted as dashed blue lines) established with the AAs of the 
active site located within the Ser-Thr/Tyr-protein kinase, catalytic domain (Leu577) and 
surrounding residues (Ser616, Ser637 and Asp638- two H-bonds). The energy grid components are 
shown as fading dots: green-steric favourable; light blue-hydrogen acceptor favourable; yellow- 
hydrogen donor favourable; red and dark blue-electrostatic interactions. 
Docking against P38β revealed that ferulic acid, hippuric acid and PCA bind into a 
small pocket described inside of protein kinase domain (located at P38β between 
positions 24-308) (Figure 33, Supplementary Table 6). All three metabolites have similar 
binding patterns, making H-bonds and steric interactions with the MAP kinase domain 
and the ATP binding site (Supplementary Table 6).  
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Figure 33. General view (top image) and detail (bottom image) of the best docking pose of 
ferulic acid (yellow), hippuric acid (pink) and PCA (green) against P38β. Target is depicted as thin 
sticks with secondary structure drawn as cartoon backbone and semi-transparent electrostatic 
molecular surface (cropped to the docking site for a better view), metabolites are figured as ball-
and-stick. 
These data suggest that anthocyanins and their metabolites can bind to cell signalling 
proteins and affect their function and phosphorylation of downstream cell signalling 
proteins that in consequence affect transcription factor activity and result in the observed 
nutrigenomic effect. 
To associate results obtained by molecular docking with the possible in vitro effect 
on cell signalling pathways, the impact of anthocyanins and their metabolites on the 
activation of cell signalling proteins or transcription factors (assessed as a ratio of 
phosphorylated to total protein levels) was investigated in endothelial cells. Results 
revealed that pretreatment of HUVECs with the mix A significantly reduced the 
phosphorylation of ERK1/2 and the p65 subunit of NF-κB by 44.2% and 42.9%, 
respectively, compared to cells treated only with TNFα (Figure 34A, B). Mix B 
significantly reduced the phosphorylation of NF-κB-p65 by 26.8% (Figure 34C). 
 
 
 
 83 
 
Figure 34. The effect of mix A on the phosphorylation of p65 (A) and ERK1/2 (B) and the mix B 
on the phosphorylation of p65 (C) in HUVECs. Data are normalised to GAPDH and 
represented relative to positive control ((+) TNFα condition). Results are displayed as the 
mean ± SD from three replicates, *p < 0.05, **p < 0.01. 
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4.1.8.&The effect of mixtures of tested compounds on miRNA expression in 
endothelial cells 
To further investigate how anthocyanins and their metabolites regulate the observed 
nutrigenomic effect, the impact of mixtures of these compounds on the expression of 
miRNAs, the post-transcriptional regulators of gene expression, was examined in 
endothelial cells.  
miRNA microarray analysis revealed that the treatment of HUVECs with TNFα 
resulted in a significant modulation of the expression of 5 miRNAs when compared to 
nontreated cells. Among these differentially expressed miRNAs, four were found 
upregulated and one downregulated with the fold-change values ranging from -1.29 to 
1.64 (Table 13). The exposure of endothelial cells to mix A, mix B or mix A+B before 
TNFα activation, significantly affected the expression of 14, 13 and 13 miRNAs, 
respectively, compared to TNFα-activated HUVECs nonexposed to mixtures. Of these 
differentially expressed miRNAs, all except one were identified as downregulated with 
fold-changes from -1.13 to -2.69 (Table 13). 
Table 13. miRNAs identified as differentially expressed in HUVECs 
FC-fold change, p<0.05 
 
(+) TNFα/ (-) TNFα Mix A/(+) TNFα Mix B/(+) TNFα Mix A+B/(+) TNFα 
miRNA FC miRNA FC miRNA FC miRNA FC 
hsa-miR-146a 1.64 hsa-let-7f -1.21 hsa-let-7a -1.22 hsa-let-7c -1.46 
hsa-miR-155 1.56 hsa-miR-126* -1.42 hsa-let-7f -1.31 hsa-let-7f -1.52 
hsa-miR-320c 1.06 hsa-miR-1260 -1.42 hsa-miR-1246 -1.62 hsa-miR-1207-5p -1.24 
hsa-miR-455-3p 1.62 hsa-miR-1268 -1.21 hsa-miR-125b -1.26 hsa-miR-1246 -1.81 
hsa-miR-923 -1.29 hsa-miR-130a -1.17 hsa-miR-126* -1.41 hsa-miR-125a-5p -1.44 
  hsa-miR-181b -1.71 hsa-miR-1260 -1.35 hsa-miR-125b -1.60 
  hsa-miR-1915 -1.13 hsa-miR-1275 1.33 hsa-miR-1305 -1.77 
  hsa-miR-26a -1.53 hsa-miR-196b 1.58 hsa-miR-181b -2.34 
  hsa-miR-30b -1.46 hsa-miR-216a 2.09 hsa-miR-1915 -1.49 
  hsa-miR-361-5p -1.26 hsa-miR-23a -1.26 hsa-miR-361-5p -1.71 
  hsa-miR-374a -1.25 hsa-miR-374a -1.26 hsa-miR-572 -1.21 
  hsa-miR-376c -1.51 hsa-miR-720 -1.15 hsa-miR-575 -2.69 
  hsa-miR-455-3p -1.44 hsa-miR-923 2.36 hsa-miR-638 -1.22 
  hsa-miR-99b -1.44     
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Hierarchical clustering of miRNAs that were identified as differentially expressed in 
at least one of the studied conditions revealed a cluster of miRNAs with an opposite 
expression profile in endothelial cells treated only with TNFα and those pretreated with 
the mixtures (Figure 35). In this cluster, miRNAs that were found upregulated by TNFα 
when compared to non-treated cells were downregulated when endothelial cells were 
pretreated with the mixtures. These results showed the ability of anthocyanins and their 
metabolites to modulate the miRNA expression in endothelial cells as well as to 
counteract the effect of TNFα. 
 
Figure 35. Heat map of miRNA expression profiles. Each column presents different studied 
condition and each line a miRNA differently expressed in at least one of the conditions. Green 
represents downregulation and red upregulation. 
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The next step of the analysis of miRNA data aimed to identify possible target genes 
of differentially expressed miRNAs by using the miRWalk database of experimentally 
confirmed miRNA-mRNA interactions. This analysis revealed 1635 target genes for the 
miRNAs which expression was significantly altered by TNFα, and 3158, 2114 and 2209 
target genes for the miRNAs which expression was modulated by pretreatment of cells 
with the mix A, mix B and mix A+B, respectively. Comparison of the miRNA target 
genes identified for all of the studied conditions showed that 192 genes were in common, 
whereas 717 target genes were shared between the mixtures (Figure 36). 
 
Figure 36. Venn diagram of the verified target genes of miRNAs found modulated by 
pretreatment of HUVECs with the mixtures. 
Further bioinformatics analyses were carried out to identify cellular pathways in 
which these target genes of differently expressed miRNAs are involved and thereby 
determine probable cellular effects of the observed modulations of miRNA expression. 
These analyses, performed using KEGG database, showed that miRNA target genes could 
regulate various cellular pathways such as cell signalling pathways, metabolic pathways, 
cell-cell adhesion, cytoskeleton reorganisation and chemokine signalling pathways. 
Comparing the top 50 over-represented pathways in which miRNA target genes of all of 
the studied conditions are involved, revealed that 29 pathways are in common (Figure 
37). These pathways included those regulating actin cytoskeleton and focal adhesion as 
well as Ras, Rap1, and chemokine signalling pathways, suggesting that the observed 
changes in the expression of miRNA can affect monocyte adhesion and transmigration 
processes and thus the integrity and function of endothelial cells. 
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Figure 37. Venn diagram of top 50 over-represented pathways in which the gene targets of 
differentially expressed miRNAs are involved. 
Finally, to establish the relationship between the differentially expressed genes and 
the target genes of differentially expressed miRNAs, the gene expression and miRNA 
expression data were compared. For the mix A, four out of seven significantly modulated 
genes were also the target genes of miRNAs which expressions were altered by the same 
mixture. Furthermore, for the mix B and mix A+B, 20% and 14.3% of significantly 
modulated genes were also miRNA target genes. These results suggest that the 
modulation of gene expression observed in response to mixtures of anthocyanins and their 
metabolites could be partly explained by the ability of these bioactives to affect the 
expression of miRNAs.  
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4.2.& Investigations of the effect of anthocyanins and their metabolites 
on platelet function  
4.2.1.&Characteristics of volunteers-blood donors 
Seven apparently healthy, non-smoking male volunteers, between 27 and 34 years 
old, were recruited for the investigations of the in vitro effect of anthocyanins and their 
metabolites on platelet function. Their characteristics are given in Table 14. 
Table 14. Characteristics of volunteers recruited for the in vitro examination of the impact of 
anthocyanins and their metabolites on platelet function 
*Results are expressed as mean ± SD, n=7. BMI-Body mass index, HGB-Hemoglobin, HCT- Hematocrit, RBC-Red 
blood cells, WBC-White blood cells, PLT-Platelet count, PCT- Plateletcrit, MPV-Mean platelet volume, LDL-Low-
density lipoprotein, HDL-High-density lipoprotein, ALT-Alanine transaminase, AST-Aspartate transaminase. 1(WHO 
1999), 2 (Mancia et al. 2007). 
 
Characteristics of volunteers Values* Reference value 
Age (years) 30.00 ± 2.38 N/A 
Height (cm) 185.14 ± 7.03 N/A 
Body weight (kg) 86.04 ± 8.80 N/A 
BMI (kg/m2) 25.08 ± 1.72 <301 
Waist-hip ratio 0.83 ± 0.03 <0.91 
Systolic blood pressure (mmHg) 119.29 ± 8.48 <120; 120-1292 
Diastolic blood pressure (mmHg) 68.07 ± 4.79 <80; 80-842 
HGB (g/l) 140.07 ± 9.99 110-165 
HCT (l/l) 0.44 ± 0.04 0.35-0.50 
RCB (x 1012/l) 5.22 ± 0.42 3.8-5.8 
WBC (x 109/l) 5.79 ± 0.72 3.5-10.0 
PLT (x 109/l) 195.21 ± 11.81 150-390 
PCT (x 10-2l/l) 0.14 ± 0.01 0.1-0.5 
MPV (fl) 7.46 ± 0.81 6.5-11.0 
Total cholesterol (mmol/L) 5.02 ± 1.11 3.87- 5.20 
LDL-cholesterol (mmol/L) 3.33 ± 1.09 < 3.4 
HDL-cholesterol (mmol/L) 1.56 ± 0.25 >1.03 
Triglycerides (mmol/L) 0.80 ± 0.31 0.46-1.70 
Glucose (mmol/L) 5.04 ± 0.34 3.89-5.84 
Iron (µmol/L) 20.90 ± 2.06 11.6-31.3 
Urea (µmol/L) 5.31 ± 1.23 2.10-7.10 
Uric acid (µmol/L) 350.29 ± 36.23 208-428 
Creatinine (µmol/L) 103.59 ± 11.70 53-115 
ALT (U/L) 21.67 ± 7.78 < 40 
AST (U/L) 26.27 ± 5.07 < 40 
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Volunteers were categorized as non-obese according to the World health organisation 
criteria, with BMI < 30 kg/m2 and waist to hip ratio < 0.9 (WHO 1999). Systolic and 
diastolic blood pressure values were within the optimal (<120 and <80 mmHg) and 
normal (120-129 and/or 80-84 mmHg) categories of blood pressure established by the 
European Society of Cardiology and the European Society of Hypertension (Mancia et 
al. 2007). The examined haematological and biochemical parameters of volunteers were 
within normal ranges (Table 14). 
4.2.2.& Impact of anthocyanins on platelet activation markers 
The impact of compounds on ADP-induced platelet activation response was evaluated 
based on their effect on P-selectin and GPIIb/IIIa activation markers assessed as the 
percentage of activated platelets in the total number of platelets and as P-selectin and 
GPIIb/IIIa receptor densities on activated platelets. 
Pre-exposure of whole blood to cy-3-arab at 0.1 µM concentration lowered platelets’ 
activation response to ADP. This effect of cy-3-arab was achieved through a reduction in 
the percentage of P-selectin positive platelets and P-selectin receptor density of 10.2% 
and 7.7%, respectively (Figure 38A, B), compared to agonist-treated control. By contrast, 
0.1 µM cy-3-glc significantly reduced only GPIIb/IIIa density by 4.9% (Figure 38D), 
while cy-3-gal did not exert a significant effect on any of the examined markers of platelet 
activation (Figure 38). Preincubation of whole blood with del-3-glc significantly reduced 
the percentage of P-selectin positive cells by 10.8% and P-selectin density on activated 
platelets by 7.5% (Figure 38A, B), and did not affect GPIIb/IIIa. Similarly, a pre-exposure 
of whole blood to pn-3-glc significantly reduced the percentage of P-selectin positive 
platelets by 10.8% and lowered the density of this receptor by 5.9%, without attaining 
statistical significance (p=0.053) (Figure 38A, B). 
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Figure 38. The effect of anthocyanins on ADP-induced platelet activation assessed as the 
percentage of P-selectin positive platelets in a total number of platelets (A), the density of P-
selectin on activated platelets (B), the percentage of GPIIb/IIIa positive platelet (C) and the 
density of GPIIb/IIIa on activated platelets (D). The results are presented as a change (%) of 
the value for each of the measured parameters in anthocyanin-treated, ADP-activated whole 
blood compared to control (vehicle-treated, ADP-activated samples). MFI-mean fluorescence 
intensity. Data are displayed as mean ± SD, n=7. *p < 0.05, **p < 0.01. 
4.2.3.&Effect of anthocyanin metabolites on platelet activation markers 
Preincubation of whole blood with 0.5 µM 4-HBAL affected ADP-induced platelet 
activation, significantly reducing the percentage of P-selectin positive platelets by 6.9% 
(Figure 39A). By contrast, PCA at 0.2 µM concentration attenuated both examined 
platelet activation markers. It significantly reduced the percentage of P-selectin and 
GPIIb/IIIa positive platelets as well as the GPIIb/IIIa density by 5.9%, 3.3% and 5.9% 
respectively (Figure 39A, C, D). A pretreatment of whole blood with hippuric acid, at 2 
µM level, significantly decreased the percentage of P-selectin positive platelets by 4.3% 
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(Figure 39A), while neither ferulic nor vanillic acids significantly affected any of the 
assessed platelet activation markers (Figure 39). 
 
Figure 39. The effect of anthocyanin metabolites on ADP-induced platelet activation assessed 
as the percentage of P-selectin positive platelets (A), density of P-selectin on activated platelets 
(B), percentage of GPIIb/IIIa positive platelet (C) and density of GPIIb/IIIa on activated 
platelets (D). The results are presented as a change (%) of the value for each of the measured 
parameters in anthocyanin-treated, ADP-activated whole blood compared to vehicle-treated, 
ADP-activated control. Data are displayed as mean ± SD, n=7. *p < 0.05, **p < 0.01. 
4.2.4.&Effect of anthocyanins on platelet-leukocyte aggregation 
The impact of compounds on agonist-induced platelet aggregation with leukocytes 
was examined based on their effect on the percentage of platelet-monocyte (PMA) and 
platelet-neutrophil aggregates (PNA). 
Pre-exposure of whole blood to 0.1 µM cy-3-arab significantly reduced the ADP-
induced formation of PNA by 15.2% and had no effect on platelet aggregation with 
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monocytes (Figure 40). Cy-3-gal significantly attenuated platelet aggregation with 
neutrophils by 19.6%, while cy-3-glc, del-3-glc and pn-3-glc showed no significant effect 
on both platelet-neutrophil and platelet-monocyte aggregation. 
 
Figure 40. Impact of anthocyanins on ADP-induced platelet-leukocyte aggregation assessed as 
the percentage of platelet-neutrophil aggregates (A) and platelet-monocyte aggregates (B). The 
results are presented as change (%) compared to vehicle-treated, ADP-activated control. Data 
are reported as mean ± SD, n=7. *p < 0.05, **p<0.01. 
4.2.5.&Impact of anthocyanin metabolites on platelet-leukocyte aggregation 
4-HBAL, tested at 0.5 µM concentration, significantly affected platelet aggregation 
with both neutrophils and monocytes, reducing the formation of PNA by 14.8% and PMA 
by 10%, compared to agonist-treated control (Figure 41). By contrast, 0.2µM PCA, 2 µM 
hippuric acid 2 µM vanillic acid did not significantly affect neither platelet-neutrophil nor 
platelet-monocyte aggregation. Pre-exposure of whole blood to 1 µM ferulic acid 
significantly reduced the percentage of PMA by 11.4% and showed no effect on platelet 
aggregation with neutrophils (Figure 41). 
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Figure 41. Impact of anthocyanin metabolites on ADP-induced platelet-leukocyte aggregation 
assessed as the percentage of platelet-neutrophil aggregates (A) and platelet-monocyte 
aggregates (B). The results are presented as change (%) compared to vehicle-treated, ADP-
activated control. Data are reported as mean ± SD, n=7. **p<0.01. 
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5.& DISCUSSION 
CVD represent the leading global cause of morbidity and mortality, with 
atherosclerosis as the major underlying pathologic process responsible for their 
development (Galkina & Ley 2009; Mendis et al. 2011). Atherosclerosis, a chronic 
inflammatory disorder of large and medium-sized arteries, is initiated by alterations in 
endothelial function that promote the recruitment and adhesion of circulating leukocytes 
and their subsequent transendothelial migration into the blood vessel wall. In the 
subendothelial space, leukocytes differentiate into activated macrophages, take up 
oxidised lipoproteins and form foam cells, which accumulation eventually leads to the 
formation of atherosclerotic lesions that restrict blood flow (Galkina & Ley 2009; Libby 
et al. 2011). Platelets also contribute to the development of this disorder through their 
interactions with leukocytes and endothelial cells that occur upon platelet activation. 
These interactions promote leukocyte adhesion and transendothelial migration, further 
increasing the inflammatory responses and the progression of atherosclerosis (van Gils et 
al. 2009; Konic-Ristic et al. 2015). Therefore, the interplay between endothelial cells, 
leukocytes and platelets represent an attractive target for the prevention of CVD.  
A growing body of evidence coming from epidemiological, clinical and preclinical 
studies suggest the important role of dietary anthocyanins, the plant-food phytochemicals, 
in the prevention and treatment of  CVD (Mauray et al. 2009; Qin et al. 2009; Cassidy et 
al. 2011; Cassidy et al. 2013; Rodriguez-Mateos, Rendeiro, et al. 2013; Li et al. 2015). 
Cardiovascular benefits of anthocyanin consumption may be attributed to their effect on 
endothelial but also platelet function. However, the molecular mechanisms through which 
they exert these effects are still not fully understood. Furthermore, given the extensive 
metabolism of dietary anthocyanins within the human body, the reported health benefits 
could be at least partly attributed to their metabolites as well (de Ferrars, Czank, et al. 
2014). Therefore, the aim of this doctoral dissertation was to investigate the impact of 
anthocyanins and their metabolites on endothelial and platelet function and identify the 
underlying mechanisms of their action, using physiologically relevant study design and 
integrated omics approaches.  
Anthocyanins that were tested in this work are present in substantial amounts in 
various fruits, particularly berry fruits, some vegetables, cereals and different fruit-
derived products (e.g. juices and wines), presenting the significant components of the 
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human diet. Also, they are all found in blueberries that are the most commonly eaten 
anthocyanin source (Andersen & Jordheim 2013). Anthocyanin metabolites that were 
examined in this thesis were previously reported in the bloodstream following the 
consumption of various anthocyanin-rich foods (Rechner et al. 2002; de Ferrars, Cassidy, 
et al. 2014; Xie et al. 2016). Moreover, they were confirmed as products of anthocyanin 
degradation created in the small intestine and colon in a relatively recent human feeding 
study with the isotopically-labelled cy-3-glc (de Ferrars, Czank, et al. 2014).  
For the investigations of the effect of anthocyanins and their metabolites on endothelial 
function, compounds were first examined over a range of concentration, from 0.1 µM to 
2 µM, which corresponded to their previously reported circulating plasma levels after the 
intake of anthocyanin-rich foods. Findings from anthocyanin bioavailability studies show 
that anthocyanins are present in the bloodstream for a short time, unlike their gut 
metabolites that are detectable up to 48 hours post-consumption (Stalmach et al. 2012; 
Czank et al. 2013; de Ferrars, Czank, et al. 2014). Also, in a two recent studies that used 
anthocyanin-rich elderberries or isotopically-labelled cy-3-glc, a significant amount of 4-
HBAL was observed early in plasma (de Ferrars, Czank, et al. 2014; de Ferrars, Cassidy, 
et al. 2014), suggesting that this compound is probably a product of anthocyanin 
degradation produced in the upper GIT. Therefore, different lengths of treatment of 
endothelial cells with anthocyanins and their metabolites were used, i.e. a 3-hour long 
treatment for anthocyanins and 4-HBAL and 18 hour-long for gut metabolites.  
The impact of tested compounds on endothelial function was evaluated by measuring 
monocyte-endothelial cells interactions, i.e. the adhesion of monocytes to activated 
endothelial cells and their transendothelial migration, which are the initial key steps in 
the development of atherosclerosis. These investigations were performed using primary 
endothelial cells, HUVECs, a commonly employed in vitro model system for exploring 
vascular inflammation in atherosclerosis (Onat et al. 2011). To create a proatherogenic 
environment, these cells were stimulated with TNFα. This cytokine is a key regulator of 
inflammation that causes endothelial dysfunction and is observed at elevated levels in the 
circulation of people at increased CVD risk (Zhang et al. 2009). This activation of 
endothelial cells, induced monocyte adhesion to an endothelial monolayer, which was in 
line with findings from previous studies (Speciale et al. 2010; Chao, Lin, et al. 2013; 
Claude et al. 2014). Results from monocyte adhesion assays showed that, with the 
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exception of 4-HBAL, treatment of HUVECs with tested anthocyanins and their 
metabolites, before TNFα activation, resulted in a significant reduction in monocyte 
adhesion to endothelial cells. Interestingly, this effect was observed especially at 
concentrations of compounds that are closest to their previously reported circulating 
plasma levels. The dose-response effect of tested compounds on monocyte-endothelial 
cell interactions mainly appeared non-linear, which was in line with a lack of a dose-
response effect reported for other polyphenols (e.g. flavanones, flavanols, flavonols) in 
endothelial or other types of cells (de Pascual-Teresa et al. 2004; Chanet et al. 2013; 
Claude et al. 2014). Among the examined anthocyanins, del-3-glc displayed the greatest 
capacity to attenuate monocyte adhesion. These results may be explained by the presence 
of an additional hydroxyl group on the B-ring of del-3-glc compared to other tested 
anthocyanins that may influence its activity. Anthocyanin metabolite 4-HBAL was the 
only compound that showed no effect on monocyte adhesion at any of the examined 
concentrations. The impact of this compound on the endothelial function has not been 
studied before. Results from monocyte adhesion assays also revealed the potency of gut 
metabolites to decrease the adhesion of monocytes to activated endothelial cells, with the 
strongest effect observed for PCA. The impact of these compounds was similar to that of 
anthocyanins, suggesting that gut microbial transformation produces metabolites that can 
have similar beneficial effects on endothelial function as their parent compounds. These 
results imply that in addition to anthocyanins, their metabolites that are detectable in the 
circulation for significantly longer time than their parent forms, can exert biological 
activity in endothelial cells and probably contribute to cardioprotective effects associated 
with the habitual intake of anthocyanin-rich foods. 
The impact of anthocyanins on the adhesion of monocytes to activated endothelial 
cells has been previously reported. For example, treatment of human aortic endothelial 
cells with 100 µg/mL of anthocyanin-based extract from purple sweet potato or 10 µM 
cyanidin, prior to TNFα stimulation, resulted in a significant decrease in the adhesion of 
monocytic U937 cells (Chao, Lin, et al. 2013). A similar reduction in monocyte adhesion 
was observed with TNFα-activated HUVECs pretreated with cy-3-glc (20-40 µM levels) 
(Speciale et al. 2010) or activated endothelial cells (EAhy92) pre-exposed to delphinidin 
(50-100 µM) (Chen et al. 2011). However, these effects were observed using 
anthocyanin-based extracts and aglycones as well as supraphysiological concentrations 
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of glycosides, with long periods of cell exposure. Thus, the findings from this thesis 
present the first physiologically relevant evidence of the impact of tested anthocyanins 
on monocyte-endothelial cell adhesion. The effects of some of the anthocyanin 
metabolites have been previously assessed in a few studies. Wang et al. (2010) showed 
that the exposure of mouse aortic endothelial cells (MAEC) to 0.05-40 µM PCA, prior to 
TNFα activation, significantly reduced monocyte adhesion only at 20 µM and 40 µM 
levels. The difference between these results and those of this thesis could be explained 
by the use of a rather high level of TNFα (10µg/l in comparison to 1 µg/l) to induce 
MAEC activation, which allowed the effect of this metabolite to be observed only at the 
highest tested concentrations. Similar to results presented in this thesis, Kuntz, Asseburg, 
et al. (2015) showed the capacity of PCA, at 1µM concentration, to significantly decrease 
the adhesion of leukocytes to TNFα-stimulated HUVECs, while no effect was observed 
at the 0.1µM level of this compound. The impact of ferulic acid on monocyte adhesion 
was previously investigated using endothelial cells exposed to radiation (Ma et al. 2010). 
However, concentrations that were used were higher than those examined in this thesis. 
The effects of hippuric and vanillic acids on monocyte adhesion to activated endothelial 
cells have not been reported before.  
To further investigate a potential synergistic effect of compounds that are 
simultaneously present in the bloodstream after the intake of anthocyanin-rich foods, two 
mixtures of compounds present in the circulation for a short (mix A) or for a long time 
(mix B) were prepared. The concentrations of compounds in these mixtures were closest 
to those previously identified in human plasma in the anthocyanin bioavailability studies 
(Czank et al. 2013; de Ferrars, Czank, et al. 2014). Additionally, the condition mix A+B 
was created to imitate as closely as possible anthocyanin pharmacokinetics following the 
ingestion of anthocyanin-rich sources by treating endothelial cells with the mixture of 
compounds that appear rapidly in the bloodstream and then with the mixture of gut 
metabolites that appear later and are present in the circulation for a longer time. Results 
from these adhesion assays revealed the ability of mixtures to significantly decrease the 
adhesion of monocytes to TNFα-activated HUVECs. However, no additive effect of the 
individual compounds of the mixtures was observed, as well as of the successive 
treatment with the mixtures in the mix A+B condition. The absence of an additive effect 
has been previously observed with different polyphenol mixtures (Boath et al. 2012; 
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Khandelwal et al. 2012; Horcajada et al. 2015) and may be explained by possible 
competition between the compounds of the mixture for the same target of action.  
The mixtures of anthocyanins and their metabolites were then used to investigate the 
impact of these compounds on monocyte transendothelial migration, the step that follows 
the adhesion. Results from these experiments showed a significant reduction in MCP-1-
induced migration of monocytes through the endothelial monolayer pretreated with the 
mixtures. There are only two studies that previously evaluated the impact of anthocyanin 
on leukocyte transendothelial migration. However, they only showed the effect of 
aglycones (e.g. pelargonidin, delphinidin) over a range of supraphysiological 
concentrations, 10 µM to 200 µM (Chen et al. 2011; Jeong et al. 2017). Thus, this thesis 
reports for the first time the ability of anthocyanins and their gut metabolites to reduce 
monocyte transendothelial migration at physiologically relevant conditions. These results 
suggest that both anthocyanins and their gut metabolites can affect the initial steps in the 
development of atherosclerosis by lowering the permeability of endothelial cells to 
leukocytes, thus implying their potential anti-atherogenic effect. This hypothesis could 
be supported by findings from several animal studies that reported the reduced formation 
of atherosclerotic lesions in ApoE−/− mice that consumed a diet supplemented with 
anthocyanin-rich extracts or pure compounds (Miyazaki et al. 2008; Mauray et al. 2009; 
Y. Wang et al. 2012).  
To identify the molecular mechanisms underlying the observed effects of the mixtures 
of anthocyanins and their metabolites on monocyte adhesion and transendothelial 
migration, the impact of these compounds on the expression of 91 genes involved in the 
regulation of endothelial cell permeability was then evaluated. The ability of 
anthocyanins and their metabolites to modulate the gene expression in endothelial cells 
has been described in several in vitro studies (Huang, Liu, et al. 2014; Amin et al. 2015; 
Edwards et al. 2015; Kuntz, Asseburg, et al. 2015; Warner et al. 2017). Of these, only a 
few recent studies reported the effect on gene expression using physiologically relevant 
forms and concentrations of compounds (Edwards et al. 2015; Kuntz, Asseburg, et al. 
2015; Warner et al. 2017). Still, these studies have largely been focused on the 
investigations of the impact on a few specific genes of interest, such as genes encoding 
different inflammatory mediators, cell adhesion molecules or enzymes involved in 
antioxidant defence. This targeted approach does not allow the evaluation of the multi-
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target mode of action of these compounds previously reported in vivo (Mauray et al. 
2012). In this thesis, macroarray analysis revealed that the pretreatment of HUVECs with 
physiologically relevant mixtures of anthocyanins and their gut metabolites significantly 
modulated the gene expression in these cells. Genes that were identified as differentially 
expressed are involved in the regulation of tight junction, cell-cell adhesion, 
reorganisation of actin cytoskeleton, focal adhesion or chemokine signalling that all 
regulate endothelial cell permeability to immune cells, i.e. their adhesion and 
transendothelial migration (van Buul & Hordijk 2004). Leukocyte adhesion and 
transendothelial migration are finely controlled multistep processes governed by 
chemoattractants, cell adhesion molecules and their receptors. Gene expression analysis 
revealed that mix A significantly reduced the expression of CXCL12, a gene encoding 
chemokine CXCL12. Chemokines are a large group of cytokines that can act as 
chemotactic factors and direct the movement of leukocytes to specific sites within tissues 
during different inflammatory situations (Speyer & Ward 2011). CXCL12 plays an 
essential role in critical functions such as leukocyte traffic, haematopoiesis, and 
vascularisation (van der Toorn et al. 2015), and its increased expression has been 
associated with the development of atherosclerotic lesions and coronary artery disease 
(Abi-Younes et al. 2000; Schutt et al. 2012). Furthermore, mix A significantly 
downregulated the expression of a gene coding for ICAM-1. This cell adhesion molecule 
regulates the initial capture, tethering and rolling of leukocytes along the endothelium as 
well as their transendothelial migration (Čejková et al. 2016). It has been shown that 
ICAM-1 increases vascular permeability and loosens endothelial barrier while its 
inactivation reduces leukocyte adhesion and vascular permeability in both mouse 
intracranial and cremaster vessels (Gaber et al. 2004; Sumagin et al. 2008; Sarelius & 
Glading 2015). Gene expression experiments also showed the ability of mix A to 
significantly decrease the expression of a gene coding for IκB kinase β (IKBKB). As 
detailed in the introduction section of this thesis, this kinase is a part of a protein complex 
that phosphorylates IκB, an inhibitor of a transcription factor NF-κB, leading to its 
dissociation and degradation and consequent NF-κB activation. The released NF-κB then 
rapidly translocates to the nucleus and induces the transcription of different inflammatory 
genes such as ICAM-1 (Anwar et al. 2004). It has been reported that IKBKB is necessary 
for the cytokine-induced inflammatory phenotype of vascular endothelium and the 
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endothelial recruitment of monocytes (Meiler et al. 2002). Taken together, these 
observations propose that the downregulation of these inflammatory genes by mix A 
results in reduced migration of monocytes toward endothelial cells and their subsequent 
interactions, which can be associated with decreased adhesion and transendothelial 
migration observed in the cell assays. 
Pretreatment of endothelial cells with the mixture of gut metabolites for 18 hours also 
significantly modulated the expression of several genes. For example, mix B decreased 
the expression of a gene encoding integrin alpha-5 (ITGA5), a member of integrin cell 
adhesion molecules. Integrins play a significant role in the firm adhesion of monocytes 
to endothelial cells (Čejková et al. 2016), and the overexpression of ITGA5 has been 
reported to increase cell adhesion and migration (Qin et al. 2011). Furthermore, mix B 
upregulated the expression of a gene encoding CDH5. This adhesion molecule is 
exclusively expressed in endothelial cells and plays a critical role in the assembly and 
maintenance of adherens junction (Ley 2013). Loss and reduction of CDH5 at cell 
junctions have been reported to reduce endothelial integrity and increase endothelial 
permeability, allowing transendothelial migration of immune cells (Del Maschio et al. 
1996; Sawant et al. 2011; Herwig et al. 2013). Gut metabolites also reduced the 
expression of CAPN1, a gene coding for calpain 1. Calpains are ubiquitously expressed, 
Ca2+ activated, neutral cysteine proteases present in the vascular wall where they control 
important endothelial functions (Scalia et al. 2011). Activation of vascular calpains has 
been reported to cause endothelial dysfunction and increases leukocyte-endothelial 
interactions in the microcirculation. The increase in calpain activity has been shown to 
induce calpain-dependent degradation of IκBα, together with the upregulation of NF-κB-
regulated cell adhesion molecules (Scalia et al. 2011). Thus, downregulation of CAPN1 
by gut metabolites may result in decreased calpain activity and IκBα degradation and 
consequently reduced NF-κB-induced expression of cell adhesion molecules and 
decreased monocyte adhesion as reported in the cell assays of this thesis.  
Pretreatment of endothelial cells with mix A and then mix B induced significant 
alterations in the expression of several genes including ITGA5, CAPN1, CDH5, and 
GJA4. GJA4, a gene that encodes gap junction alpha-4 protein also known as connexin 
37, was found upregulated by mix A+B. Connexins represent transmembrane proteins 
that form gap junctions and allow direct cell-cell communication. The expression of GJA4 
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was found to be modulated in advanced atherosclerotic plaques, with a loss of GJA4 in 
endothelial cells covering plaques (Kwak et al. 2002; Pfenniger et al. 2015). It has also 
been reported that ApoE−/− GJA4−/− mice present an increase in the size of atherosclerotic 
plaques compared to ApoE−/− mice, with an increase in the number of macrophages in the 
plaques (Wong et al. 2006; Pfenniger et al. 2015), suggesting lower transendothelial 
migration of leukocytes. Thus, modulations in endothelial cell gene expression by mix 
A+B can be associated with a decrease in monocyte adhesion and transendothelial 
migration, presenting molecular targets underlying the observed effect on endothelial 
cells.  
The results form gene expression experiments were further analysed with different 
bioinformatics tools to identify possible transcription factors and signalling proteins that 
could mediate the observed nutrigenomic effect of tested compounds. Molecular docking 
was employed to predict whether anthocyanins and their metabolites can bind these cell 
signalling proteins and transcription factors and theoretically affect their biological 
activity. This computational technique is more and more used as a tool for the 
identification of molecular targets of natural bioactive compounds. Several studies have 
previously described possible binding interactions between anthocyanins or their 
metabolites and a few targets including membrane transporters (Oliveira et al. 2015; 
Muthusamy et al. 2016), digestive enzymes (Olivas-Aguirre et al. 2016; Zengin et al. 
2017), protein kinases (Hou & Kumamoto 2010; Doss et al. 2016; Bhattacharjee et al. 
2017), estrogen receptors (Nanashima et al. 2015) or antioxidant defence enzymes 
(Laksmiani et al. 2016). In this thesis, molecular docking was performed with 62 
identified signalling proteins and transcription factors that are involved in the regulation 
of different cellular processes such as inflammation, cell proliferation, migration and 
survival. Results from these analyses suggest that anthocyanins and their metabolites 
present the capacity to bind cell signalling proteins. Anthocyanins appear to be stronger 
binders then their metabolites. The similar BAs for the same targets were observed when 
comparing compounds within the anthocyanin and metabolite groups, contributing to the 
hypothesis that the lack of cumulative effect of compounds within the mixtures is the 
result of their competition for the same target of action. Docking results revealed that 
anthocyanins could bind to the protein kinase domain of cell signalling proteins such as 
FAK1, ROCK2 and MEK2 and possibly affect the kinase activity of these targets. 
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Binding of mitoxantrone to the kinase domain of FAK has been shown to inhibit FAK 
kinase activity (Golubovskaya et al. 2013). This non-receptor kinase has an essential role 
in the regulation of cell adhesion, migration and actin cytoskeleton rearrangement, and 
its reduced activity has been associated with lower monocyte adhesion to endothelial cells 
(Hu et al. 2018). Previous studies have also shown that binding of fasudil and Y-27632 
to kinase domains of ROCK1/2, the signalling proteins involved in cell migration by 
regulation of actin cytoskeletal assembly and cell contractility (Noma et al. 2012), inhibits 
their activity (Liao et al. 2007). These ROCK1/2 inhibitors led to improvements in 
endothelial cell integrity and decreased transmigration of immune cells (Breslin & Yuan 
2004; Rao et al. 2017), results that could be correlated with the ones observed in this 
thesis. Furthermore, several inhibitors of MEK1/2, kinases involved in ERK signalling 
pathway, have been previously described (Krepinsky et al. 2002). The reduced activity 
of MEK1/2 has been associated with a decrease in the ERK activation and reduced 
transmigration of leukocytes across a monolayer of activated endothelial cells (Stein et 
al. 2003; Hu et al. 2018). In this thesis, following the treatment of endothelial cells with 
the mix A, a significant decrease in ERK1/2 phosphorylation, as well as lower monocyte-
endothelial cell interactions were observed. These results suggest that the binding to 
MEK2 may present one of the mechanisms by which anthocyanins may induce the 
observed changes in endothelial function. Results from docking analyses also showed 
that anthocyanins could bind IKKα within its active site, suggesting an inhibitory effect. 
Inhibition of this cell signalling protein results in reduced NF-κB activation and has been 
associated with reduced neutrophil infiltration in LPS-induced TNFα production rat 
model (Llona-Minguez et al. 2013). In this thesis, mix A induced significant decrease in 
NF-κB-p65 phosphorylation and attenuated monocyte adhesion and transendothelial 
migration, proposing that binding of anthocyanins to IKKα may represent one of the 
anthocyanin targets that underlies their observed impact on the expression of 
proinflammatory genes and ultimately endothelial cell function. It is noteworthy, that the 
effects of anthocyanins on the phosphorylation of NF-κB-p65 and ERK1/2 have been 
previously reported in different endothelial cells but only using anthocyanin-based 
extracts, aglycones or high concentrations of glycosides (Martin et al. 2003; Speciale et 
al. 2010; Favot et al. 2015; Medda et al. 2015; Sivasinprasasn et al. 2016). 
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As for anthocyanins, their metabolites have also displayed a potential for binding 
several cell signalling proteins. For example, docking results revealed that ferulic acid 
could bind to the protein kinase domain of JAK3 and MLCK. Binding of molecule 
NSC163088 to the JAK3-kinase domain has been reported to inhibit its catalytic function 
(Kim et al. 2011). This signalling protein is involved in the regulation of inflammatory 
cascade and its suppressed activity has been associated with alleviated inflammatory 
responses and lower endothelial permeability (Kim et al. 2011; Lee et al. 2012). 
Furthermore, several inhibitors of MLCK, a kinase involved in the regulation of cell 
contractility, have been previously described (Krepinsky et al. 2002). The treatment of 
endothelial cells with the inhibitors such as ML-9 and ML-7 has been reported to result 
in reduced myosin filament formation, F-actin formation, and lower neutrophil 
transmigration (Saito et al. 1998; Stroka & Aranda-Espinoza 2011). Docking analyses 
also revealed that PCA could interact with b-Raf within its active site, suggesting an 
inhibitory effect. The activation of this protein of ERK signalling pathway, has been 
shown to result in the phosphorylation of the cytoskeletal protein caldesmon, stress fibre 
formation and increased endothelial permeability (Liu et al. 2001). Recently, suppression 
of b-Raf activity by an inhibitor, dabrafenib, has been associated with reduced barrier 
disruption and decreased leukocyte adhesion and transmigration through LPS-activated 
HUVECs (Lee et al. 2017). Regarding these published data, it can be suggested that 
binding of anthocyanin metabolites to these signaling proteins will decrease endothelial 
cell permeability, a hypothesis that can be correlated with the observed reduced monocyte 
adhesion and transendothelial migration. Docking results also showed that hippuric, 
ferulic acid and PCA could bind to the kinase domain of p38β, a signalling protein of p38 
MAPK pathway involved in the regulation of inflammation and cellular stress responses 
(Adams et al. 2016). Inhibition of p38 has been associated with a reduced NF-κB 
activation (Schulze-Osthoff et al. 1997; Rahman et al. 2004; Olson et al. 2007). 
Furthermore, treatment of endothelial cells with specific p38 inhibitors have been shown 
to decrease not only leukocyte adhesion but also leukocyte transmigration (Scaldaferri et 
al. 2009). In agreement with these observations, pretreatment of endothelial cells with the 
mix B resulted in a significant decrease in the phosphorylation of NF-κB-p65 as well as 
in reduced monocyte-endothelial cell interactions. This observed effect on NF-κB-p65 
activation is in line with a recently reported ability of physiologically relevant doses of 
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vanillic acid and PCA to decrease phosphorylation of NF-κB-p65 in IL-6-activated 
HUVECs (Amin 2015). 
Taken together, anthocyanins and their metabolites by binding to different cell 
signalling proteins may affect their activity and consequently that of transcription factors 
and result in decrease endothelial permeability, presenting new mechanisms of action 
underlying their health properties. 
Aside from regulation by cell signalling proteins and transcription factors, gene 
expression can also be regulated at the posttranscriptional level by miRNAs. These non-
coding RNAs control various cellular processes, and changes in their expression profiles 
have been described in different diseases including CVD (Miska 2005). The capacity of 
anthocyanins or their metabolites to modulate miRNA expression has been reported in 
few in vivo studies (Milenkovic et al. 2012; D. Wang et al. 2012), however the in vitro 
evidence is still limited (Du et al. 2017; Murata et al. 2017; Su et al. 2017). In this thesis, 
the effect of anthocyanins and their metabolites on miRNA expression was examined 
using the microarray-based holistic approach. Findings from these experiments revealed 
the capacity of inflammatory cytokine TNFα to induce the changes in miRNA expression 
compared to non-activated endothelial cells. A significant increase in the expression of 
miRNAs like miR-155, miR-455 or miR-146a was observed, which was in line with the 
previously described upregulation of these miRNAs in endothelial cells exposed to 
inflammatory stress (Ruan et al. 2012; Lee et al. 2015; Pfeiffer et al. 2017; Yee et al. 
2017). Results from microarray analysis have shown for the first time the capacity of 
anthocyanins and their metabolites, at physiologically relevant conditions, to modulate 
the expression of miRNA in TNFα-stimulated endothelial cells. Interestingly, 
pretreatment of endothelial cells with mixtures predominantly resulted in decreased 
miRNA expression, an expression profile that is opposite to the one observed in 
endothelial cells following their stimulation with TNFα (Figure 35). This observation 
suggests that anthocyanins and their metabolites can possibly prevent the harmful effects 
of TNFα by counteracting miRNA expression induced by this inflammatory cytokine. 
The miRNAs identified as downregulated by mix A included let-7f, miR-181b and miR-
125a. The let-7 family of miRNAs is associated with the development of atherosclerosis 
and coronary artery disease, and the increased expression of let-7f has been reported in 
the sclerotic intima of peripheral artery disease patients (Li et al. 2010). Furthermore, 
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miR-181b and miR-125a have been found overexpressed in human atherosclerotic lesions 
(Bidzhekov et al. 2012; Di Gregoli et al. 2017), while the administration of miR-181b 
inhibitor (anti-miR-181b) has been shown to delay both the development and progression 
of plaques in ApoE−/− mice (Di Gregoli et al. 2017). Mix A also reduced the expression 
of miR-130a. An increase in the expression of this miRNA has been recently observed in 
the brain endothelial cells and associated with an increase in endothelial monolayer 
permeability following ischemia (Wang et al. 2018). This effect was reduced when an 
agonist of miR-130a was used. Additionally, mix A significantly decreased the 
expression of other miRNAs involved in endothelial dysfunction such as miR-361-5p 
(H.-W. Wang et al. 2014), miR-26a (Silambarasan et al. 2016) or miR-455-3p (Pearson-
Leary et al. 2017). As for the mix A, treatment of endothelial cells with the mix B also 
induced changes in miRNA expression, revealing for the first time the ability of gut 
metabolites to modulate the expression of these post-transcriptional mRNA regulators in 
endothelial cells. Similar to mix A, mix B modulated the expression of let-7f, miR-126*, 
miR-374a and miR-1260 but also of other miRNAs like miR-23a that was shown to 
increase endothelial permeability by targeting tight junction proteins (Hsu et al. 2017). It 
is noteworthy, that mix B also upregulated the expression of miR-923, the only miRNA 
which expression was significantly reduced by TNFα treatment. This miRNA is involved 
in cancer development and have also been proposed to affect leukocyte diapedesis 
(Altmäe et al. 2013). Treatment of endothelial cells with the mix A and then mix B also 
affected miRNA expression. As for the two other mixtures, a significant reduction in the 
expression of let-7f was observed, presenting a shared molecular target between these 
three experimental conditions. Additionally, miR-125b and miR-1246 were identified in 
common with the mix B and miR-181b, miR-361-5p and miR-1915 with the mix A. The 
changes in the expression profiles of these miRNAs have been previously described in 
endothelial cell dysfunction (Lee et al. 2015; Silambarasan et al. 2016; Fang et al. 2017). 
These results suggest that the treatment of endothelial cells with anthocyanins and 
their gut metabolites, at physiologically relevant levels and times of cell exposure, results 
in changes in the expression of miRNAs that are involved in the regulation of endothelial 
function, presenting a novel mechanism underlying their observed cellular effects.  
In addition to investigations of the effect of anthocyanins and their metabolites on 
endothelial cell function as one of the important targets in CVD prevention, this thesis 
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also aimed to evaluate the impact of these compounds on platelet function. These 
investigations included the assessments of the in vitro effect of anthocyanins and their 
metabolites on platelet activation and platelet-leukocyte aggregation in response to 
exogenously added ADP. This molecule is a platelet agonist that is stored in their dense 
granule and released following their activation (Brass et al. 2013). Platelet 
activation/aggregation response to low levels of ADP has been reported as a parameter 
with a predictive value for cardiovascular events (Elwood et al. 1991) and therefore 
presents a rational target for the evaluation of beneficial effects of these compounds on 
cardiovascular health. Anthocyanins and their metabolites were examined at 
concentrations that were closest to their previously reported circulating plasma levels 
(Czank et al. 2013; de Ferrars, Czank, et al. 2014). Their impact on platelet function was 
evaluated by measuring the surface expression of activation markers P-selectin and 
GPIIb/IIIa as well as platelet-monocyte and platelet-neutrophil aggregates, using the 
whole blood flow cytometry. P-selectin, a cell adhesion molecule, is stored in the α 
granules of platelets and translocated to platelet surface only upon their activation. It 
mediates the initial contact with neutrophils and monocytes by binding to its ligand 
PSGL-1 expressed on the leukocyte surface (Evangelista & Smyth 2013). Platelet 
activation is also associated with a conformational activation of GPIIb/IIIa, a receptor for 
fibrinogen that mediates platelet aggregation with other platelets but also contributes to 
platelet-leukocyte aggregation (Jennings 2009; Aukrust et al. 2010). The use of whole 
blood flow cytometry allowed not only to sensitively measure these markers that are 
highly relevant in the prevention of CVD but also to diminish platelet extracorporeal 
activation and produce reliable results that can be exclusively attributed to a direct effect 
of tested compounds on platelet function. 
Results from these experiments showed that except vanillic acid, both anthocyanins 
and their metabolites significantly affected at least one of the investigated parameters, i.e. 
platelet activation or platelet-leukocyte aggregation. These findings imply that the 
beneficial, anti-platelet effects associated with the anthocyanin-rich food consumption 
could also be a consequence of the combined action of anthocyanins and their metabolites 
on platelet function. The tested compounds had a variable effect on platelet function. 
Among tested anthocyanins, cy-3-arab displayed the greatest capacity to modulate 
platelet function, as it reduced the percentage of P-selectin positive platelets as well as 
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the density of this surface receptor that was reflected in a significantly reduced formation 
of platelet-neutrophil aggregates. By contrast, pn-3-glc, del-3-glc or cy-3-glc affected 
platelet activation by attenuating P-selectin or GPIIb/IIIa surface expression, while cy-3-
gal only showed the effect on platelet aggregation with neutrophils. These variable effects 
could possibly be explained by differences in the type of sugar moiety attached to the C-
ring of investigated anthocyanins, suggesting that the presence of arabinose is responsible 
for the higher effect on platelet function. 4-HBAL was the most effective among 
anthocyanin metabolites, as it induced a significant reduction in platelet activation as well 
as in their aggregation with both neutrophils and monocytes. Interestingly, 4-HBAL was 
the only tested compound that did not show a significant effect on the adhesion of 
monocytes to activated endothelial cells as observed in cell adhesion experiments. These 
results suggest that by acting on platelets and not on endothelial cells, this metabolite 
could potentially still lower the leukocyte-endothelial cell interactions and exert a 
protective effect against atherosclerosis development. 
The effects of anthocyanins and their metabolites on platelet activation have been 
studied before. A few studies failed to observe the effect of lower concentrations of cy-
3-glc (0.5µM and 1µM) on P-selectin surface expression (Rechner & Kroner 2005; Song 
et al. 2014; Yao et al. 2017), which was in agreement with the lack of impact of 0.1µM 
cy-3-glc reported in this thesis. Studies of Yang et al. (2012) and Song et al. (2014) 
showed that a pre-exposure of human platelet-rich plasma or gel-filtered platelets to del-
3-glc, significantly reduced the agonist-induced P-selectin and GPIIb/IIIa surface 
expressions at 5 µM and 50 µM levels, and not at 0.5 µM concentration. By contrast, the 
results from this thesis revealed the capacity of 0.1 µM del-3-glc to reduce platelet 
activation by modulating P-selectin expression. These observed discrepancies could be 
explained by differences in the methodology used to assess the effect on platelet 
activation. Unlike whole blood flow cytometry, the use of platelet-rich plasma or gel-
filtered platelets requires the additional manipulation of blood samples and therefore 
increases the probability of platelet artefactual activation that can mask subtle changes in 
platelet activation induced by low physiological concentrations of tested anthocyanin. 
Furthermore, the use of platelet agonists at relatively high levels (e.g. 200 µM ADP) may 
also explain why these studies only reported the effect at supraphysiological levels of this 
anthocyanin. The capacity of hippuric acid and PCA to modulate platelet function has 
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been previously described (Rechner & Kroner 2005; Kim et al. 2012; Santhakumar, 
Stanley, et al. 2015). However, these compounds were examined at levels that were 
higher than those achieved in the bloodstream after the ingestion of anthocyanin-rich 
sources (Vitaglione et al. 2007; de Ferrars, Czank, et al. 2014). Finally, recent work of 
Baeza et al. showed that pretreatment of whole blood with ferulic acid, at 0.01µM to 
100µM levels, significantly reduced ADP-induced P-selectin expression only at higher 
tested concentrations (Baeza et al. 2017). Similar to findings from this thesis, the effect 
was not observed at 1µM level. The impact of anthocyanins pn-3-glc, cy-3-gal and cy-3-
arab, as well as metabolites 4-HBAL and vanillic acid on platelet activation, has not been 
evaluated before. Also, this thesis reports, for the first time, the capacity of anthocyanins 
and their metabolites to affect platelet aggregation with leukocytes, a marker that has 
been shown to be an even more sensitive indicator of CVD risk!than platelet activation 
(Michelson et al. 2001).   
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6.& CONCLUSION 
In accordance with the aim of this thesis, based on the obtained results the following 
conclusions can be made: 
−* Pretreatment of endothelial cells with anthocyanin and their metabolites, at 
physiologically relevant concentrations and time of cell exposure, can reduce the 
adhesion of monocytes to TNFα-activated endothelial cells. Of tested 
compounds, 4-HBAL is the only compound that does not seem to impact 
monocyte adhesion, while the most prominent effects are caused by anthocyanin 
del-3-glc and the gut metabolite PCA. Mixtures of anthocyanins and their 
metabolites that are simultaneously present in the circulation following the 
consumption of anthocyanin-rich sources also significantly reduce monocyte 
adhesion to activated endothelial cells. Lack of the additive effect of individual 
compounds suggests the competition for the same target of action between 
compounds of the mixtures. 
−* Pre-exposure of endothelial cells to mixtures of anthocyanins and their gut 
metabolites also attenuates the migration of monocytes through the endothelial 
monolayer. 
−* Mixtures of tested compounds also show the capacity to modulate the expression 
of genes in endothelial cells, especially those involved in the regulation of cell-
cell adhesion, actin cytoskeleton reorganisation and focal adhesion. 
−* The observed nutrigenomic effects can be explained by the affinity of 
anthocyanins and their metabolites to bind different signalling proteins (as 
predicted by molecular docking) and affect their activity and the activity of 
transcription factors that they regulate (as shown by Western blot analysis), 
consequently modulating the expression of target genes.  
−* Mixtures of anthocyanins and their metabolites also exert their nutrigenomic 
effect by significantly altering the miRNA expression in endothelial cells, 
especially those miRNAs associated with endothelial cell permeability, 
dysfunction and atherosclerosis development. 
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−* In platelets, anthocyanins and their metabolites display the capacity to modulate 
at least one of the investigated parameters of platelet function, i.e. agonist-induced 
platelet activation and their aggregation with neutrophils and monocytes. Of these 
compounds, vanillic acid does not seem to affect platelet function, while 
anthocyanin cy-3-arab and metabolite 4-HBAL are the most efficient in 
attenuating both platelet activation and aggregation. 
Taken together, results from this thesis show that both anthocyanins and their 
metabolites, at physiologically relevant conditions, can reduce monocyte adhesion and 
transendothelial migration, the initial steps in the development of atherosclerosis, by 
maintaining the endothelial integrity and function during the inflammatory stress. These 
effects seem to be mediated by complex molecular mechanisms of action of these 
compounds. These mechanisms include the ability of anthocyanins and their metabolites 
to interact with cell signalling proteins and modulate their activity and consequently the 
activity of transcription factors, leading to changes in gene expression as well as their 
capacity to modulate miRNA expression (Figure 42). Furthermore, results from this thesis 
also showed the potency of physiologically relevant levels of circulating anthocyanins 
and their metabolites to attenuate platelet activation and aggregation with leukocytes, the 
processes that are key contributors to the development of CVD. Thus, these findings 
provide potential proof of a cause-and-effect relationship for the beneficial effect of the 
habitual consumption of anthocyanin-rich foods on endothelial and platelet function and 
mechanisms underlying their cardioprotective effects.  
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Figure 42. Summary of the effects of anthocyanins and their metabolites. 
(In red-cell signaling proteins for which binding affinity of tested compounds was identified as lower than 
 -8.5 kcal/mol).  
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8.!SUPPLEMENTARY FILES 
Supplementary Table 1. List of genes examined by TaqMan-low density arrays and their function in the cell 
Gene symbol Gene name Biological process 
ADAM10 ADAM metallopeptidase domain 10 proteolysis 
SOD1 superoxide dismutase 1, soluble response to odative stress 
VWF von Willebrand factor cell adhesion 
F11R F11 receptor cell adhesion 
CXCL12 chemokine (C-X-C motif) ligand 12 cell chemotaxis 
RHO rhodopsin actin cytoskeleton organization  
CXCR5 chemokine (C-X-C motif) receptor 5 cell chemotaxis 
CCR2 chemokine (C-C motif) receptor 2 cell chemotaxis 
CCR1 chemokine (C-C motif) receptor 1 cell chemotaxis 
CDH5 cadherin 5, type 2 (vascular endothelium) cell adhesion 
IKBKG inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma inflammatory response 
PDPK1 3-phosphoinositide dependent protein kinase-1 regulation of protein phosphorylation 
CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) cytoskeletal reorganization  
CASK calcium/calmodulin-dependent serine protein kinase (MAGUK family) cell adhesion 
PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 protein amino acid phosphorylation 
MYLK myosin light chain kinase actin-myosin interactions 
MYD88 myeloid differentiation primary response gene (88) signal transduction 
PDGFRB platelet-derived growth factor receptor, beta polypeptide cell chemotaxis 
RASGRF1 Ras protein-specific guanine nucleotide-releasing factor 1 signal transduction 
PDGFRA platelet-derived growth factor receptor, alpha polypeptide cell cell signaling 
CAV1 caveolin 1, caveolae protein, 22kDa cholesterol homeostasis 
ADAM12 ADAM metallopeptidase domain 12 cell adhesion 
ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa regulation of actin filament polymerization 
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Supplementary Table 1 (Continued) 
Gene symbol Gene name Biological process 
VAV3 vav 3 guanine nucleotide exchange factor angiogenesis 
TLN1 talin 1 cell-cell junction assembly 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 cytoskeletal reorganization  
JAM2 junctional adhesion molecule 2 cell adhesion 
JAM3 junctional adhesion molecule 3 cell adhesion 
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 inflammatory response 
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta inflammatory response 
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) cell adhesion 
PLCG1 phospholipase C, gamma 1 lipid metabolic process 
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 regulation of protein phosphorylation 
CCL2 chemokine (C-C motif) ligand 2 cell chemotaxis 
ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) cell adhesion 
CALM1 calmodulin 1 (phosphorylase kinase, delta) cell adhesion 
ACTN1 actinin, alpha 1 actin cytoskeleton organization  
VCL vinculin cell adhesion 
AGTR1 angiotensin II receptor, type 1 regulation of vasoconstriction 
MYLK2 myosin light chain kinase 2 actin-myosin interactions 
CALD1 caldesmon 1 cell adhesion 
TJP1 tight junction protein 1 (zona occludens 1) cell-cell junction assembly 
FABP3 fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) lipid metabolic process 
ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa regulation of actin filament polymerization 
RRAS2 related RAS viral (r-ras) oncogene homolog 2 signal transduction 
TJP3 tight junction protein 3 (zona occludens 3) cell-cell junction assembly 
S100A8 S100 calcium binding protein A8 inflammatory response  
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Supplementary Table 1 (Continued) 
Gene symbol Gene name Biological process 
RACGAP1 Rac GTPase activating protein 1 mitotic cytokinesis 
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 cytoskeletal reorganization  
MYL9 myosin, light chain 9, regulatory actin-myosin interactions 
ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 signal transduction 
CAPN1 calpain 1, (mu/I) large subunit cytoskeletal reorganization  
FABP4 fatty acid binding protein 4, adipocyte lipid metabolic process 
S100A9 S100 calcium binding protein A9 inflammatory response  
GJA4 gap junction protein, alpha 4, 37kDa cell-cell junction assembly 
RHOC ras homolog gene family, member C actin cytoskeleton organization  
MSN moesin actin cytoskeleton organization  
CDC42 cell division cycle 42 (GTP binding protein, 25kDa) actin cytoskeleton organization  
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa regulation of actin filament polymerization 
TJP2 tight junction protein 2 (zona occludens 2) cell-cell junction assembly 
CLDN11 claudin 11 cell adhesion 
AKT1 v-akt murine thymoma viral oncogene homolog 1 protein amino acid phosphorylation 
EZR ezrin actin filament bundle assembly 
PAK1 p21 protein (Cdc42/Rac)-activated kinase 1 protein amino acid phosphorylation 
SELE selectin E cell adhesion 
MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) proteolysis of the extracellular matrix 
VIM vimentin movement of cell or subcellular component 
GJA5 gap junction protein, alpha 5, 40kDa cell-cell junction assembly 
RDX radixin actin filament capping 
VCAM1 vascular cell adhesion molecule 1 cell adhesion 
RND3 Rho family GTPase 3 actin cytoskeleton organization  
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Supplementary Table 1 (Continued) 
Gene symbol Gene name Biological process 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) cell adhesion 
RAC1 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) cell adhesion 
ARPC2 actin related protein 2/3 complex, subunit 2, 34kDa regulation of actin filament polymerization 
RAC2 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) actin filament organization 
OCLN occludin cell adhesion 
RHOA ras homolog gene family, member A actin cytoskeleton organization  
PTK2 PTK2 protein tyrosine kinase 2 angiogenesis 
PECAM1 platelet/endothelial cell adhesion molecule cell adhesion 
NOS2 nitric oxide synthase 2, inducible nitrite oxyde biosynthetic process 
CLDN1 claudin 1 cell adhesion 
JUN jun proto-oncogene angiogenesis 
PXN paxillin cell adhesion 
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 actin cytoskeleton organization  
18S Eukaryotic 18S rRNA  
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) proteolysis of the extracellular matrix 
CLDN5 claudin 5 cell adhesion 
NOS3 nitric oxide synthase 3 (endothelial cell) nitrite oxyde biosynthetic process 
AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) regulation of vasoconstriction 
IGF1R insulin-like growth factor 1 receptor signal transduction 
IL7 interleukin 7 inflammatory response 
CCL5 chemokine (C-C motif) ligand 5 cell chemotaxis 
ICAM1 intercellular adhesion molecule 1 cell adhesion 
GAPDH glyceraldehyde-3-phosphate dehydrogenase glycolysis 
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Supplementary Table 2. List of cell signalling proteins used in molecular docking analyses 
Protein 
ID 
Alias UniProt 
ID 
3D structure Gene Full name Classification 
Akt AKT3 Q9Y243 HM based on 4ENJ AKT3 RAC-gamma serine/threonine-protein 
kinase 
Protein kinase superfamily. AGC Ser/Thr protein 
kinase family. RAC subfamily 
ASK1 M3K5 Q99683 HM based on 4BIB MAP3K5 Mitogen-activated protein kinase kinase 
kinase 5 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase kinase 
subfamily 
ASK2 M3K6 O95382 HM based on 2CLQ MAP3K6 Mitogen-activated protein kinase kinase 
kinase 6 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase kinase 
subfamily 
b-Raf BRAF P15056 HM based on 4RZV BRAF B-Raf proto-oncogene, serine/threonine-
protein kinase 
Protein kinase superfamily. TKL Ser/Thr protein 
kinase family. RAF subfamily 
c-JUN JUN P05412 HM based on 1T2K JUN Transcription factor AP-1 bZIP family. Jun subfamily 
c-Raf RAF1 P04049 HM based 3OMV RAF1 Raf-1 proto-oncogene, serine/threonine-
protein kinase 
Protein kinase superfamily. TKL Ser/Thr protein 
kinase family. RAF subfamily 
Cdc42 CDC42 P60953 HM based on 5C2J CDC42 Cell division control protein 42 homolog Small GTPase superfamily. Rho family. CDC42 
subfamily 
CREB1 CREB1 P16220 HM based on 1DH3 CREB1 Cyclic AMP-responsive element-binding 
protein 1 
 bZIP family 
CREBBP CBP Q92793 HM based on 5LKZ CREBBP CREB binding protein Transcription coregulator. Coactivator 
(Bromodomain, Repeat, Zinc-finger) 
EP300 EP300 Q09472 HM based on 5LKZ EP300 Histone acetyltransferase p300 Transcription coregulator. Coactivator 
(Bromodomain, Repeat, Zinc-finger) 
ERK1 MK03 P27361 4QTB MAPK3 Mitogen-activated protein kinase 3 Protein kinase superfamily. CMGC Ser/Thr 
protein kinase family. MAP kinase subfamily 
ERK2 MK01 P28482 4QTA MAPK1 Mitogen-activated protein kinase 1  Protein kinase superfamily. CMGC Ser/Thr 
protein kinase family. MAP kinase subfamily 
FAK FAK1 Q05397 HM based on 2J0K PTK2 Focal Adhesion Kinase 1 Protein kinase superfamily. Tyr protein kinase 
family. FAK subfamily 
IKKɣ NEMO Q9Y6K9 HM based on 4UXV IKBKG Inhibitor of nuclear factor kappa-B 
kinase subunit gamma/NEMO 
Protein (family membership not predicted) 
IKKα IKKA O15111 HM based on 5EBZ CHUK Inhibitor of nuclear factor kappa-B 
kinase subunit alpha 
Protein kinase superfamily. Ser/Thr protein kinase 
family. I-kappa-B kinase subfamily 
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Supplementary Table 2 (Continued) 
Protein 
ID 
Alias UniProt 
ID 
3D structure Gene Full name Classification 
IKKβ IKKB O14920 HM based on 4E3C IKBKB Inhibitor of nuclear factor kappa-B 
kinase subunit alpha 
Protein kinase superfamily. Ser/Thr protein kinase 
family. I-kappa-B kinase subfamily 
IKBα IKBA P25963 HM based on 1NFI NFKBIA NF-kappa-B inhibitor alpha  NF-kappa-B inhibitor family 
Jak2 JAK2 O60674 HM based on 4OLI JAK2 Janus kinase 2 Protein kinase superfamily. Tyr protein kinase 
family. JAK subfamily 
Jak3 JAK3 P52333 HM based on 4OLI JAK3 Janus kinase 3 Protein kinase superfamily. Tyr protein kinase 
family. JAK subfamily 
JNK1 MK08 P45983 HM based on 4QTD MAPK8 Mitogen-activated protein kinase 8  Protein kinase superfamily. CMGC Ser/Thr 
protein kinase family. MAP kinase subfamily 
JNK2 MK09 P45984 HM based on 1JNK MAPK9 Mitogen-activated protein kinase 9 Protein kinase superfamily. CMGC Ser/Thr 
protein kinase family. MAP kinase subfamily 
JNK3 MK10 P53779 HM based on 1JNK MAPK10 Mitogen-activated protein kinase 10 Protein kinase superfamily. CMGC Ser/Thr 
protein kinase family. MAP kinase subfamily 
MEK1 MP2K1 Q02750 HM based on 5KKR MAP2K1 Dual Specificity Mitogen-Activated 
Protein Kinase Kinase 1 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase subfamily 
MEK2 MP2K2 P36507 HM based on 1S9I MAP2K2 Dual Specificity Mitogen-Activated 
Protein Kinase Kinase 2 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase subfamily 
MEK4 MP2K4 P45985 HM based on 3ALO MAP2K4 Dual specificity mitogen-activated 
protein kinase kinase 4 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase subfamily 
MEK7 MP2K7 O14733 HM based on 5B2L MAP2K7 Dual specificity mitogen-activated 
protein kinase kinase 7 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase subfamily 
MEKK1 M3K1 Q13233 HM based on 4YSM MAP3K1 Mitogen-activated protein kinase kinase 
kinase 1 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase kinase 
subfamily 
MKK3 MP2K3 P46734 HM based on 3VN9 MAP2K3 Dual specificity mitogen-activated 
protein kinase kinase 3 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase subfamily 
MKK6 MP2K6 P52564 HM based on 3VN9 MAP2K6 Dual Specificity Mitogen-Activated 
Protein Kinase Kinase 6 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase subfamily 
MLCK MYLK4 Q86YV6 HM based on 2X4F MYLK4 Myosin light chain kinase family 
member 4 
Protein kinase superfamily. CAMK Ser/Thr 
protein kinase family 
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Supplementary Table 2 (Continued) 
Protein 
ID 
Alias UniProt 
ID 
3D structure Gene Full name Classification 
MLK2 M3K10 Q02779 HM based on 4UY9 MAP3K10 Mitogen-activated protein kinase kinase 
kinase 10 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase kinase 
subfamily 
MLK3 M3K11 Q16584 HM based on 4UY9 MAP3K11 Mitogen-activated protein kinase kinase 
kinase 11 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase kinase 
subfamily 
MNK1 MKNK1 Q9BUB5 HM based on 2AC3 MKNK1 MAP kinase-interacting 
serine/threonine-protein kinase 1 
Protein kinase superfamily. CAMK Ser/Thr 
protein kinase family 
MNK2 MKNK2 Q9HBH9 HM based on 2AC3 MKNK2 MAP kinase-interacting 
serine/threonine-protein kinase 2 
Protein kinase superfamily. CAMK Ser/Thr 
protein kinase family 
MSK1RP KS6A5 O75582 HM based on 1VZO RPS6KA5 Ribosomal protein S6 kinase alpha-5 Protein kinase superfamily. AGC Ser/Thr protein 
kinase family. S6 kinase subfamily 
MSK2RP KS6A4 O75676 HM based on 4OLI RPS6KA4 Ribosomal protein S6 kinase alpha-4 Protein kinase superfamily. AGC Ser/Thr protein 
kinase family. S6 kinase subfamily 
mTOR MTOR P42345 HM based on 5H64 MTOR Serine/threonine-protein kinase mTOR PI3/PI4-kinase family 
NIK M3K14 Q99558 HM based on 5T8Q MAP3K14 Mitogen-activated protein kinase kinase 
kinase 14 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase kinase 
subfamily 
p38ɣ MAK12 P53778 HM based on 1CM8 MAPK12 Mitogen-activated protein kinase 12 Protein kinase superfamily. CMGC Ser/Thr 
protein kinase family. MAP kinase subfamily. 
p38α MAK14 Q16539 3FMK MAPK14 Mitogen-activated protein kinase 14  Protein kinase superfamily. CMGC Ser/Thr 
protein kinase family. MAP kinase subfamily. 
p38β MAK11 Q15759 HM based on 3GP0 MAPK11 Mitogen-activated protein kinase 11  Protein kinase superfamily. CMGC Ser/Thr 
protein kinase family. MAP kinase subfamily. 
p38δ MAK13 O15264 HM based on 3COI MAPK13 Mitogen-activated protein kinase 13 Protein kinase superfamily. CMGC Ser/Thr 
protein kinase family. MAP kinase subfamily. 
p53 P53 P04637 HM based on 4MZR TP53 Cellular tumor antigen p53 P53 family 
p65 TF65 Q04206 HM based on 1NFI RELA Transcription factor p65 Transcription factor 
PAK PAK4 O96013 HM based on 4FIE PAK4 Serine/threonine-protein kinase PAK 4 Protein kinase superfamily. STE Ser/Thr protein 
kinase family. STE20 subfamily 
RhoA RHOA P61586 HM based on 5C2K RHOA Transforming protein RhoA Small GTPase superfamily. Rho family 
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Supplementary Table 2 (Continued) 
Protein 
ID 
Alias UniProt 
ID 
3D structure Gene Full name Classification 
RIP1 RIPK1 Q13546 HM based on 4ITJ RIPK1 Receptor-interacting serine/threonine-
protein kinase 1 
Protein kinase superfamily. TKL Ser/Thr protein 
kinase family 
ROCK1 ROCK1 Q13464 HM based on 3NCZ ROCK1 Rho-associated protein kinase 1 Protein kinase superfamily. AGC Ser/Thr protein 
kinase family 
ROCK2 ROCK2 O75116 HM based on 4WOT ROCK2 Rho-associated protein kinase 2 Protein kinase superfamily. AGC Ser/Thr protein 
kinase family 
RSK2RP KS6A3 P51812 HM based on 4NIF RPS6KA3 Ribosomal protein S6 kinase alpha-3  Protein kinase superfamily. AGC Ser/Thr protein 
kinase family. S6 kinase subfamily 
Smad2 SMAD2 Q15796 HM based on 1KHX SMAD2 Mothers against decapentaplegic 
homolog 2 
Dwarfin/SMAD family 
Smad3 SMAD3 P84022 HM based on 1KHX SMAD3 Mothers against decapentaplegic 
homolog 3 
Dwarfin/SMAD family 
Smad4 SMAD4 Q13485 HM based on 1DD1 SMAD4 Mothers against decapentaplegic 
homolog 4 
Dwarfin/SMAD family 
Smuf2 SMUF2 Q9HAU4 HM based on 1ZVD SMUF2 E3 ubiquitin-protein ligase SMURF2 Ligase 
Sp1 SP1 P08047 HM based on 5KE6 SP1 Transcription factor Sp1 Sp1 C2H2-type zinc-finger protein family 
Stat3 STAT3 P40763 HM based on 1YVL STAT3 Signal transducer and activator of 
transcription 3 
Transcription factor 
TAB1 TAB1 Q15750 HM based on 2J4O TAB1 TGF-beta-activated kinase 1 and 
MAP3K7-binding protein 1 
Binding (regulation) protein 
TAK1 M3K7 O43318 HM based on 5GJF MAP3K7 Mitogen-activated protein kinase kinase 
kinase 7 
Protein kinase superfamily. STE Ser/Thr protein 
kinase family. MAP kinase kinase kinase 
subfamily 
TNFR1 TNR1A P19438 HM based on 1EXT TNFRSF1A Tumor necrosis factor receptor 
superfamily member 1A 
Receptor protein 
TRADD TRADD Q15628 HM based on 1F2H TRADD Tumor necrosis factor receptor type 1-
associated DEATH domain protein 
Binding protein 
TRAF2 TRAF2 Q12933 HM based on 1CA9 TRAF2 TNF receptor-associated factor 2 TNF receptor-associated factor family. A 
subfamily 
TRAF5 TRAF5 O00463 HM based on 1FLL TRAF5 TNF receptor-associated factor 5 TNF receptor-associated factor family. A 
subfamily 
HM - Homologue model, RP - Ribosomal protein 
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Supplementary Table 3. The most significant transcription factors identified from significantly 
modulated genes using Metacore 
Anthocyanins  Metabolites 
# Transcription factor p-Value  # Transcription factor p-Value 
1 SP1 1.220E-36  1 SP1 1.100E-32 
2 CREB1 1.830E-32  2 CREB1 1.620E-28 
3 HIF1A 1.830E-32  3 GCR 2.170E-24 
4 c-Jun 2.490E-28  4 Androgen receptor 2.170E-24 
5 p53 3.110E-24  5 p53 2.170E-24 
6 RelA (p65 NF-kB subunit) 3.110E-24  6 ESR1 (nuclear) 2.940E-16 
7 STAT3 3.540E-20  7 SP3 2.940E-16 
8 C/EBPbeta 3.680E-16  8 RelA (p65 NF-kB subunit) 2.940E-16 
9 C/EBPalpha 3.680E-16  9 EPAS1 2.940E-16 
10 ESR1 (nuclear) 3.680E-16  10 HIF1A 2.940E-16 
11 RelB (NF-kB subunit) 3.680E-16  11 STAT3 2.940E-16 
12 EPAS1 3.680E-16  12 TWIST1 2.940E-16 
13 Androgen receptor 3.680E-16  13 KLF4 2.930E-12 
14 Lef-1 3.680E-16  14 C/EBPalpha 2.930E-12 
15 TWIST1 3.680E-16  15 SLUG 2.930E-12 
16 p63 3.680E-16  16 ETS1 2.930E-12 
17 Beta-catenin 3.680E-16  17 c-Jun 2.930E-12 
18 NF-kB1 (p105) 3.680E-16  18 SRF 2.930E-12 
19 SP3 3.680E-16  19 FKHR 2.930E-12 
20 c-Fos 3.680E-16  20 Lef-1 2.930E-12 
21 NF-kB1 (p50) 3.680E-16  21 NF-kB1 (p50) 2.930E-12 
22 c-Myc 3.450E-12  22 NANOG 2.930E-12 
23 GCR 3.450E-12  23 EGR1 2.580E-08 
24 FOXO3A 3.450E-12  24 C/EBPbeta 2.580E-08 
25 E2F1 3.450E-12  25 STAT6 2.580E-08 
26 SLUG 3.450E-12  26 KLF2 2.580E-08 
27 ETS1 3.450E-12  27 E2F1 2.580E-08 
28 STAT1 3.450E-12  28 FOXM1 2.580E-08 
29 MKL1 3.450E-12  29 RelB (NF-kB subunit) 2.580E-08 
30 EGR1 3.450E-12  30 c-Myc 2.580E-08 
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Supplementary Table 4. Values of binding affinities (BA) for all targets and ligand (in kcal/mol). 
Protein ID 
C
y-
3-
ar
ab
 
C
y-
3-
ga
l 
C
y-
3-
gl
c 
D
el
-3
-g
lc
 
Pn
-3
-g
lc
 
4-
H
B
A
L 
F
er
ul
ic
 a
ci
d 
H
ip
pu
ri
c 
ac
id
 
PC
A
 
V
an
ill
ic
 a
ci
d 
AKT3 -9.0 -8.8 -9.2 -8.8 -8.9 -5.3 -6.7 -6.4 -6.2 -6.0 
ASK1 -9.6 -8.9 -9.0 -8.7 -9.2 -5 -6.4 -6.2 -5.6 -5.6 
ASK2 -8.6 -8.5 -8.8 -8.9 -8.8 -5 -6.0 -5.8 -5.3 -5.4 
b-Raf -8.0 -7.2 -7.5 -8.1 -7.6 -6.4 -7.5 -7.9 -7.1 -6.8 
JUN -5.2 -5.0 -4.9 -5.1 -4.9 -3.4 -4.3 -4.3 -3.7 -3.7 
c-Raf -8.5 -7.5 -8.9 -7.9 -7.9 -6.5 -6.9 -7.2 -7.1 -6.7 
CDC42 -8.1 -7.0 -7.6 -7.7 -7.3 -5.2 -6.5 -6.7 -6.0 -6.0 
CREB1 -5.9 -5.2 -5.6 -5.5 -5.2 -3.7 -4.7 -4.6 -3.7 -3.9 
CREBBP -7.6 -8.2 -8.0 -7.9 -8.1 -5.1 -6.7 -6.7 -7.2 -5.8 
EP300 -8.5 -8.1 -8.2 -8.0 -8.0 -5.2 -6.7 -6.6 -5.9 -5.8 
ERK1 -8.7 -8.7 -8.5 -8.5 -8.6 -5.1 -6.4 -7.1 -6.2 -5.9 
ERK2 -7.7 -7.6 -7.7 -7.6 -7.7 -4.8 -6.1 -5.9 -5.8 -5.7 
FAK -9.0 -8.8 -8.5 -9.1 -8.7 -5.2 -6.9 -6.4 -6.1 -6.1 
IKKɣ -7.6 -7.3 -7.1 -7.4 -7.1 -4.8 -6.3 -5.7 -5.6 -5.1 
IKKα -8.2 -8.6 -8.0 -8.2 -8.1 -5.4 -6.7 -6.4 -5.9 -6.0 
IKKβ -8.8 -9.6 -8.9 -9.0 -8.9 -5.1 -6.4 -5.9 -6.2 -5.8 
IKBα -7.9 -6.6 -7.0 -6.8 -6.8 -4.1 -5.4 -5.4 -4.7 -4.7 
JAK2 -8.7 -9.1 -9.2 -8.8 -9.1 -5.5 -6.9 -6.8 -5.9 -6.1 
JAK3 -8.4 -7.9 -8.7 -8.8 -8.7 -5.7 -7.2 -6.8 -6.1 -6.1 
JNK1 -9.8 -8.7 -9.9 -9.8 -9.4 -5.3 -6.5 -6.1 -5.6 -5.8 
JNK2 -8.5 -8.6 -8.6 -8.8 -8.5 -5.1 -6.3 -6.1 -5.5 -5.7 
JNK3 -8.7 -8.2 -8.9 -8.6 -8.1 -5.2 -6.3 -6.1 -5.9 -5.7 
MEK1 -8.9 -8.4 -8.8 -8.5 -8.4 -0.5 -5.9 -6.1 -5.6 -5.6 
MEK2 -8.5 -8.7 -8.6 -8.9 -8.1 -5.2 -6.6 -6.6 -6.0 -5.9 
MEK4  -9.3 -9.2 -9.3 -8.9 -8.6 -5.2 -6.7 -6.3 -6.0 -5.8 
MEK7 -7.8 -7.6 -8.1 -8.1 -7.9 -4.6 -5.6 -5.5 -5.2 -5.3 
MEKK1 -7.0 -7.0 -6.7 -6.8 -6.9 -4.9 -5.4 -5.4 -5.1 -5.0 
MKK3 -8.9 -8.5 -8.7 -8.4 -7.9 -5.2 -6.5 -6.4 -5.9 -5.8 
MKK6 -8.6 -8.8 -8.6 -8.3 -7.7 -5.1 -6.6 -6.4 -5.9 -5.8 
MLCK -8.3 -7.9 -8.1 -8.2 -7.9 -5.6 -7.0 -6.5 -6.4 -6.3 
MLK2 -9.3 -8.8 -9.1 -8.8 -8.2 -5 -5.9 -5.8 -5.6 -5.5 
MLK3 -9.4 -8.5 -9.1 -8.7 -8.2 -4.9 -5.9 -5.9 -5.6 -5.5 
MNK1 -7.9 -8.0 -7.9 -7.6 -7.8 -5.4 -6.4 -6.6 -6.2 -6.4 
MNK2 -7.8 -8.3 -8.0 -8.3 -8.3 -4.9 -6.2 -6.2 -5.7 -5.7 
MSK1RP -8.8 -8.4 -8.9 -8.9 -8.0 -5.5 -5.9 -6.9 -6.5 -5.8 
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Supplementary Table 4 (Continued) 
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MSK2RP -8.7 -7.7 -7.7 -8.4 -7.7 -5.4 -6.5 -6.9 -6.0 -6.1 
mTOR -8.4 -8.5 -8.6 -8.5 -8.5 -5.5 -6.7 -6.5 -6.7 -6.5 
NIK -7.9 -7.6 -7.9 -7.3 -7.3 -5.8 -6.3 -6.4 -6.9 -5.9 
p38ɣ -8.9 -8.7 -8.8 -8.6 -8.5 -5.8 -6.7 -6.4 -6.4 -6.0 
p38α -7.8 -7.6 -7.9 -7.2 -7.8 -4.8 -5.9 -5.6 -5.6 -5.3 
p38β -8.2 -9.1 -8.2 -8.1 -8.3 -5.9 -7.4 -7.1 -6.3 -6.4 
p38δ -7.9 -7.7 -8.0 -7.7 -7.6 -4.9 -6.1 -5.9 -5.9 -5.6 
p53 -7.3 -7.4 -7.3 -7.4 -7.2 -4.7 -5.8 -6.0 -5.5 -5.4 
p65 -7.8 -7.0 -7.3 -7.5 -7.4 -4.9 -5.9 -5.6 -5.8 -5.4 
PAK -8.4 -8.2 -7.9 -8.1 -8.0 -5.1 -6.1 -5.9 -5.8 -5.8 
RHOA -8.3 -8.9 -8.1 -8.1 -8.2 -5.8 -6.7 -6.7 -6.1 -6.1 
RIP1 -8.0 -7.7 -8.1 -8.3 -7.8 -5.4 -6.6 -6.8 -6.0 -6.0 
ROCK1 -8.3 -8.4 -8.4 -8.4 -8.1 -5.2 -6.2 -6.1 -6.1 -6.0 
ROCK2 -8.9 -9.3 -8.9 -9.1 -8.8 -5.6 -6.5 -6.7 -6.7 -6.3 
RSK2RP -9.4 -8.7 -9.1 -8.8 -9.0 -4.7 -6.1 -6.1 -5.4 -5.1 
SMAD2 -9.3 -9.7 -9.7 -9.8 -9.5 -5.5 -6.6 -6.6 -6.1 -6.4 
SMAD3 -9.3 -9.7 -9.7 -9.9 -9.6 -5.5 -6.6 -6.5 -6.3 -5.5 
SMAD4 -9.2 -8.9 -9.4 -9.4 -9.2 -5.5 -6.3 -6.3 -6.0 -5.9 
SMURF2 -9.3 -8.7 -8.7 -8.5 -8.3 -5.5 -6.7 -6.6 -6.6 -6.2 
SP1 -6.2 -6.6 -6.7 -6.7 -6.1 -4.4 -5.1 -4.7 -5.3 -5.1 
STAT3 -8.1 -7.9 -8.2 -8.3 -8.0 -5.5 -6.8 -6.3 -6.5 -6.1 
TAB1 -7.7 -7.5 -7.6 -7.8 -7.6 -5.1 -6.0 -5.7 -6.1 -6.1 
TAK1 -8.1 -8.1 -8.0 -8.0 -8.0 -4.9 -5.9 -6.0 -5.9 -5.9 
TNFR1 -6.8 -6.3 -6.9 -7.4 -7.3 -4 -5.0 -5.1 -4.8 -4.6 
TRADD -7.2 -6.9 -6.8 -6.9 -6.9 -4.6 -5.6 -6.0 -5.1 -5.1 
TRAF2 -7.3 -7.6 -7.3 -7.2 -6.9 -4.9 -5.2 -5.2 -5.3 -5.3 
TRAF5 -7.1 -7.0 -6.9 -7.0 -7.1 -4.7 -5.6 -5.4 -5.0 -5.1 
 RP - Ribosomal protein 
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Supplementary Figure 1. Heat map representation of BA for all targets and ligand. Each column 
presents different examined ligand and each line different target. Lighter shades of blue present 
lower BA, i.e. stronger binders. 
 
 
Energy 
donor
Bonding 
energy 
(KJ/mol)
H-bond 
length 
(Å)
Ligand 
contribution 
with atom 
type (no.)
Target 
contribution
AA 
residue
Localisation
EPair 
(KJ/mol)*
target -0.958805 3.12045 O (34) Ser154 Leu78 Protein kinase domain -8.70731
ligand -2.5 2.84628 O (34) Gln157 Gly79 Protein kinase domain -4.14582
either -2.5 2.78607 O (22) Ser154 Ala80 Protein kinase domain -7.31413
target -2.5 3.00686 O (22) Gln157 Gly81 Protein kinase domain -6.81849
ligand -0.0846128 3.58308 O (20) Asp156 Asn82 Protein kinase domain -2.25093
ligand -1.83742 2.88328 O (32) Gly81 Gly84 Protein kinase domain -0.540116
either -2.44647 3.11071 O (30) Ser198 Val86 Protein kinase domain -8.56736
ligand -2.5 2.88042 O (30) Asn199 Ala99 Protein kinase domain -0.938854
target -1.11876 3.2355 O (30) Asn199 Lys101 Protein kinase domain -2.96826
Met147 Protein kinase domain -2.08473
Met150 Protein kinase domain -1.69911
Gly153 Protein kinase domain -1.56612
Ser154 Protein kinase domain -13.4514
Asp156 Protein kinase domain -4.79669
Gln157 Protein kinase domain -15.8214
Lys160 Protein kinase domain -1.10912
Lys196 Protein kinase domain -1.86355
Ser198 Protein kinase domain -20.1535
Asn199 Protein kinase domain -9.58221
Leu201 Protein kinase domain -9.43612
Cys211 Protein kinase domain -0.860976
Asp212 Protein kinase domain -3.16923
target -1.09368 3.11535 O (37) Ser154 Leu78 Protein kinase domain -7.13973
ligand -2.5 2.70228 O (37) Gln157 Gly79 Protein kinase domain -2.13809
either -2.5 3.03054 O (25) Ser154 Ala80 Protein kinase domain -10.0251
target -2.5 2.79768 O (25) Gln157 Gly81 Protein kinase domain -13.3508
ligand -1.83681 2.92798 O (23) Asp156 Asn82 Protein kinase domain -2.91642
ligand -2.5 2.95098 O (19) Ala80 Gly84 Protein kinase domain -4.18052
ligand -2.5 2.71842 O (35) Gly81 Val86 Protein kinase domain -9.36782
target -0.0293223 3.27686 O (33) Gly81 Ala99 Protein kinase domain -0.988764
ligand -2.5 2.69506 O (33) Gly81 Lys101 Protein kinase domain -5.08145
ligand -2.13172 3.17366 O (33) Gly84 Met147 Protein kinase domain -1.85852
His149 Protein kinase domain -0.309629
Met150 Protein kinase domain -2.92664
Gly153 Protein kinase domain -2.02888
Ser154 Protein kinase domain -13.6046
Asp156 Protein kinase domain -7.473
Gln157 Protein kinase domain -12.7897
Lys160 Protein kinase domain -0.549381
Lys196 Protein kinase domain -1.15392
Ser198 Protein kinase domain -20.4991
Asn199 Protein kinase domain -5.50698
Leu201 Protein kinase domain -9.88294
Cys211 Protein kinase domain -0.958946
Asp212 Protein kinase domain -4.39603
ligand -2.5 2.96463 O (37) Leu78 Leu78 Protein kinase domain -16.8185
ligand -2.5 2.97878 O (37) Gln157 Gly79 Protein kinase domain -8.14971
target -2.12729 3.17454 O (37) Gln157 Ala80 Protein kinase domain -12.6958
ligand -2.5 3.08275 O (25) Ala80 Gly81 Protein kinase domain -8.81552
ligand -1.86472 3.05115 O (21) Asp156 Asn82 Protein kinase domain -2.24504
either -2.39222 3.12156 O (19) Ser154 Gly84 Protein kinase domain -1.17276
ligand -1.37883 3.21548 O (19) Asp156 Val86 Protein kinase domain -9.13943
ligand -2.5 3.02429 O (35) Gly81 Lys101 Protein kinase domain -3.62662
either -2.5 2.94544 O (33) Ser198 Met150 Protein kinase domain -2.41926
ligand -2.07085 2.9783 O (33) Asn199 Gly153 Protein kinase domain -3.971
target -2.08553 3.13239 O (33) Asn199 Ser154 Protein kinase domain -10.1626
Asp156 Protein kinase domain -10.2972
Gln157 Protein kinase domain -16.1986
Lys160 Protein kinase domain -2.71117
Lys196 Protein kinase domain -2.16182
Ser198 Protein kinase domain -16.812
Asn199 Protein kinase domain -9.62154
Leu201 Protein kinase domain -5.6016
Asp212 Protein kinase domain -3.55274
ligand -2.39188 3.12162 O (39) Leu78 Leu78 Protein kinase domain -17.1584
ligand -2.5 2.86091 O (39) Gln157 Gly79 Protein kinase domain -8.84265
target -2.17702 3.1646 O (39) Gln157 Ala80 Protein kinase domain -13.4655
ligand -2.5 3.02218 O (25) Ala80 Gly81 Protein kinase domain -12.3195
ligand -1.38228 3.16124 O (21) Asp156 Asn82 Protein kinase domain -1.97977
either -2.5 3.05366 O (19) Ser154 Gly84 Protein kinase domain -4.71225
ligand -1.09869 3.23626 O (19) Asp156 Val86 Protein kinase domain -9.61557
target -0.0837623 3.28578 O (37) Gly81 Lys101 Protein kinase domain -4.67926
ligand -2.5 2.62064 O (37) Gly81 Met150 Protein kinase domain -3.05856
ligand -2.48855 3.10229 O (37) Gly84 Gly153 Protein kinase domain -4.8706
ligand -2.5 2.93276 O (35) Gly81 Ser154 Protein kinase domain -10.706
either -2.5 3.05341 O (33) Ser198 Asp156 Protein kinase domain -9.20782
ligand -1.07312 3.13439 O (33) Asn199 Gln157 Protein kinase domain -16.2255
target -2.44505 3.11099 O (33) Asn199 Lys160 Protein kinase domain -2.55438
Lys196 Protein kinase domain -0.981435
Ser198 Protein kinase domain -16.0853
Asn199 Protein kinase domain -8.73065
Leu201 Protein kinase domain -5.93964
Asp212 Protein kinase domain -3.62141
target -0.195522 3.5609 O (1) Gln157 Leu78 Protein kinase domain -11.4296
ligand -2.5 2.97423 O (39) Met150 Gly79 Protein kinase domain -8.23925
target -2.5 2.80572 O (25) Lys101 Ala80 Protein kinase domain -7.79422
ligand -2.38147 3.12371 O (25) Asp212 Gly81 Protein kinase domain -9.66031
ligand -1.81225 3.23755 O (23) Gly81 Asn82 Protein kinase domain -3.06648
target -2.5 2.96384 O (23) Lys101 Val86 Protein kinase domain -9.29691
ligand -1.57326 3.28535 O (23) Asp212 Ala99 Protein kinase domain -0.625892
target -1.61234 3.27753 O (21) Lys196 Lys101 Protein kinase domain -8.4458
either -2.5 3.02394 O (19) Ser198 Met147 Protein kinase domain -1.26104
Met150 Protein kinase domain -6.81132
Gly153 Protein kinase domain -4.39568
Ser154 Protein kinase domain -9.29673
Asp156 Protein kinase domain -2.91008
Gln157 Protein kinase domain -10.6831
Lys160 Protein kinase domain -0.705827
Lys196 Protein kinase domain -4.67905
Ser198 Protein kinase domain -16.4962
Asn199 Protein kinase domain -3.58847
Leu201 Protein kinase domain -9.55088
Cys211 Protein kinase domain -0.879063
Asp212 Protein kinase domain -7.22799
Supplementary Table 5. Results of the molecular docking analyses for the most relevant targets 
Target Ligand
Hydrogen bonding Steric interactions
BA 
(kcal/mol)
Cy-3-glc -8.6
Del-3-glc -8.9
Pn-3-glc -8.1
MEK2
Ligand map with depiction of  H-bonds interactions
Cy-3-arab -8.5
Cy-3-gal -8.7
Energy 
donor
Bonding 
energy 
(KJ/mol)
H-bond 
length 
(Å)
Ligand 
contribution 
with atom 
type (no.)
Target 
contribution
AA 
residue
Localisation
EPair 
(KJ/mol)*
ligand -1.51653 3.29669 O (34) Glu109 Ile32 Protein kinase domain -4.3533
target -2.05041 3.09281 O (36) Met111 Gly33 Protein kinase domain -5.33913
ligand -0.754338 3.15141 O (36) Met111 Ser34 Protein kinase domain -8.17859
ligand -1.59148 3.2817 O (22) Leu168 Gly35 Protein kinase domain -2.48219
target -1.2662 3.31309 O (20) Lys55 Gln37 Protein kinase domain -6.64229
ligand -2.5 3.07369 O (20) Glu73 Gly38 Protein kinase domain -0.643803
ligand -2.5 2.9044 O (20) Leu168 Val40 Protein kinase domain -12.515
ligand -2.5 2.68272 O (18) Gln37 Ala53 Protein kinase domain -3.33504
ligand -2.5 2.73071 O (32) Ser34 Lys55 Protein kinase domain -8.90095
ligand -2.5 2.70895 O (30) Ser155 Glu73 Protein kinase domain -4.65616
ligand -2.5 2.99876 O (30) Asn156 Ile86 Protein kinase domain -3.17396
Met108 Protein kinase domain -7.55751
Glu109 Protein kinase domain -3.90021
Leu110 Protein kinase domain -6.24495
Met111 Protein kinase domain -9.40684
Asn114 Protein kinase domain -1.08501
Ser155 Protein kinase domain -6.74051
Asn156 Protein kinase domain -12.2007
Val158 Protein kinase domain -7.24434
Leu168 Protein kinase domain -31.2161
Asp169 Protein kinase domain -4.95215
target -2.25318 3.03615 O (39) Met111 Ile32 Protein kinase domain -6.65509
ligand -2.24511 3.15098 O (39) Met111 Gly33 Protein kinase domain -6.89674
ligand -0.585833 3.48283 O (25) Leu168 Ser34 Protein kinase domain -8.16323
ligand -2.5 2.70191 O (23) Gln37 Gly35 Protein kinase domain -2.72442
target -2.5 2.7964 O (23) Lys55 Gln37 Protein kinase domain -9.9494
ligand -0.356212 3.52876 O (23) Glu73 Gly38 Protein kinase domain -0.320576
ligand -2.5 3.03613 O (21) Gln37 Val40 Protein kinase domain -11.9136
ligand -2.5 2.96479 O (19) Asn156 Ala53 Protein kinase domain -3.73958
target -1.73317 3.25337 O (19) Asn156 Lys55 Protein kinase domain -8.27181
ligand -2.5 2.88379 O (35) Ser34 Glu73 Protein kinase domain -1.19596
target -2.5 3.06097 O (33) Asn114 Ile86 Protein kinase domain -2.37069
ligand -2.5 2.92095 O (33) Ser155 Met108 Protein kinase domain -5.17397
Glu109 Protein kinase domain -2.34468
Leu110 Protein kinase domain -5.1026
Met111 Protein kinase domain -11.0628
Asn114 Protein kinase domain -5.56896
Ser155 Protein kinase domain -8.61214
Asn156 Protein kinase domain -14.5702
Val158 Protein kinase domain -6.86399
Leu168 Protein kinase domain -19.2392
Asp169 Protein kinase domain -1.72792
ligand -1.20949 3.3581 O (37) Glu109 Ile32 Protein kinase domain -3.93138
target -1.86692 3.13895 O (39) Met111 Gly33 Protein kinase domain -5.04226
ligand -1.67198 3.2656 O (25) Leu168 Ser34 Protein kinase domain -8.10112
target -0.753198 3.32609 O (23) Lys55 Gly35 Protein kinase domain -3.2235
ligand -2.30956 3.13809 O (23) Glu73 Gln37 Protein kinase domain -4.76853
ligand -2.5 2.84924 O (23) Leu168 Gly38 Protein kinase domain -0.697418
target -2.5 2.97507 O (21) Asn156 Val40 Protein kinase domain -12.1267
ligand -2.5 2.79241 O (19) Asn156 Ala53 Protein kinase domain -3.13272
target -1.91447 3.21711 O (19) Asn156 Lys55 Protein kinase domain -8.54192
ligand -2.5 2.74124 O (35) Ser34 Glu73 Protein kinase domain -4.56026
ligand -2.5 2.83449 O (33) Ser155 Ile86 Protein kinase domain -3.24935
ligand -2.5 2.77183 O (33) Asn156 Met108 Protein kinase domain -7.62319
Glu109 Protein kinase domain -3.55203
Leu110 Protein kinase domain -5.59937
Met111 Protein kinase domain -8.04897
Asn114 Protein kinase domain -1.02123
Ser155 Protein kinase domain -6.75459
Asn156 Protein kinase domain -21.2905
Val158 Protein kinase domain -7.37457
Leu168 Protein kinase domain -31.5828
Asp169 Protein kinase domain -4.95338
ligand -1.99865 3.20027 O (39) Glu109 Ile32 Protein kinase domain -3.85583
target -1.91152 3.12435 O (41) Met111 Gly33 Protein kinase domain -5.48384
ligand -2.29899 3.1402 O (25) Leu168 Ser34 Protein kinase domain -3.12251
target -0.582712 3.28866 O (23) Lys55 Gly35 Protein kinase domain -3.75022
ligand -2.5 3.0155 O (23) Glu73 Gln37 Protein kinase domain -4.92628
ligand -2.5 2.8362 O (23) Leu168 Gly38 Protein kinase domain -3.20607
target -2.5 3.07001 O (21) Asn156 Ile39 Protein kinase domain -0.327181
ligand -1.67589 2.96591 O (19) Asn156 Val40 Protein kinase domain -12.376
target -2.5 2.97641 O (19) Asn156 Ala53 Protein kinase domain -3.26889
ligand -2.5 2.78154 O (37) Ser155 Lys55 Protein kinase domain -8.30276
ligand -2.5 3.00855 O (37) Asn156 Glu73 Protein kinase domain -4.94823
ligand -2.5 2.8611 O (35) Ser34 Ile86 Protein kinase domain -3.63057
ligand -1.93757 3.21249 O (33) Gly38 Met108 Protein kinase domain -8.09609
Glu109 Protein kinase domain -4.37629
Leu110 Protein kinase domain -5.98106
Met111 Protein kinase domain -8.34731
Asn114 Protein kinase domain -0.952609
Ser155 Protein kinase domain -6.4215
Asn156 Protein kinase domain -20.4376
Val158 Protein kinase domain -7.52768
Leu168 Protein kinase domain -32.3861
Asp169 Protein kinase domain -4.92197
ligand -1.8165 3.2367 O (37) Glu109 Ile32 Protein kinase domain -4.21036
target -1.71821 3.17388 O (39) Met111 Gly33 Protein kinase domain -5.73266
ligand -0.234642 3.22837 O (39) Met111 Ser34 Protein kinase domain -7.91157
ligand -2.04814 3.19037 O (25) Leu168 Gly35 Protein kinase domain -3.07994
target -0.646789 3.33148 O (23) Lys55 Gln37 Protein kinase domain -4.6766
ligand -2.5 3.08532 O (23) Glu73 Gly38 Protein kinase domain -0.841993
ligand -2.5 2.86609 O (23) Leu168 Val40 Protein kinase domain -11.5144
target -2.5 2.94328 O (21) Asn156 Ala53 Protein kinase domain -3.3479
ligand -1.45261 3.0306 O (19) Asn156 Lys55 Protein kinase domain -8.40906
target -2.5 2.98135 O (19) Asn156 Glu73 Protein kinase domain -4.75666
ligand -2.30009 2.57601 O (35) Ser34 Ile86 Protein kinase domain -3.38861
Met108 Protein kinase domain -7.87837
Glu109 Protein kinase domain -4.17578
Leu110 Protein kinase domain -5.97472
Met111 Protein kinase domain -8.54614
Asn114 Protein kinase domain -1.8454
Ser155 Protein kinase domain -2.99974
Asn156 Protein kinase domain -17.8322
Val158 Protein kinase domain -7.37627
Leu168 Protein kinase domain -31.8014
Asp169 Protein kinase domain -5.12863
Supplementary Table 5. (Continued)
Target Ligand
Hydrogen bonding Steric interactions
BA 
(kcal/mol)
Ligand map with depiction of  H-bonds interactions
JNK1 Cy-3-arab -9.8
Cy-3-gal -8.7
Pn-3-glc -9.4
Cy-3-glc -9.9
Del-3-glc -9.8
Energy 
donor
Bonding 
energy 
(KJ/mol)
H-bond 
length 
(Å)
Ligand 
contribution 
with atom 
type (no.)
Target 
contribution
AA 
residue
Localisation
EPair 
(KJ/mol)*
ligand -2.5 2.78631 O (34) Ile428 Ile428 Protein kinase domain -19.3835
target -0.590916 3.30325 O (36) Cys502 Gly429 Protein kinase domain -8.05173
ligand -2.5 2.64044 O (36) Cys502 Glu430 Protein kinase domain -9.97306
target -0.277513 3.33865 O (13) Glu430 Gly431 Protein kinase domain -0.637014
ligand -2.5 3.01172 O (20) Asn551 Phe433 Protein kinase domain -1.19162
ligand -2.5 2.92756 O (18) Glu430 Val436 Protein kinase domain -13.5346
target -2.5 2.80825 O (32) Lys454 Ala452 Protein kinase domain -1.15332
ligand -2.5 2.75113 O (32) Glu471 Lys454 Protein kinase domain -11.8114
ligand -2.5 2.81952 O (32) Asp564 Glu471 Protein kinase domain -4.67251
target -2.5 2.88436 O (30) Lys454 Val484 Protein kinase domain -0.436098
ligand -2.5 2.98725 O (30) Asp564 Met499 Protein kinase domain -2.74567
Leu501 Protein kinase domain -3.01758
Cys502 Protein kinase domain -8.11531
Thr503 Protein kinase domain -0.312845
Gly505 Protein kinase domain -1.69448
Glu506 Protein kinase domain -1.22462
Arg550 Protein kinase domain -2.35843
Asn551 Protein kinase domain -5.22722
Leu553 Protein kinase domain -11.5558
Gly563 Protein kinase domain -2.96267
Asp564 Protein kinase domain -17.387
Gly566 Protein kinase domain -0.48297
ligand -1.21619 3.35676 O (37) Ile428 Ile428 Protein kinase domain -14.6138
target -0.834313 3.19175 O (39) Cys502 Gly429 Protein kinase domain -4.94723
ligand -2.5 2.77932 O (39) Cys502 Glu430 Protein kinase domain -14.0403
ligand -2.5 2.9667 O (25) Asp564 Gly431 Protein kinase domain -0.690979
ligand -1.93555 3.21289 O (23) Asn551 Val436 Protein kinase domain -9.92503
ligand -2.2915 3.1417 O (23) Asp564 Ala452 Protein kinase domain -1.21647
ligand -2.5 2.9589 O (21) Glu430 Lys454 Protein kinase domain -8.00962
target -1.87829 3.13366 O (19) Glu430 Glu471 Protein kinase domain -4.56558
ligand -2.5 2.70415 O (19) Glu430 Met475 Protein kinase domain -0.541482
target -2.5 2.81247 O (35) Lys454 Val484 Protein kinase domain -1.2592
ligand -2.5 2.73769 O (35) Glu471 Met499 Protein kinase domain -3.57753
ligand -2.5 2.82183 O (35) Asp564 Leu501 Protein kinase domain -1.67315
ligand -2.5 2.70012 O (33) Gly563 Cys502 Protein kinase domain -8.88988
ligand -1.74096 3.25181 O (33) Asp564 Thr503 Protein kinase domain -0.309132
Gly505 Protein kinase domain -2.41967
Glu506 Protein kinase domain -1.51257
Arg550 Protein kinase domain -1.73123
Asn551 Protein kinase domain -6.15944
Leu553 Protein kinase domain -13.6558
Gly563 Protein kinase domain -7.16757
Asp564 Protein kinase domain -26.2551
Gly566 Protein kinase domain -0.394005
target -2.5 2.95864 O (37) Trp97 Arg86 FERM domain -4.6009
target -1.30221 3.33956 O (25) Arg86 Val95 FERM domain -0.473331
target -0.0777386 3.07119 O (25) Arg125 Trp97 FERM domain -10.1382
target -2.23705 3.02449 O (23) Arg125 Arg125 FERM domain -10.9962
ligand -2.5 2.88181 O (23) Ile126 Ile126 FERM domain -8.40551
target -2.5 3.02576 O (23) Gln150 Arg127 FERM domain -10.9881
ligand -2.5 2.76454 O (21) Ile126 Leu129 FERM domain -1.45842
ligand -2.39631 3.12074 O (19) Phe253 Phe147 FERM domain -0.670751
either -0.370844 3.35308 O (35) Tyr251 Gln150 FERM domain -6.28643
ligand -2.5 2.72453 O (35) Arg252 Asp154 FERM domain -1.43335
ligand -2.5 2.75963 O (33) Arg252 Glu158 FERM domain -3.48663
ligand -2.25931 3.14814 O (33) Lys255 Tyr251 FERM domain -7.05939
Arg252 FERM domain -14.2623
Phe253 FERM domain -7.25417
Asp254 FERM domain -1.02438
Lys255 FERM domain -7.45798
Glu256 FERM domain -28.6701
Cys257 FERM domain -1.18251
Phe258 FERM domain -7.06819
Ile336 FERM domain -0.917517
Asn339 FERM domain -4.38361
either -2.5 2.96793 O (41) Ser463 His41 FERM domain -7.49264
target -2.5 3.00589 O (25) His41 Phe43 FERM domain -7.23045
ligand -1.7136 3.25728 O (25) Phe43 Glu44 FERM domain -6.34625
ligand -0.976273 2.8489 O (23) Phe43 Ser45 FERM domain -12.4378
ligand -2.5 2.72539 O (23) Glu44 Ser47 FERM domain -8.54256
ligand -2.5 2.69844 O (21) Asp573 Thr51 FERM domain -11.1571
ligand -2.5 2.92741 O (19) Asp573 Trp52 FERM domain -5.71532
ligand -2.5 3.02604 O (19) Ser574 Ala53 FERM domain -9.06047
ligand -2.5 2.75684 O (37) Thr51 Ser54 FERM domain -6.16734
ligand -2.5 2.706 O (37) Glu403 Ile55 FERM domain -3.96006
either -2.5 2.9683 O (35) Ser47 His75 FERM domain -8.56406
ligand -2.5 3.07879 O (35) Thr51 Ile400 Protein kinase domain -11.9829
either -0.762197 3.44756 O (35) Thr51 Ile401 Protein kinase domain -8.4377
either -2.5 2.92853 O (33) Ser45 Asp402 Protein kinase domain -5.98489
either -2.5 2.73763 O (33) Ser47 Glu403 Protein kinase domain -6.88544
target -2.5 2.90931 O (33) Arg569 Ser463 Protein kinase domain -3.40974
Arg569 Protein kinase domain -8.38305
Asp573 Protein kinase domain -15.1464
Ser574 Protein kinase domain -5.45127
Thr575 Protein kinase domain -5.09553
Tyr576 Protein kinase domain -1.79229
target -1.21021 3.27794 O (37) Trp97 Arg86 FERM domain -2.12782
ligand -1.74881 3.21167 O (37) Glu256 Val95 FERM domain -5.18153
target -0.601477 3.27478 O (25) Arg125 Trp97 FERM domain -5.33383
ligand -2.5 2.81516 O (25) Asp154 Arg125 FERM domain -3.70614
target -2.5 2.89396 O (23) Gln150 Ile126 FERM domain -4.3775
ligand -2.5 2.98748 O (23) Asp154 Arg127 FERM domain -5.71102
ligand -2.5 2.93071 O (21) Ile126 Leu129 FERM domain -1.91991
target -2.5 2.90434 O (21) Gln150 Phe147 FERM domain -2.24795
ligand -2.5 2.86628 O (19) Phe253 Gln150 FERM domain -8.93921
target -0.0696032 3.58608 O (33) Arg252 Val151 FERM domain -1.15858
Asp154 FERM domain -8.59771
Glu158 FERM domain -3.69262
Tyr251 FERM domain -5.59171
Arg252 FERM domain -13.7078
Phe253 FERM domain -7.31449
Asp254 FERM domain -1.27291
Lys255 FERM domain -4.92663
Glu256 FERM domain -24.893
Cys257 FERM domain -3.63614
Phe258 FERM domain -0.713526
Asn339 FERM domain -1.05442
Supplementary Table 5. (Continued)
Target Ligand
Hydrogen bonding Steric interactions
BA 
(kcal/mol)
Cy-3-glc -8.5
Ligand map with depiction of  H-bonds interactions
FAK1 Cy-3-arab -9.0
Cy-3-gal -8.8
Pn-3-glc -8.7
Del-3-glc -9.1
Energy 
donor
Bonding 
energy 
(KJ/mol)
H-bond 
length 
(Å)
Ligand 
contribution 
with atom 
type (no.)
Target 
contribution
AA 
residue
Localisation
EPair 
(KJ/mol)*
target -0.989466 3.24158 O (13) Arg100 Ile98 Protein kinase domain -1.08868
ligand -2.5 2.95696 O (20) Asp218 Gly99 Protein kinase domain -5.27951
ligand -2.11124 3.17775 O (18) Arg100 Arg100 Protein kinase domain -12.4983
target -2.31788 3.13642 O (32) Phe103 Gly101 Protein kinase domain -10.1176
ligand -2.5 3.06889 O (30) Asp232 Ala102 Protein kinase domain -4.43168
Phe103 Protein kinase domain -6.91318
Gly104 Protein kinase domain -4.13237
Glu105 Protein kinase domain -3.2347
Val106 Protein kinase domain -11.6344
Ala119 Protein kinase domain -0.318821
Lys121 Protein kinase domain -15.3976
Leu122 Protein kinase domain -0.567196
Leu123 Protein kinase domain -2.52246
Val153 Protein kinase domain -1.78325
Met169 Protein kinase domain -4.43228
Met172 Protein kinase domain -0.42389
Asp176 Protein kinase domain -1.1908
Asp218 Protein kinase domain -10.3982
Leu221 Protein kinase domain -6.3043
Ala231 Protein kinase domain -8.36264
Asp232 Protein kinase domain -12.2317
Phe384 AGC-kinase C-terminal domain -1.05269
target -2.35198 2.79738 O (39) Met172 Ile98 Protein kinase domain -10.6908
ligand -1.71928 3.25614 O (39) Met172 Gly99 Protein kinase domain -8.88427
target -1.53488 3.29302 O (25) Lys121 Arg100 Protein kinase domain -10.7359
target -1.56451 3.2871 O (23) Lys121 Gly101 Protein kinase domain -2.96415
ligand -2.5 2.94632 O (19) Asn219 Val106 Protein kinase domain -11.4048
target -0.727846 3.38138 O (33) Arg100 Ala119 Protein kinase domain -2.42063
ligand -2.5 2.65726 O (33) Arg100 Lys121 Protein kinase domain -7.99534
Val153 Protein kinase domain -1.78213
Met169 Protein kinase domain -3.56375
Glu170 Protein kinase domain -1.35306
Tyr171 Protein kinase domain -4.31707
Met172 Protein kinase domain -10.9348
Asp176 Protein kinase domain -4.15871
Lys216 Protein kinase domain -1.40979
Asp218 Protein kinase domain -8.33534
Asn219 Protein kinase domain -7.99573
Leu221 Protein kinase domain -12.8657
Ala231 Protein kinase domain -5.64848
Asp232 Protein kinase domain -12.8251
Phe384 AGC-kinase C-terminal domain -10.0599
Ile387 AGC-kinase C-terminal domain -0.614797
ligand -2.22477 3.15505 O (23) Asp218 Ile98 Protein kinase domain -0.624485
ligand -2.5 2.97464 O (21) Asp218 Gly99 Protein kinase domain -4.02096
ligand -2.5 2.97614 O (19) Asp176 Arg100 Protein kinase domain -9.73222
target -0.0018934 3.34878 O (35) Ala102 Gly101 Protein kinase domain -10.7862
target -2.5 3.03995 O (35) Phe103 Ala102 Protein kinase domain -4.76164
ligand -2.5 3.06525 O (33) Asp232 Phe103 Protein kinase domain -7.11543
Gly104 Protein kinase domain -4.17929
Glu105 Protein kinase domain -3.16826
Val106 Protein kinase domain -11.5444
Ala119 Protein kinase domain -0.319893
Lys121 Protein kinase domain -14.9476
Leu122 Protein kinase domain -0.500899
Leu123 Protein kinase domain -2.26875
Val153 Protein kinase domain -1.77138
Met169 Protein kinase domain -4.38797
Met172 Protein kinase domain -0.389118
Asp176 Protein kinase domain -5.48688
Val178 Protein kinase domain -1.12772
Lys216 Protein kinase domain -0.478855
Asp218 Protein kinase domain -16.1899
Asn219 Protein kinase domain -0.602131
Leu221 Protein kinase domain -6.23002
Ala231 Protein kinase domain -8.31887
Asp232 Protein kinase domain -12.586
Phe384 AGC-kinase C-terminal domain -1.36677
ligand -2.36362 3.12728 O (23) Asp218 Ile98 Protein kinase domain -0.936166
ligand -2.5 2.98229 O (21) Asp218 Gly99 Protein kinase domain -3.57837
ligand -2.5 2.94509 O (19) Asp176 Arg100 Protein kinase domain -9.94353
target -0.103789 3.25017 O (35) Ala102 Gly101 Protein kinase domain -11.3397
target -2.5 3.09736 O (35) Phe103 Ala102 Protein kinase domain -5.16204
ligand -2.5 2.99472 O (33) Asp232 Phe103 Protein kinase domain -7.94873
Gly104 Protein kinase domain -2.7129
Glu105 Protein kinase domain -3.54646
Val106 Protein kinase domain -11.6461
Ala119 Protein kinase domain -0.359882
Lys121 Protein kinase domain -15.5628
Leu122 Protein kinase domain -0.725341
Leu123 Protein kinase domain -2.61811
Val153 Protein kinase domain -1.74347
Met169 Protein kinase domain -4.38147
Met172 Protein kinase domain -0.430175
Asp176 Protein kinase domain -5.55861
Val178 Protein kinase domain -1.14393
Lys216 Protein kinase domain -0.488526
Asp218 Protein kinase domain -16.63
Asn219 Protein kinase domain -0.652372
Leu221 Protein kinase domain -6.45535
Ala231 Protein kinase domain -8.20139
Asp232 Protein kinase domain -12.8494
Phe384 AGC-kinase C-terminal domain -1.53531
Target Ligand
Hydrogen bonding Steric interactions
BA 
(kcal/mol)
Ligand map with depiction of  H-bonds interactions
Cy-3-glc -8.9
Del-3-glc -9.1
Cy-3-arab -8.9
Supplementary Table 5. (Continued)
Cy-3-gal -9.3
ROCK2
Energy 
donor
Bonding 
energy 
(KJ/mol)
H-bond 
length 
(Å)
Ligand 
contribution 
with atom 
type (no.)
Target 
contribution
AA 
residue
Localisation
EPair 
(KJ/mol)*
ligand -2.31279 3.13744 O (23) Asp218 Ile98 Protein kinase domain -0.587221
ligand -2.5 2.94494 O (21) Asp218 Gly99 Protein kinase domain -3.95869
ligand -2.5 2.9887 O (19) Asp176 Arg100 Protein kinase domain -9.65929
target -2.5 2.95484 O (35) Phe103 Gly101 Protein kinase domain -12.16
Ala102 Protein kinase domain -6.33161
Phe103 Protein kinase domain -7.50571
Gly104 Protein kinase domain -4.46784
Glu105 Protein kinase domain -3.43505
Val106 Protein kinase domain -11.3496
Lys121 Protein kinase domain -15.09
Leu122 Protein kinase domain -0.589805
Leu123 Protein kinase domain -2.3976
Val153 Protein kinase domain -1.74482
Met169 Protein kinase domain -4.21298
Met172 Protein kinase domain -0.336137
Asp176 Protein kinase domain -5.45748
Val178 Protein kinase domain -1.14287
Lys216 Protein kinase domain -0.497045
Asp218 Protein kinase domain -16.3781
Asn219 Protein kinase domain -0.576024
Leu221 Protein kinase domain -5.99112
Ala231 Protein kinase domain -8.36595
Asp232 Protein kinase domain -11.0729
Phe384 AGC-kinase C-terminal domain -0.95591
target -1.95278 3.20944 O (34) Gln260 Gly115 Protein kinase domain -1.24993
target -1.85608 3.13613 O (34) Asn262 Lys117 Protein kinase domain -0.33155
ligand -1.43597 3.31281 O (34) Asn262 Gln260 Protein kinase domain -5.06319
ligand -2.5 2.78835 O (34) Asn262 Pro261 Protein kinase domain -2.41996
target -0.34228 3.43202 O (13) Arg443 Asn262 Protein kinase domain -20.3728
ligand -2.5 2.69103 O (22) Asn262 Ser263 Protein kinase domain -13.3991
either -2.5 2.98657 O (22) Ser263 Leu264 Protein kinase domain -2.31861
target -0.371335 3.41092 O (22) His432 Cys265 Protein kinase domain -0.439987
target -0.980082 3.15097 O (20) His432 His314 NA -3.81379
ligand -2.5 2.699 O (18) Glu439 Ile323 NA -10.7088
target -0.329882 3.0746 O (18) Arg443 Asp380 NA -5.95592
target -1.17486 3.36503 O (32) Arg443 Met383 NA -1.49096
target -0.316863 3.06003 O (30) His314 Arg401 NA -4.68817
ligand -2.5 2.93576 O (30) Asp380 His432 NA -6.91256
Gly436 NA -1.2159
Glu439 NA -8.25046
Asp440 NA -1.87208
Arg443 NA -15.0648
ligand -2.5 2.70358 O (37) Asp380 Gly115 Protein kinase domain -0.812102
ligand -2.5 2.71507 O (39) Ile323 Leu116 Protein kinase domain -0.876259
either -2.5 2.99318 O (39) Ser325 Lys117 Protein kinase domain -6.66495
target -0.0743586 3.2243 O (13) Arg443 Gln260 Protein kinase domain -3.9837
target -0.0824638 2.7973 O (25) Arg401 Pro261 Protein kinase domain -4.87845
target -1.65509 3.26898 O (23) Arg401 Asn262 Protein kinase domain -16.0839
target -2.5 2.87245 O (23) Arg401 Ser263 Protein kinase domain -14.6044
ligand -0.421153 3.5154 O (23) Gly436 Leu264 Protein kinase domain -5.22754
ligand -2.23228 3.15354 O (21) Glu439 Cys265 Protein kinase domain -11.0853
target -1.21085 3.23898 O (19) Lys117 Ser266 Protein kinase domain -2.46205
either -2.5 2.84283 O (19) Ser263 His314 NA -5.38707
target -2.5 3.09926 O (33) Gln260 Ile323 NA -14.2498
target -1.90618 2.85941 O (33) Asn262 Ile324 NA -0.976057
ligand -1.95904 3.20819 O (33) Asn262 Ser325 NA -5.36831
ligand -2.5 2.75452 O (33) Asn262 Asp380 NA -6.54345
Arg401 NA -14.0768
His432 NA -3.84939
Gly436 NA -2.58155
Glu439 NA -10.5082
Asp440 NA -1.12969
Arg443 NA -7.26105
target -2.31294 3.13741 O (39) Gln260 Lys117 Protein kinase domain -3.50616
ligand -2.5 3.02847 O (25) Asp440 Glu118 Protein kinase domain -1.50064
target -1.92062 3.21588 O (23) Arg443 Gln260 Protein kinase domain -5.46867
target -0.0576321 3.26945 O (21) His314 Pro261 Protein kinase domain -5.88759
ligand -1.53457 3.29309 O (21) Asp380 Asn262 Protein kinase domain -8.14388
ligand -2.5 3.09447 O (19) Ser263 Ser263 Protein kinase domain -14.9934
ligand -2.5 3.01884 O (19) Asp380 Leu264 Protein kinase domain -2.87839
ligand -1.98611 2.88482 O (35) Glu439 Cys265 Protein kinase domain -3.12405
ligand -0.283207 3.03285 O (35) Glu439 His314 NA -3.98179
either -2.45732 2.99843 O (33) Ser263 Ile323 NA -9.05072
Asp380 NA -8.51323
Met383 NA -0.883239
Arg401 NA -15.6476
His432 NA -10.229
Gly436 NA -2.27427
Glu439 NA -7.86641
Asp440 NA -4.99381
Arg443 NA -12.5079
target -2.5 2.97173 O (41) Gln260 Lys117 Protein kinase domain -2.97891
ligand -2.5 3.00702 O (25) Asp440 Glu118 Protein kinase domain -1.49373
target -2.38209 3.12358 O (23) Arg443 Gln260 Protein kinase domain -5.91544
target -0.104725 3.22389 O (21) His314 Pro261 Protein kinase domain -5.88643
ligand -1.82715 3.23457 O (21) Asp380 Asn262 Protein kinase domain -8.49888
ligand -2.07353 3.18529 O (19) Ser263 Ser263 Protein kinase domain -14.045
ligand -2.5 3.01443 O (19) Asp380 Leu264 Protein kinase domain -2.84971
ligand -2.5 2.70541 O (37) Glu439 Cys265 Protein kinase domain -3.14341
ligand -1.30599 3.04224 O (35) Glu439 His314 NA -4.08838
ligand -1.23231 3.05214 O (35) Glu439 Ile323 NA -9.183
either -1.8175 3.09881 O (33) Ser263 Asp380 NA -8.72677
Met383 NA -0.954067
Arg401 NA -14.9397
His432 NA -11.3597
Ser435 NA -0.491019
Gly436 NA -2.76156
Glu439 NA -11.4591
Asp440 NA -4.96654
Arg443 NA -12.8573
Pn-3-glc -8.8
Cy-3-glc -8.0
Del-3-glc -8.2
Cy-3-gal -8.6
IKKα
ROCK2
Supplementary Table 5. (Continued)
Target Ligand
Hydrogen bonding Steric interactions
BA 
(kcal/mol)
Ligand map with depiction of  H-bonds interactions
Cy-3-arab -8.2
Energy 
donor
Bonding 
energy 
(KJ/mol)
H-bond 
length 
(Å)
Ligand 
contribution 
with atom 
type (no.)
Target 
contribution
AA 
residue
Localisation
EPair 
(KJ/mol)*
target -2.5 3.04661 O (39) Gln260 Lys117 Protein kinase domain -5.92493
ligand -2.5 2.98759 O (25) Asp440 Glu118 Protein kinase domain -2.45351
target -2.36162 3.12768 O (23) Arg443 Gln260 Protein kinase domain -5.79015
target -0.106498 3.24617 O (21) His314 Pro261 Protein kinase domain -5.91525
ligand -1.82107 3.23579 O (21) Asp380 Asn262 Protein kinase domain -8.544
ligand -2.32512 3.13498 O (19) Ser263 Ser263 Protein kinase domain -17.3831
ligand -2.5 3.00509 O (19) Asp380 Leu264 Protein kinase domain -2.84707
ligand -2.30936 2.88309 O (35) Glu439 Cys265 Protein kinase domain -3.01275
target -2.5 3.04841 O (33) Ser263 His314 NA -3.98636
Ile323 NA -9.20259
Asp380 NA -10.1967
Met383 NA -0.953811
Arg401 NA -15.4146
His432 NA -9.77698
Gly436 NA -2.21965
Glu439 NA -8.20338
Asp440 NA -5.03907
Arg443 NA -13.7896
*The H-bonding mode and steric interactions evaluated as EPair (the pairwise steric and hydrogen bonding energy between a ligand atom and a receptor atom)
IKKα Pn-3-glc -8.1
Supplementary Table 5. (Continued)
Target Ligand
Hydrogen bonding Steric interactions
BA 
(kcal/mol)
Ligand map with depiction of  H-bonds interactions
Energy 
donor
Bonding 
energy 
(KJ/mol)
H-bond 
length 
(Å)
Ligand 
contributio
n 
with atom 
type (no.)
Target 
contributio
n
AA 
residue Localisation
EPair 
(KJ/mol)*
target -2.5 2.83082 O (6) Leu905 Leu828 Tyr-protein kinase (catalytic domain): ATP binding site (PROSITE pattern) -10.2467
target -1.51054 3.08687 O (13) Asp967 Gly831 Tyr-protein kinase (catalytic domain): ATP binding site (PROSITE pattern) -0.841605
Val836 Tyr-protein kinase (catalytic domain): ATP binding site (PROSITE pattern) -9.29768
Ala853 Tyr-protein kinase (catalytic domain): ATP binding site (PROSITE pattern) -2.96766
Lys855 Tyr-protein kinase (catalytic domain): ATP binding site (PROSITE pattern) -3.31742
Val884 Tyr-protein kinase (catalytic domain) -1.50362
Met902 Tyr-protein kinase (catalytic domain) -4.12008
Glu903 Tyr-protein kinase (catalytic domain) -2.26633
Tyr904 Tyr-protein kinase (catalytic domain) -5.50754
Leu905 Tyr-protein kinase (catalytic domain) -12.1934
Gly908 Tyr-protein kinase (catalytic domain) -1.32869
Cys909 Tyr-protein kinase (catalytic domain) -0.389102
Leu956 Tyr-protein kinase (catalytic domain): active site (PROSITE pattern) -11.8097
Ala966 Tyr-protein kinase (catalytic domain) -4.46084
Asp967 Tyr-protein kinase (catalytic domain) -8.06463
target -0.016612 3.58347 O (14) Gly114 Leu112 Protein kinase domain: ATP binding site -11.3077
target -0.61673 3.25957 O (13) Gly115 Gly113 Protein kinase domain: ATP binding site -4.93206
target -0.731165 2.94101 O (13) Lys135 Gly114 Protein kinase domain: ATP binding site -2.66587
ligand -2.5 3.02163 O (6) Glu181 Gly115 Protein kinase domain: ATP binding site -3.60319
target -1.83815 3.17565 O (6) Val183 Gly118 Protein kinase domain: ATP binding site -0.461835
Val120 Protein kinase domain: ATP binding site -7.92989
Ala133 Protein kinase domain: ATP binding site -2.2211
Lys135 Protein kinase domain: ATP binding site -5.26166
Ile164 Protein kinase domain -3.94931
Met180 Protein kinase domain -2.84847
Glu181 Protein kinase domain -4.69027
Tyr182 Protein kinase domain -5.08338
Val183 Protein kinase domain -8.57903
Gly186 Protein kinase domain -0.39823
Leu188 Protein kinase domain -2.85422
Glu231 Protein kinase domain: Ser/Thr-protein kinase (active site) -0.516769
Leu234 Protein kinase domain: Ser/Thr-protein kinase (active site) -5.34382
Ile246 Protein kinase domain -14.2058
target -1.74543 3.15179 O (6) Lys53 Tyr35 Protein kinase domain: ATP binding site -3.47938
target -2.5 3.03162 O (14) Met109 Val38 Protein kinase domain: ATP binding site -5.92623
ligand -2.5 2.99261 O (6) Asp168 Ala51 Protein kinase domain: ATP binding site -2.40556
Lys53 Protein kinase domain: ATP binding site -7.80963
Glu71 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -1.44468
Leu75 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -0.657765
Ile84 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -6.53897
Leu104 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -0.317307
Thr106 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -4.65628
Thr107 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -2.69625
Leu108 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -5.28779
Met109 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -7.86754
Ala157 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -2.32137
Leu167 Protein kinase domain -12.1546
Asp168 Protein kinase domain -7.62261
Phe169 Protein kinase domain -15.1884
target -2.5 2.92987 O (13) Ser32 Val30 Protein kinase domain: ATP binding site -0.738123
target -0.436909 3.05264 O (13) Gly33 Ser32 Protein kinase domain: ATP binding site -5.85536
Gly33 Protein kinase domain: ATP binding site -2.7515
Tyr35 Protein kinase domain: ATP binding site -4.43439
Val38 Protein kinase domain: ATP binding site -5.04828
Ala51 Protein kinase domain: ATP binding site -1.8803
Lys53 Protein kinase domain: ATP binding site -1.15227
Ile84 Protein kinase domain -3.79686
Thr106 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -2.96228
Thr107 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -0.586252
Leu108 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -0.391025
Ala111 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -2.06044
Asp112 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -5.37423
Ser154 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -2.2229
Asn155 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -0.322758
Val156 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -1.05801
Ala157 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -3.8809
Leu167 Protein kinase domain -13.4209
Asp168 Protein kinase domain -1.70321
Phe169 Protein kinase domain -16.6541
target -1.74708 3.10962 O (6) Lys53 Tyr35 Protein kinase domain: ATP binding site -2.90708
either -0.46772 2.99203 O (12) Thr107 Val38 Protein kinase domain: ATP binding site -5.00382
ligand -1.98139 3.01518 O (12) Thr107 Ala51 Protein kinase domain: ATP binding site -1.81706
ligand -2.3468 3.13064 O (6) Asp168 Lys53 Protein kinase domain: ATP binding site -6.1784
ligand -2.5 3.07181 O (8) Asp168 Glu71 Protein kinase domain -0.30562
Ile84 Protein kinase domain -6.24366
Thr106 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -4.20513
Thr107 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -3.60769
Leu108 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -0.877834
Ala157 Protein kinase domain: Mitogen-activated protein (MAP) kinase, conserved site -0.582068
Leu167 Protein kinase domain -12.8966
Asp168 Protein kinase domain -9.77978
Phe169 Protein kinase domain -15.1579
PCA
p38β
-6.3
Ferulic 
acid
-7.4
Hippuric
 acid
-7.1
JAK3 Ferulic 
acid
-7.2
MLCK Ferulic 
acid
-7.0
Supplementary Table 6. Results of the molecular docking analyses for the most relevant targets of metabolites
Target Ligand
Hydrogen bonding Steric interactions
BA 
(kcal/mol)
Ligand map
H-bonds: blue dashed lines
Strong steric interactions: red dashed lines (if present)
Weak steric interactions: not figured (only the corresponding AAs are presented)
Energy 
donor
Bonding 
energy 
(KJ/mol)
H-bond 
length 
(Å)
Ligand 
contributio
n 
with atom 
type (no.)
Target 
contributio
n
AA 
residue Localisation
EPair 
(KJ/mol)*
target -2.5 2.98147 O (8) Leu577 His574
Ser-Thr/Tyr-protein kinase, catalytic domain: 
active site (PROSITE pattern) -0.914093
ligand -1.13197
3.18683
O (12) Ser616 Arg575 Ser-Thr/Tyr-protein kinase, catalytic domain: active site (PROSITE pattern) -11.4905
either -2.5
2.96425
O (6) Ser637 Asp576 Ser-Thr/Tyr-protein kinase, catalytic domain: active site (PROSITE pattern) -9.8462
ligand -1.60628
3.27874
O (6) Asp638 Leu577 Ser-Thr/Tyr-protein kinase, catalytic domain: active site (PROSITE pattern) -10.5461
ligand -2.5
2.88301
O (8) Asp638 Lys578 Ser-Thr/Tyr-protein kinase, catalytic domain: active site (PROSITE pattern) -2.45119
Leu613 Ser-Thr/Tyr-protein kinase, catalytic domain -6.29863
Ser616 Ser-Thr/Tyr-protein kinase, catalytic domain -3.1669
Ile617 Ser-Thr/Tyr-protein kinase, catalytic domain -0.776705
Trp619 Ser-Thr/Tyr-protein kinase, catalytic domain -12.2616
Met620 Ser-Thr/Tyr-protein kinase, catalytic domain -9.47326
Ala621 Ser-Thr/Tyr-protein kinase, catalytic domain -0.964415
Val624 Ser-Thr/Tyr-protein kinase, catalytic domain -3.50425
Tyr633 Ser-Thr/Tyr-protein kinase, catalytic domain -5.20433
Ser637 Ser-Thr/Tyr-protein kinase, catalytic domain -8.21781
Asp638 Ser-Thr/Tyr-protein kinase, catalytic domain -10.8485
Ala641 Ser-Thr/Tyr-protein kinase, catalytic domain -3.81597
b-Raf PCA -7.1
Supplementary Table 6. (Continued)
Target Ligand
Hydrogen bonding Steric interactions
BA 
(kcal/mol)
Ligand map
H-bonds: blue dashed lines
Strong steric interactions: red dashed lines (if present)
Weak steric interactions: not figured (only the corresponding AAs are presented)
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